,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,377,1,3,,10321683,5284373,Active,42741659.0,5243.0,,,MDR-1,Other,,
1,781,1,1,,11532934,5284373,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
2,782,1,2,,11532934,5284373,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
3,782,1,2,,11532934,5284373,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
4,798,2,12,,11532934,5284373,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
5,800,2,11,,11532934,5284373,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
6,873,1,13,,11532934,5284373,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
7,880,2,1,,11532934,5284373,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
8,880,2,1,,11532934,5284373,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
9,940,1,2,,11532934,5284373,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
10,1021,1,1,,11532934,5284373,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
11,1022,1,1,,11532934,5284373,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
12,1046,1,6,,11532934,5284373,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
13,1085,1,1,,11532934,5284373,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
14,1189,1,5,,48413506,5284373,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
15,1194,1,3,,48413506,5284373,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
16,1199,1,3,,48413506,5284373,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
17,1205,1,4,,48413506,5284373,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
18,1208,1,3,,48413506,5284373,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
19,1230,1,3,,11532934,5284373,Inactive,89993689.0,4193.0,,,E3 Ligase HTS_1536,Screening,,
20,1236,1,1,,11532934,5284373,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
21,1242,1,1,,11532934,5284373,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
22,1274,1,2,,11532934,5284373,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
23,1332,1,1,,49698490,5284373,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
24,1376,1,2,,11532934,5284373,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
25,1377,1,1,,11532934,5284373,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
26,1381,1,1,,11532934,5284373,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
27,1385,2,2,,11532934,5284373,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
28,1415,1,2,,11532934,5284373,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
29,1415,1,2,,11532934,5284373,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
30,1422,1,1,,11532934,5284373,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
31,1423,1,2,,11532934,5284373,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
32,1423,1,2,,11532934,5284373,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
33,1430,1,1,,11532934,5284373,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
34,1434,2,3,,11532934,5284373,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
35,1434,2,3,,11532934,5284373,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
36,1439,1,1,,11532934,5284373,Inconclusive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
37,1439,1,1,,11532934,5284373,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
38,1440,1,1,,11532934,5284373,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
39,1440,1,1,,11532934,5284373,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
40,1441,1,1,,11532934,5284373,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
41,1441,1,1,,11532934,5284373,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
42,1443,1,3,,11532934,5284373,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
43,1445,1,1,,11532934,5284373,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
44,1454,1,1,,11532934,5284373,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
45,1456,1,1,,11532934,5284373,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
46,1460,1,3,,11532934,5284373,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
47,1461,1,2,,11532934,5284373,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
48,1463,1,1,,11532934,5284373,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
49,1465,1,1,,11532934,5284373,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
50,1467,1,3,,11532934,5284373,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
51,1468,1,1,,11532934,5284373,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
52,1469,1,1,,11532934,5284373,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
53,1469,1,1,,26757675,5284373,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
54,1471,2,1,,11532934,5284373,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
55,1477,1,1,,11532934,5284373,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
56,1479,1,2,,11532934,5284373,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
57,1479,1,2,,26757675,5284373,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
58,1490,2,1,,11532934,5284373,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
59,1496,1,4,,11532934,5284373,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
60,1496,1,4,,11532934,5284373,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
61,1529,1,1,,11532934,5284373,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
62,1530,1,1,,11532934,5284373,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
63,1531,1,1,,11532934,5284373,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
64,1532,1,1,,11532934,5284373,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
65,1565,2,2,,11532934,5284373,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
66,1566,2,3,,11532934,5284373,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
67,1578,3,2,,11532934,5284373,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
68,1619,1,2,,11532934,5284373,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
69,1621,1,2,,11532934,5284373,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
70,1625,2,2,,11532934,5284373,Inactive,,,,EC50,HCS for Compounds that Up-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
71,1626,1,2,,11532934,5284373,Inconclusive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
72,1628,2,2,,11532934,5284373,Inactive,,,,IC50,HCS for Compounds that Down-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
73,1631,3,1,,11532934,5284373,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
74,1634,3,1,,11532934,5284373,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
75,1654,2,2,,11532934,5284373,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
76,1656,2,2,,11532934,5284373,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
77,1665,2,2,,11532934,5284373,Inactive,4503131.0,1499.0,,IC50_Mean,High Throughput Imaging Assay for Beta-Catenin,Confirmatory,,
78,1688,1,1,,11532934,5284373,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
79,1721,1,2,,11532934,5284373,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
80,1722,1,2,,11532934,5284373,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
81,1766,1,1,,11532934,5284373,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
82,1766,1,1,,11532934,5284373,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
83,1775,1,2,,11532934,5284373,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
84,1777,3,2,,11532934,5284373,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
85,1778,3,3,,11532934,5284373,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
86,1779,2,2,,11532934,5284373,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
87,1817,2,2,,11532934,5284373,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
88,1850,2,1,,56422786,5284373,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
89,1863,2,1,,11532934,5284373,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
90,1863,2,1,,56422786,5284373,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
91,1865,1,1,,11532934,5284373,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
92,1868,1,4,,11532934,5284373,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
93,1899,1,3,,56422786,5284373,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
94,1903,2,3,,56422786,5284373,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
95,1906,1,3,,56422786,5284373,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
96,1947,1,2,,56422786,5284373,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
97,1950,1,3,,56422786,5284373,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
98,1956,1,1,,11532934,5284373,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
99,1961,2,2,,11532934,5284373,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
100,1962,1,2,,56422786,5284373,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
101,1974,1,2,,56422786,5284373,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
102,1984,1,3,,11532934,5284373,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
103,1986,1,2,,11532934,5284373,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
104,1987,1,2,,56422786,5284373,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
105,1996,2,2,,56422786,5284373,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
106,2006,3,2,,11532934,5284373,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
107,2006,3,2,,11532934,5284373,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
108,2006,3,2,,11532934,5284373,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
109,2012,3,2,,11532934,5284373,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
110,2013,2,2,,11532934,5284373,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
111,2014,3,2,,11532934,5284373,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
112,2016,1,3,,56422786,5284373,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
113,2023,1,3,,56422786,5284373,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
114,2025,1,3,,56422786,5284373,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
115,2029,1,3,,56422786,5284373,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
116,2052,2,1,,56422786,5284373,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
117,2057,1,2,,56422786,5284373,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
118,2058,3,2,,11532934,5284373,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
119,2066,1,4,,56422786,5284373,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
120,2071,2,2,,11532934,5284373,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
121,2073,2,3,,11532934,5284373,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
122,2073,2,3,,11532934,5284373,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
123,2100,1,1,,11532934,5284373,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
124,2101,1,1,,11532934,5284373,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
125,2107,1,1,,11532934,5284373,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
126,2112,1,1,,11532934,5284373,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
127,2129,1,2,,56422786,5284373,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
128,2130,1,3,,56422786,5284373,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
129,2147,1,1,,11532934,5284373,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
130,2174,1,3,,56422786,5284373,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
131,2177,1,3,,56422786,5284373,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
132,2234,1,2,,56422786,5284373,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
133,2235,1,2,,56422786,5284373,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
134,2240,1,1,,85788570,5284373,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
135,2241,1,1,,85788570,5284373,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
136,2275,1,1,,85788570,5284373,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
137,2280,2,3,,56422786,5284373,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
138,2288,1,1,,11532934,5284373,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
139,2289,1,1,,11532934,5284373,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
140,2300,1,3,,56422786,5284373,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
141,2313,1,1,,85788570,5284373,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
142,2314,1,2,,11532934,5284373,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
143,2314,1,2,,11532934,5284373,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
144,2315,1,2,,11532934,5284373,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
145,2315,1,2,,11532934,5284373,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
146,2322,1,1,,85788570,5284373,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
147,2326,1,1,,11532934,5284373,Inactive,194352380.0,,4.4668,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
148,2330,1,1,,85788570,5284373,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
149,2380,1,2,,56422786,5284373,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
150,2391,1,1,,56422786,5284373,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
151,2435,1,2,,56422786,5284373,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
152,2445,1,2,,56422786,5284373,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
153,2451,1,2,,11532934,5284373,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
154,2462,1,1,,56422786,5284373,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
155,2462,1,1,,56422786,5284373,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
156,2472,1,2,,11532934,5284373,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
157,2517,2,1,,11532934,5284373,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
158,2517,2,1,,144204218,5284373,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
159,2520,1,4,,56422786,5284373,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
160,2521,1,3,,56422786,5284373,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
161,2524,1,2,,56422786,5284373,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
162,2528,1,2,,11532934,5284373,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
163,2540,1,2,,56422786,5284373,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
164,2544,1,2,,56422786,5284373,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
165,2546,1,1,,11532934,5284373,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
166,2549,1,1,,11532934,5284373,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
167,2551,1,1,,11532934,5284373,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
168,2557,1,3,,56422786,5284373,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
169,2599,1,2,,56422786,5284373,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
170,2606,1,2,,56422786,5284373,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
171,2629,1,1,,56422786,5284373,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
172,2650,2,1,,56422786,5284373,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
173,2661,1,1,,56422786,5284373,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
174,2662,2,1,,11532934,5284373,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
175,2675,1,1,,11532934,5284373,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
176,2676,1,2,,11532934,5284373,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
177,2685,1,1,,11532934,5284373,Inconclusive,,,20.5962,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
178,2690,1,2,,56422786,5284373,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
179,2716,1,1,,56422786,5284373,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
180,2717,1,2,,56422786,5284373,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
181,2718,1,1,,56422786,5284373,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
182,2732,1,1,,11532934,5284373,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
183,2751,2,2,,56422786,5284373,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
184,2796,1,4,,56422786,5284373,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
185,2797,1,2,,56422786,5284373,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
186,2805,2,2,,56422786,5284373,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
187,2806,2,2,,56422786,5284373,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
188,2825,1,2,,56422786,5284373,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
189,13302,5,3,,103230651,5284373,Unspecified,51702775.0,5478.0,,,Dissociation constant against binding to human cyclophilin A,Other,10794694.0,
190,15680,3,3,,103230651,5284373,Unspecified,,,,,Partition coefficient (logP),Other,8254605.0,
191,19254,3,4,,103230651,5284373,Unspecified,,,,,Partition coefficient of compound was measured in haptane/water system,Other,8254605.0,
192,19255,3,3,,103230651,5284373,Unspecified,,,,,Partition coefficient (logP),Other,8254605.0,
193,19468,3,3,,103230651,5284373,Unspecified,,,,,Partition coefficient (logP),Other,12699389.0,
194,38028,3,4,,103230651,5284373,Unspecified,,,,,Tested for inhibitory activity against B lymphocyte proliferation induced by LPS; suppressed the proliferation no significant effect,Other,9871657.0,
195,45446,6,2,,103230651,5284373,Active,,,0.183,IC50,Compound was evaluated for its inhibitory activity in a calcineurin inhibition assay,Confirmatory,12593646.0,
196,45450,7,3,,103230651,5284373,Active,,,0.004,Kd,"Binding affinity to protein phosphatase, calcineurin (CN) was determined",Confirmatory,,
197,50622,5,1,,103230651,5284373,Active,,,0.05,ED50,In Vitro neurotrophic effect was measured in cultured chick DRG sensory neurons.,Confirmatory,9857082.0,
198,50896,3,4,,103230651,5284373,Unspecified,,,,,Relative immunosuppressive activity tested against inhibition of concanavalin A stimulated thymocytes,Other,2308150.0,
199,54720,3,4,,103230651,5284373,Unspecified,,,,,"In vitro binding affinity of compound was measured to Cyclophilin under competitive ELISA system, activity relative to compound 1",Other,,
200,54721,4,4,,103230651,5284373,Active,,,0.006,Kd,Compound was evaluated for its binding affinity towards cyclophilin (Cyp),Confirmatory,,
201,54723,6,2,,103230651,5284373,Active,,,0.009000000000000001,IC50,Compound was evaluated for in vitro binding affinity to cyclophilin A (CyP-A),Confirmatory,7966126.0,
202,54724,6,2,,103230651,5284373,Active,,,0.062,IC50,In vitro binding affinity against cyclophilin A by ELISA,Confirmatory,7650689.0,
203,54725,6,2,,103230651,5284373,Active,,,0.027000000000000003,IC50,In vitro binding affinity against cyclophilin A by rotamase assay,Confirmatory,7650689.0,
204,54727,10,5,,103230651,5284373,Active,51702775.0,5478.0,0.3,Kd,Binding affinity towards cyclophilin A by fluorescence,Confirmatory,11472213.0,
205,54735,3,8,,103230651,5284373,Unspecified,,,,,In vitro affinity towards cyclophilin A was determined under competitive ELISA systems using protein-conjugated ligand CsA,Other,,
206,54923,6,5,,103230651,5284373,Active,,,6.5,IC50,Inhibition of human cytochrome P450 3A4,Confirmatory,12699389.0,
207,55740,9,2,,103230651,5284373,Unspecified,,,50.0,IC50,In vitro inhibitory activity against human dihydroorotate dehydrogenase (DHODH),Confirmatory,9719606.0,
208,67781,4,4,,103230651,5284373,Active,,,0.44,IC50,Reversal effect on the accumulation of [3H]- daunorubicin in mouse mammary carcinoma cell line EMT6/AR 1.0,Confirmatory,10098671.0,
209,69108,7,2,,103230651,5284373,Active,,,0.02,Ki,Compound was tested for its ability to inhibit FK506 binding protein 12 rotamase activity,Confirmatory,9857082.0,
210,69251,7,5,,103230651,5284373,Unspecified,,,,,Binding affinity to FK506 binding protein 12 was determined*,Other,,
211,72182,7,1,,103230651,5284373,Active,,,,,Inhibitory activity against Human formylpeptide receptor (FPR) of human leukemia HL-60 cells,Other,12361388.0,
212,72183,8,1,,103230651,5284373,Unspecified,,,10.0,IC50,Inhibitory activity against human formylpeptide receptor (FPR) of human leukemia HL-60 cells,Confirmatory,12361388.0,
213,90133,6,2,,103230651,5284373,Active,,,0.6,EC50,Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%,Confirmatory,11784143.0,
214,90135,6,2,,103230651,5284373,Active,,,0.5,EC50,Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%.,Confirmatory,11784143.0,
215,90140,3,4,,103230651,5284373,Unspecified,,,,,Ratio of effect of compound on DOX accumulation (antiPgp activity) to its intrinsic cellular toxicity;,Other,11784143.0,
216,90142,3,4,,103230651,5284373,Unspecified,,,,,Ratio of effect of compound on VBL accumulation (antiPgp activity) to its intrinsic cellular toxicity;,Other,11784143.0,
217,90143,3,4,,103230651,5284373,Unspecified,,,,,Potency relative to progesterone in reducing the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells,Other,11784143.0,
218,90144,3,5,,103230651,5284373,Unspecified,,,,,Potency relative to progesterone in reducing the difference in reversing of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells,Other,11784143.0,
219,90145,3,5,,103230651,5284373,Unspecified,,,,,"To estimate the extent of resistance conferred by Pgp, the ratio of IC50 in MDA-435/LCC6-MDR1 and MDA-435/LCC6 cells (relative resistance of Pgp-positive cells) was used",Other,11784143.0,
220,91645,4,4,,103230651,5284373,Active,,,0.023,EC50,The compound was tested for inhibition of human splenocyte proliferation by [3H]thymidine incorporation,Confirmatory,7932542.0,
221,91888,3,7,,103230651,5284373,Active,,,,,Tested in vitro for inhibition of Interleukin-2 (IL-2) release; Active,Other,,
222,91889,4,6,,103230651,5284373,Active,,,0.005,IC50,The compound was evaluated in vitro for the immunosuppressive activity in interleukin-2 by interleukin-2 reporter gene assay (IL2-RGA),Confirmatory,7650689.0,
223,91898,4,3,,103230651,5284373,Active,,,0.005,IC50,Compound was evaluated for in vitro immunosuppressive activity in the interleukin-2 reporter gene assay (IL2-RG),Confirmatory,7966126.0,
224,94163,4,4,,103230651,5284373,Unspecified,,,,,"MDR-reversal property tested in vitro on KB-A1 cells, resistance was induced by adriamycin",Other,8831775.0,
225,94168,4,4,,103230651,5284373,Unspecified,,,,,Percent of cell viability of KB-A1 human epidermoid carcinoma remaining after inoculation with the modulator alone,Other,8831775.0,
226,94960,6,2,,103230651,5284373,Unspecified,,,10.0,IC50,In vitro inhibitory activity against Jurkat cell proliferation,Confirmatory,9719606.0,
227,94996,3,4,,103230651,5284373,Unspecified,,,,,Rhodamine-123 accumulation in K562 cells with or without expression of PGP protein at a concentration of 0.01 uM,Other,12747785.0,
228,94997,3,4,,103230651,5284373,Unspecified,,,,,Rhodamine-123 accumulation in K562 cells with or without expression of PGP protein at a concentration of 0.1 uM,Other,12747785.0,
229,94998,3,4,,103230651,5284373,Unspecified,,,,,Rhodamine-123 accumulation in K562 cells with or without expression of PGP protein at a concentration of 1 uM,Other,12747785.0,
230,94999,3,4,,103230651,5284373,Unspecified,,,,,Rhodamine-123 accumulation in K562 cells with or without expression of PGP protein at a concentration of 1 nM,Other,12747785.0,
231,95286,6,3,,103230651,5284373,Active,,,0.008,IC50,Effect on the transcription and release of IL-2 in a reporter-gene assay (RGA),Confirmatory,,
232,95298,4,4,,103230651,5284373,Active,,,0.012,IC50,The compound was tested in vitro for inhibition of IL-2 release stimulated with PMA/ionomycin by Jurkat cells.,Confirmatory,7473543.0,
233,95447,6,2,,103230651,5284373,Unspecified,,,10.0,IC50,In vitro inhibition of Jurkat cell proliferation.,Confirmatory,11384243.0,
234,95450,6,2,,103230651,5284373,Active,,,0.006999999999999999,IC50,Inhibition of production of IL-2 secretion in Jurkat cells,Confirmatory,11881984.0,
235,95451,6,2,,103230651,5284373,Active,,,0.008,IC50,Inhibition of production of beta-galactosidase IL-2 RGA in Jurkat cells,Confirmatory,11881984.0,
236,95452,6,2,,103230651,5284373,Unspecified,,,1.0,IC50,Inhibition of production of beta-galactosidase thymidine kinase RGA in Jurkat cells,Confirmatory,11881984.0,
237,95464,4,7,,103230651,5284373,Active,,,0.002,IC50,Immunosuppressive activity was measured by inhibition of the IL-2 production in Jurkat cells.,Confirmatory,14643337.0,
238,102700,6,2,,103230651,5284373,Unspecified,,,,,In vitro efficacy on humoral immune response by Mishell-Dutton assay (MD).,Other,7783117.0,
239,102701,6,2,,103230651,5284373,Unspecified,,,,,In vitro efficacy to suppress lymphocyte proliferation as measured by the incorporation of a labeled precursor ([3H]- thymidine) into DNA in Mixed Lymphocyte reaction (MLR).,Other,7783117.0,
240,102704,3,4,,103230651,5284373,Active,,,,,Tested in vitro for mixed Lymphocyte reaction; Active,Other,,
241,102709,6,3,,103230651,5284373,Unspecified,,,,,In vitro inhibition of interleukin-2 (IL-2) production induced by stimulating lymphocytes derived from mouse spleens with the mitogen canavalin A,Other,7783117.0,
242,105423,6,3,,103230651,5284373,Active,,,0.7,EC50,Effect on reversal of DOX accumulation in MDA-435/LCC6 (Pgp-negative) cells.,Confirmatory,11784143.0,
243,105424,6,3,,103230651,5284373,Active,,,0.6,EC50,Effect on reversal of [3H]- VBL accumulation in MDA-435/LCC6 (Pgp-negative) cells.,Confirmatory,11784143.0,
244,105426,6,2,,103230651,5284373,Active,,,1.0,IC50,Growth inhibitory activity on MDA-435/LCC6 (Pgp-positive) human breast cancer cells.,Confirmatory,11784143.0,
245,105429,3,3,,103230651,5284373,Unspecified,,,,,Ability of compound to inhibit MDA-435/LCC6 cell growth relative to progesterone.,Other,11784143.0,
246,105431,3,4,,103230651,5284373,Unspecified,,,,,Potency relative to progesterone in reversing of DOX accumulation in MDA-435/LCC6 (Pgp-negative) cells.,Other,11784143.0,
247,105432,3,4,,103230651,5284373,Unspecified,,,,,Potency relative to progesterone in reversing of [3H]- VBL accumulation in MDA-435/LCC6 (Pgp-negative) cells.,Other,11784143.0,
248,105434,3,3,,103230651,5284373,Unspecified,,,,,Ability of compound to inhibit MDA-435/LCC6-MDR cell growth relative to progesterone.,Other,11784143.0,
249,105436,6,2,,103230651,5284373,Active,,,1.1,IC50,Growth inhibitory activity on MDA-435/LCC6-MDRI (Pgp-negative) human breast cancer cells.,Confirmatory,11784143.0,
250,106877,6,2,,103230651,5284373,Active,,,0.006,IC50,In vitro T-cell immunosuppressive activity in the mouse mixed lymphocyte reaction (MLR),Confirmatory,11384243.0,
251,114448,6,2,,103230651,5284373,Unspecified,,,,,Compound was tested for Immunosuppression activity by mixed lymphocyte reaction (MLR) in murine splenocytes of mice,Other,8709118.0,
252,122891,6,2,,103230651,5284373,Active,,,0.073,IC50,Compound was evaluated for IL 4 production inhibition from mice splenocytes stimulated by anti-CD3 mAb,Confirmatory,10052971.0,
253,122892,6,2,,103230651,5284373,Active,,,0.242,IC50,Compound was evaluated for IL 5 production inhibitio from mice splenocytes stimulated by anti-CD3 mAb,Confirmatory,10052971.0,
254,123809,2,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity by mouse mixed lymphocyte reaction (MLR_M) relative to cyclosporin as 1,Other,,
255,129220,2,4,,103230651,5284373,Unspecified,,,,,Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique(GVHR); body weight at a dose of 25.0 mg/kg,Other,,
256,130695,6,2,,103230651,5284373,Unspecified,,,,,In vivo immunosuppressive activity in the delayed type hypersensitivity model induced by SRBC-TH cells in mouse after peroral administration,Other,10386928.0,
257,132340,4,3,,103230651,5284373,Active,,,0.02,IC50,Compound was evaluated for in vitro immunosuppressive activity in the mouse mixed lymphocyte reaction (MLR-M),Confirmatory,7966126.0,
258,132491,4,3,,103230651,5284373,Active,,,0.013999999999999999,IC50,Immunosuppressive activity on mouse allogenic MLR in vitro,Confirmatory,8893839.0,
259,132510,4,4,,103230651,5284373,Active,,,0.013999999999999999,IC50,Inhibition of mouse allogenic mixed leukocyte response (MLR),Confirmatory,,
260,132511,8,2,,103230651,5284373,Unspecified,,,,,Compound was tested in vivo for immunosuppressive activity in the serum free mixed lymphocyte reaction,Other,10386928.0,
261,132677,6,2,,103230651,5284373,Active,,,0.006,IC50,In vitro inhibitory activity against mouse mixed lymphocyte reaction (MLR),Confirmatory,9719606.0,
262,132693,4,3,,103230651,5284373,Active,,,0.0025,IC50,Inhibitory activity against the production of interleukin 4 (IL-4),Confirmatory,10617078.0,
263,132694,4,3,,103230651,5284373,Active,,,0.0075,IC50,Inhibitory activity against the proliferation of lymphocytes in mouse allogenic mixed lymphocyte reaction (MLR).,Confirmatory,10617078.0,
264,132849,5,3,,103230651,5284373,Unspecified,,,,,Tested for immunosuppressive activity in mouse using allogenic MLR method,Other,,
265,132859,4,3,,103230651,5284373,Active,,,0.02,IC50,The compound was evaluated in vitro for the immunosuppressive activity in mouse mixed lymphocyte reaction (MLR_M),Confirmatory,7650689.0,
266,134107,5,1,,103230651,5284373,Unspecified,,,,,Tested in vivo for immunosuppressive activity in mouse using allogenic skin grafting technique(SG); mean graft survival at a dose of 25.0 mg/kg,Other,,
267,135185,3,3,,103230651,5284373,Unspecified,,,,,Inhibition of paw edema formation in mouse after an ip dose of 50 mg/kg; Thickness of paw = 2.10+/-0.06 mm,Other,9207942.0,
268,135186,3,3,,103230651,5284373,Unspecified,,,,,Inhibition of paw edema formation in mouse after an ip dose of 5 mg/kg; Thickness of paw = 2.42+/-0.12 mm,Other,9207942.0,
269,135324,3,3,,103230651,5284373,Unspecified,,,,,Evaluated for the delayed type hypersensitivity (DTH) response to methylated BSA (mBSA) in sensitive mice after peroral administration of 50 mg/kg,Other,2115585.0,
270,138255,5,1,,103230651,5284373,Unspecified,,,,,Tested in vivo for immunosuppressive activity in mouse using allogenic skin grafting technique(SG); graft survival relative to cyclophosphamide at a dose of 25.0 mg/kg,Other,,
271,139029,2,5,,103230651,5284373,Unspecified,,,,,Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique(GVHR); weight change at a dose of 25.0 mg/kg,Other,,
272,140315,3,3,,103230651,5284373,Unspecified,,,,,Compound was tested for the immunomodulatory activity in vitro expressed as stimulation index by lymphocyte transformation test at 1.0 ug/mL,Other,9871679.0,
273,140322,2,4,,103230651,5284373,Unspecified,,,,,"The immunosuppressive activity of compound was measured with the help of a mixed lymphocyte reaction in mouse (MLR_M), activity relative to compound 1",Other,,
274,140778,4,4,,103230651,5284373,Active,,,0.01,IC50,Effect of compound on IL-2 production from alloantigen-stimulated mouse spleen cells,Confirmatory,8893839.0,
275,140779,4,4,,103230651,5284373,Active,,,0.04,IC50,The compound was tested in vitro for inhibition of proliferation in BDF1 mouse spleen cells stimulated with concanavalin A (ConA).,Confirmatory,7473543.0,
276,140793,6,2,,103230651,5284373,Unspecified,,,,,Compound was tested for Cytotoxic activity by lymphocyte viability assay.,Other,8709118.0,
277,142318,6,2,,103230651,5284373,Unspecified,,,100.0,IC50,In vitro inhibitory activity against murine antibody response to T-cell independent B-cell antigen TNP-LPS (type I),Confirmatory,9719606.0,
278,142578,5,2,,103230651,5284373,Active,,,0.0178,EC50,The compound was tested for inhibition of murine splenocyte proliferation by [3H]thymidine incorporation,Confirmatory,7932542.0,
279,150364,4,4,,103230651,5284373,Unspecified,,,,,"MDR-reversal property tested in vitro on P388/VCR-20 cells, resistance was induced by vincristine",Other,8831775.0,
280,150619,8,1,,103230651,5284373,Active,,,3.4,IC50,Inhibitory activity against Human MDR1 P-Glycoprotein ABC Transporter using leukemia CEM cells,Confirmatory,12361387.0,
281,150751,7,1,,103230651,5284373,Unspecified,,,,,Inhibition of P-glycoprotein using ATPase in MDR1 membranes,Other,12699389.0,
282,150752,6,3,,103230651,5284373,Active,,,0.8,IC50,"Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
283,150753,6,3,,103230651,5284373,Active,,,4.8,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
284,150754,6,3,,103230651,5284373,Active,,,0.7,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
285,150755,6,3,,103230651,5284373,Active,,,0.5,IC50,Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC,Confirmatory,12699389.0,
286,150756,3,7,,103230651,5284373,Unspecified,,,,,Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells,Other,12699389.0,
287,150757,3,7,,103230651,5284373,Unspecified,,,,,"P-gp activity was measured by a direct transport assay, using polarized LLC-MDR1 epithelial cells",Other,12699389.0,
288,150758,3,7,,103230651,5284373,Unspecified,,,,,"P-gp activity was measured by a direct transport assay, using polarized LLC-PK1 epithelial cells",Other,12699389.0,
289,150759,3,7,,103230651,5284373,Unspecified,,,,,"P-gp activity was measured by a direct transport assay, using polarized LLC-mdr1a epithelial cells",Other,12699389.0,
290,154221,4,4,,103230651,5284373,Unspecified,,,,,Percent of cell viability of P388/VCR-20 murine leukemia cells remaining after inoculation with the modulator alone,Other,8831775.0,
291,155303,6,2,,103230651,5284373,Active,,,8.97,IC50,Effect on proliferation of human peripheral blood mononuclear cells (PMBC) at 72 hr using MTT assay,Confirmatory,15203163.0,
292,157232,6,2,,103230651,5284373,Active,,,0.006,Ki,The compound was tested for inhibition of Peptidyl-propyl isomerase (PPIase).,Confirmatory,7473543.0,
293,161464,3,5,,103230651,5284373,Unspecified,,,,,"Bronchoalveolar lavages was collected after 48 hr (for eosinophil influx, eos) at 25 mg/kg dose",Other,10956206.0,
294,161615,3,5,,103230651,5284373,Unspecified,,,,,Bronchoalveolar lavages was collected after 6 hr in an ascaris-induced nonhuman primate model of asthma at 25 mg/kg dose (for IL-5),Other,10956206.0,
295,161616,3,5,,103230651,5284373,Unspecified,,,,,Bronchoalveolar lavages was collected after 6 hr in an ascaris-induced nonhuman primate model of asthma at 25 mg/kg dose (for IL-8),Other,10956206.0,
296,161617,3,5,,103230651,5284373,Unspecified,,,,,Bronchoalveolar lavages was collected after 6 hr in an ascaris-induced nonhuman primate model of asthma at 25 mg/kg dose (for eotaxin),Other,10956206.0,
297,161622,3,4,,103230651,5284373,Unspecified,,,,,Resistance evaluated in an ascaris-induced nonhuman primate model of asthma after 10 min at 25 mg/kg dose,Other,10956206.0,
298,161625,3,4,,103230651,5284373,Unspecified,,,,,Resistance evaluated in an ascaris-induced nonhuman primate model of asthma after 6 hour at 25 mg/kg dose,Other,10956206.0,
299,170367,3,4,,103230651,5284373,Unspecified,,,,,Percent reduction in arthritis score was measured in CP-20961 injected rats on day 11 and 16,Other,,
300,173625,3,3,,103230651,5284373,Unspecified,,,,,In vivo immunosuppressive activity was evaluated by surgically implanting the hearts from Brown Norway rats into the peritoneal cavity of histoincompatible Lewis rats and rejection was assessed,Other,7537331.0,
301,177347,6,2,,103230651,5284373,Unspecified,,,,,In vivo immunosuppressive activity was evaluated by inducing arthritis in lewis rats and measuring the primary lesions after 16 days,Other,7537331.0,
302,177348,6,2,,103230651,5284373,Unspecified,,,,,In vivo immunosuppressive activity was evaluated by inducing arthritis in lewis rats and measuring the secondary lesions after 16 days,Other,7537331.0,
303,182789,6,2,,103230651,5284373,Unspecified,,,,,Decrease in number of T cells in peripheral blood after administration for 4 days in rat,Other,9925439.0,
304,182934,6,2,,103230651,5284373,Unspecified,,,,,In vivo immunosuppressive effect of compound was determined on host versus graft reaction (HvGR) using popliteal lymph node gain assay in rat,Other,9925439.0,
305,183137,6,2,,103230651,5284373,Unspecified,,,,,Lymphocyte-decreasing effect against F344 rats.,Other,10956203.0,
306,183445,7,3,,103230651,5284373,Unspecified,,,,,T cell-decreasing effect in spleen cells of WKAH rat which were injected into foot-pad of LEW rat.,Other,10956203.0,
307,183454,7,3,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity against LEW rats transfected with spleen cells of WKAH rat in Popliteal Lymph Node Gain Assay.,Other,10956203.0,
308,183610,3,3,,103230651,5284373,Unspecified,,,,,Lymphocyte-decreasing effect against F344 rats.,Other,10956203.0,
309,185377,5,1,,103230651,5284373,Unspecified,,,,,Compound was evaluated in vivo for the immunosuppressive activity on rat skin allograft at ip dose of 1 mg/Kg,Other,,
310,185379,5,1,,103230651,5284373,Unspecified,,,,,Compound was evaluated in vivo for the immunosuppressive activity on rat skin allograft at ip dose of 10 mg/Kg,Other,,
311,185381,4,3,,103230651,5284373,Unspecified,,,,,Compound was evaluated in vivo for the immunosuppressive activity on rat skin allograft at ip dose of 100 mg/Kg; toxic(animals died),Other,,
312,185382,5,1,,103230651,5284373,Unspecified,,,,,Compound was evaluated in vivo for the immunosuppressive activity on rat skin allograft at ip dose of 3 mg/Kg,Other,,
313,185383,5,1,,103230651,5284373,Unspecified,,,,,Compound was evaluated in vivo for the immunosuppressive activity on rat skin allograft at ip dose of 30 mg/Kg,Other,,
314,185386,5,2,,103230651,5284373,Unspecified,,,,,Mean survival time of rats after skin allograft (intraperitoneal administration) at 100 mg/kg; toxic - animals died,Other,8893839.0,
315,185387,6,1,,103230651,5284373,Unspecified,,,,,Mean survival time of rats after skin allograft (intraperitoneal administration) at 10 mg/kg,Other,8893839.0,
316,185388,6,1,,103230651,5284373,Unspecified,,,,,Mean survival time of rats after skin allograft (intraperitoneal administration) at 1 mg/kg,Other,8893839.0,
317,185391,6,1,,103230651,5284373,Unspecified,,,,,Mean survival time of rats after skin allograft (intraperitoneal administration) at 30 mg/kg,Other,8893839.0,
318,185516,6,1,,103230651,5284373,Unspecified,,,,,Mean survival time of rats after skin allograft (intraperitoneal administration) at 3 mg/kg,Other,8893839.0,
319,185522,5,2,,103230651,5284373,Unspecified,,,,,Mean survival time of rats after skin allograft (oral administration) at 100 mg/kg; toxic - animals died,Other,8893839.0,
320,185523,6,1,,103230651,5284373,Unspecified,,,,,Mean survival time of rats after skin allograft (oral administration) at 10 mg/kg,Other,8893839.0,
321,185524,6,1,,103230651,5284373,Unspecified,,,,,Mean survival time of rats after skin allograft (oral administration) at 1 mg/kg,Other,8893839.0,
322,185525,6,1,,103230651,5284373,Unspecified,,,,,Mean survival time of rats after skin allograft (oral administration) at 30 mg/kg,Other,8893839.0,
323,185527,6,1,,103230651,5284373,Unspecified,,,,,Mean survival time of rats after skin allograft (oral administration) at 3 mg/kg,Other,8893839.0,
324,187617,2,5,,103230651,5284373,Unspecified,,,,,"Antiarthritic activity by measuring % reduction in paw volume in Sprague Dawley rat, peroral administration of 10 mg/kg, activity expressed as % reduction in paw volume(joint mobility)",Other,,
325,187618,2,5,,103230651,5284373,Unspecified,,,,,"Antiarthritic activity by measuring % reduction in paw volume in Sprague Dawley rat, peroral administration of 10 mg/kg, volume change in the uninjected paw(left primary lesion) measured from day 9 to day 18",Other,,
326,187620,2,4,,103230651,5284373,Unspecified,,,,,"Percent reduction in paw volume (right primary lesion, days 9-18) by 33 mg/kg p.o. in rats.",Other,,
327,189040,4,1,,103230651,5284373,Unspecified,,,,,"Percent reduction in paw volume (right primary lesion, days 0-8) by 33 mg/kg p.o. in rats.",Other,,
328,196255,6,1,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity against skin allograft in F344 recipient (rat) from LEW donor (rat) at a concentration of 1 mg/kg,Other,10956203.0,
329,196256,6,1,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity against skin allograft in F344 recipient (rat) from LEW donor (rat) at a concentration of 10 mg/kg,Other,10956203.0,
330,196258,5,2,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity against skin allograft in F344 recipient (rat) from LEW donor (rat) at a concentration of 100 mg/kg; Toxic,Other,10956203.0,
331,196259,6,1,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity against skin allograft in F344 recipient (rat) from LEW donor (rat) at a concentration of 3 mg/kg,Other,10956203.0,
332,196261,6,1,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity against skin allograft in F344 recipient (rat) from LEW donor (rat) at a concentration of 30 mg/kg,Other,10956203.0,
333,197947,6,5,,103230651,5284373,Active,82310930.0,,0.455,IC50,In vitro inhibitory activity against HIV-1 RT in CEM4 cell line,Confirmatory,14643337.0,
334,200742,8,1,,103230651,5284373,Active,,,0.005,IC50,Exogenous inhibition concentration of Serine/threonine protein phosphatase 2B (PP2B),Confirmatory,11881984.0,
335,209834,3,5,,103230651,5284373,Unspecified,,,,,"The immunosuppressive activity of compound was measured with the help of a reporter gene assay (IL2_RGA), activity relative to compound 1",Other,,
336,209947,3,3,,103230651,5284373,Unspecified,,,,,Tested for inhibitory activity against T lymphocyte proliferation induced by Con A at 10e-7 M; showed potent suppressive effect,Other,9871657.0,
337,209948,3,3,,103230651,5284373,Unspecified,,,,,Tested for inhibitory activity against T lymphocyte proliferation induced by PHA at 10e-7 M; showed potent suppressive effect,Other,9871657.0,
338,209953,4,3,,103230651,5284373,Active,,,0.06,IC50,Immunosuppressive activity was evaluated by the inhibition of human T-lymphocyte proliferation,Confirmatory,9871643.0,
339,210154,6,2,,103230651,5284373,Unspecified,,,10.0,IC50,In vitro inhibition of Ab formation from trinitrophenyl-lipopolysaccharide (TNP-LPS) B-cells.,Confirmatory,11384243.0,
340,210270,4,4,,103230651,5284373,Active,,,0.0081,IC50,In vitro inhibitory activity against human T-cell production of lymphokine IL-2,Confirmatory,7537331.0,
341,210271,4,4,,103230651,5284373,Active,,,0.0137,IC50,In vitro inhibitory activity against human T-cell proliferation.,Confirmatory,7537331.0,
342,210275,6,3,,103230651,5284373,Active,,,0.006999999999999999,IC50,Compound was tested for inhibition of IL-2 secretion in mouse T cell line,Confirmatory,,
343,210937,4,3,,103230651,5284373,Active,,,0.005,IC50,Compound tested for inhibition of concanavalin A stimulated thymocytes in Tolypocladium inflatum gams,Confirmatory,3261799.0,
344,213152,4,1,,103230651,5284373,Unspecified,,,,,Compound was tested for inhibition of Interleukin-2 synthesis in a thymocyte assay.,Other,,
345,223386,9,2,,103230651,5284373,Active,,,0.016,IC50,50% inhibitory concentration of competitive binding against hCyp-18 PPIase activity using uncoupled assay,Confirmatory,10794694.0,
346,226686,6,3,,103230651,5284373,Unspecified,,,1.0,IC50,Effect on the transcription and release of thymidine kinase in a reporter-gene assay (RGA),Confirmatory,,
347,226837,6,3,,103230651,5284373,Unspecified,,,,,In vitro viable cell inhibitory towards interleukin-2 antiproducing effect was determined.,Other,,
348,226865,4,3,,103230651,5284373,Active,,,0.004,IC50,Inhibitory concentration against Con A stimulated thymocytes,Confirmatory,3712387.0,
349,228502,5,1,,103230651,5284373,Unspecified,,,,,Tested in vitro for cytotoxicity against leukocytoclastic vasculitis(LcV) in cells,Other,,
350,231043,3,4,,103230651,5284373,Unspecified,,,,,Non-cytotoxic IMS activity (ratio LcV/MLR) was determined,Other,,
351,234407,3,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity with the help of a reporter gene assay for IL-2 (IL2-RGA) relative to cyclosporin as 1,Other,,
352,234689,4,3,,103230651,5284373,Unspecified,,,,,Relative IC50 is the ratio of IC50 of the compound/IC50 CsA,Other,7650689.0,
353,234690,3,3,,103230651,5284373,Unspecified,,,,,Relative IC50 is the ratio of IC50 of the compound/IC50 CsA (IL2-RGA),Other,7650689.0,
354,234691,3,3,,103230651,5284373,Unspecified,,,,,Relative IC50 is the ratio of IC50 of the compound/IC50 CsA (MLR),Other,7650689.0,
355,235867,3,3,,103230651,5284373,Unspecified,,,,,Non cytotoxic IM activity index which is the ratio of IC50 of LcV to IC50 of MLR,Other,8709118.0,
356,238355,6,2,,103230651,5284373,Active,,,0.02,Ki,Inhibition of cyclophilin A rotamase,Confirmatory,15357990.0,
357,240399,5,1,,103230651,5284373,Active,,,0.05,ED50,Inhibition of T-cell proliferation,Confirmatory,15357990.0,
358,241041,4,3,,103230651,5284373,Active,,,0.014419999999999999,IC50,"Inhibition of Peptidyl-prolyl cis-trans isomerase Trypanosoma cruzi cyclophilin (CL Brener strain, p19)",Confirmatory,15324878.0,
359,242628,6,2,,103230651,5284373,Active,,,19.4,IC50,Inhibitory concentration against proliferation of mouse splenocytes was determined by measuring mitochondrial dehydrogenase activity using MTT assay,Confirmatory,15916418.0,
360,242724,8,2,,103230651,5284373,Inactive,,,,,In vitro inhibitory activity against recombinant p56 lck tyrosine kinase expressed as a His-tagged protein in insect cells'' NA denotes not active,Other,15546730.0,
361,243422,3,10,,103230651,5284373,Unspecified,116241312.0,1576.0,,,log (1/Km) value for human liver microsome cytochrome P450 3A4,Other,15990295.0,
362,245888,7,1,,103230651,5284373,Unspecified,,,,,Maximum intracellular vinblastine accumulation of the KB/MDR cells caused by the compound in 1 h,Other,15481991.0,
363,245962,6,3,,103230651,5284373,Active,,,1.29,CC50,In vitro concentration of compound required to reduced spleen cell viability to 50% in BALB/c mice,Confirmatory,15999998.0,
364,246154,6,2,,103230651,5284373,Active,,,1.2,EC50,Concentration that causes 50% of maximum vinblastine accumulation in KB/MDR cells in 1 h,Confirmatory,15481991.0,
365,246433,6,2,,103230651,5284373,Active,,,7.19,EC50,Effective concentration required for the lysis of Trypanosoma cruzi trypomastigotes in blood stream after 24 hours of treatment,Confirmatory,15324878.0,
366,247607,6,2,,103230651,5284373,Active,,,0.6,IC50,Inhibitory activity against KB cell line after 72 h of drug exposure,Confirmatory,15481991.0,
367,247665,6,2,,103230651,5284373,Active,,,1.5,IC50,Inhibitory activity against KB/MDR cell line after 72 hr of drug exposure,Confirmatory,15481991.0,
368,248381,6,2,,103230651,5284373,Active,,,5.39,IC50,Compound was tested for the inhibition of Trypanosoma cruzi epimastigote growth after 72 hours of treatment,Confirmatory,15324878.0,
369,248433,6,2,,103230651,5284373,Active,,,0.184,IC50,In vitro concentration of compound required to inhibit LPS-induced B cell proliferation to 50% in BALB/c mice,Confirmatory,15999998.0,
370,248451,6,3,,103230651,5284373,Active,,,0.00134,IC50,In vitro concentration of compound required to inhibit ConA-induced T cell proliferation to 50% in BALB/c mice,Confirmatory,15999998.0,
371,248495,4,4,,103230651,5284373,Active,,,0.05,IC50,In vivo inhibitory activity against proliferation of normal human peripheral blood T lymphocytes,Confirmatory,15546730.0,
372,252956,3,3,,103230651,5284373,Unspecified,,,,,Ratio of concentration that reduced cell viability to inhibitory concentration for LPS-induced B cell proliferation,Other,15999998.0,
373,252957,3,3,,103230651,5284373,Unspecified,,,,,Ratio of concentration that reduced cell viability to inhibitory concentration for ConA-induced T cell proliferation,Other,15999998.0,
374,259532,3,3,,103230651,5284373,Unspecified,,,,,Reduction of HIV1 virion infectivity in the replication-deffective one-round infection assay,Other,16451056.0,
375,284361,6,4,,103230651,5284373,Active,,,1.35,CC50,Cytotoxicity against BALB/c mouse spleen cells,Confirmatory,17081761.0,
376,284362,6,2,,103230651,5284373,Active,,,0.00137,IC50,Inhibition of ConA-induced BALB/c mouse T cell proliferation,Confirmatory,17081761.0,
377,284363,6,2,,103230651,5284373,Active,,,0.159,IC50,Inhibition of LPS-induced BALB/c mouse B cell proliferation,Confirmatory,17081761.0,
378,284364,3,4,,103230651,5284373,Unspecified,,,,,"Selectivity index, ratio of CC50 for BALB/c mouse spleen cells to IC50 for BALB/c mouse T cells",Other,17081761.0,
379,284365,3,3,,103230651,5284373,Unspecified,,,,,"Selectivity index, ratio of CC50 for BALB/c mouse T cells to IC50 for BALB/c mouse B cells",Other,17081761.0,
380,290715,4,5,,103230651,5284373,Active,,,4.7e-05,IC50,Inhibition of fMLP-OMe-induced chemotaxis in human neutrophils,Confirmatory,17475488.0,
381,303928,3,3,,103230651,5284373,Unspecified,,,,,Permeability in biomimetic membrane layer DMPC vesicles assessed as decrease in fluorescence at 30 uM by colorimetric mixed-vesicle assay,Other,17983214.0,
382,307316,3,4,,103230651,5284373,Active,,,,,Inhibition of Jurkat cell activation assessed as blocking of T-cell antigen receptor-induced IL-2 expression at 10 uM by luciferase assay,Other,17418581.0,
383,310120,7,4,,103230651,5284373,Active,238054374.0,5243.0,1.41254,IC50,Inhibition of P-glycoprotein expressed in A2780/ADR cells by calcein AM assay,Confirmatory,17890094.0,
384,310121,6,6,,103230651,5284373,Unspecified,238054374.0,5243.0,4265800000.0,IC50,Inhibition of P-glycoprotein expressed in MDCK-MDR1 cells by calcein AM assay,Confirmatory,17890094.0,
385,310122,7,4,,103230651,5284373,Active,238054374.0,5243.0,1.41254,IC50,Inhibition of P-glycoprotein by Hoechst assay,Confirmatory,17890094.0,
386,317949,10,5,,103230651,5284373,Unspecified,238054374.0,5243.0,80.0,EC50,Inhibition of human P-glycoprotein mediated [3H]vinblastine transport in human Caco-2 cells,Confirmatory,18257545.0,
387,317950,3,11,,103230651,5284373,Inactive,238054374.0,5243.0,,,Activation of human P-glycoprotein ATPase in Caco-2 cells assessed as ATP depletion at 100 uM,Other,18257545.0,
388,317951,3,4,,103230651,5284373,Unspecified,,,,,Ratio of permeability from apical to basolateral side over basolateral to apical side in human Caco-2 cells,Other,18257545.0,
389,321879,10,5,,103230651,5284373,Unspecified,238054374.0,5243.0,80.0,EC50,Inhibition of human Pgp mediated [3H]vinblastine transport in human Caco-2 cells,Confirmatory,17936633.0,
390,321881,7,1,,103230651,5284373,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco-2 cell membrane,Other,17936633.0,
391,321882,7,1,,103230651,5284373,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco-2 cell membrane,Other,17936633.0,
392,321883,3,4,,103230651,5284373,Unspecified,,,,,Ratio of apparent permeability from apical to basolateral over basolateral to apical side of human Caco-2 cell membrane,Other,17936633.0,
393,321887,3,11,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of human Pgp in adriamycin resistant MCF7 cells assessed as fold increase in accumulation of doxorubicin at 20 uM relative to control,Other,17936633.0,
394,322362,3,11,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of human multidrug resistant gene Pgp expressed in MDCK2 cells assessed as calcein-AM accumulation at 10 uM after 40 mins,Other,17964170.0,
395,322363,3,11,,103230651,5284373,Active,238054374.0,5243.0,,,Inhibition of human wild type Pgp expressed in MDCK2 cells assessed as calcein-AM accumulation at 10 uM after 40 mins,Other,17964170.0,
396,324389,3,4,,103230651,5284373,Unspecified,,,,,Induction of light chain 3-GFP level in human H4 cells at 2.1 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
397,324441,3,4,,103230651,5284373,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 2.1 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
398,324493,3,4,,103230651,5284373,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 2.1 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
399,324545,3,4,,103230651,5284373,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 2.1 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
400,324576,3,4,,103230651,5284373,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control,Other,18024584.0,
401,324577,3,4,,103230651,5284373,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control,Other,18024584.0,
402,324578,3,4,,103230651,5284373,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control,Other,18024584.0,
403,324582,3,4,,103230651,5284373,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control,Other,18024584.0,
404,324583,3,4,,103230651,5284373,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control,Other,18024584.0,
405,324584,3,4,,103230651,5284373,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control,Other,18024584.0,
406,324585,3,4,,103230651,5284373,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control,Other,18024584.0,
407,326367,8,5,,103230651,5284373,Active,238054374.0,5243.0,1.41254,IC50,Inhibition of human Pgp in A2780 cells after 30 mins by Hoechst 33342 assay,Confirmatory,18083034.0,
408,326368,8,5,,103230651,5284373,Active,238054374.0,5243.0,1.41254,IC50,Inhibition of human Pgp in A2780 cells after 30 mins by calcein AM assay,Confirmatory,18083034.0,
409,326369,11,1,,103230651,5284373,Active,,,0.44,IC50,Inhibition of Pgp by daunorubicin accumulation assay,Confirmatory,18083034.0,
410,326743,6,2,,103230651,5284373,Unspecified,,,,,Inhibition of anti-CD3-induced IL2 production in BALB/c mouse,Other,18321037.0,
411,330502,6,2,,103230651,5284373,Unspecified,,,80.0,EC50,Inhibition of human P-gp mediated [3H]vinblastine transport activity in human Caco-2 cells,Confirmatory,18276145.0,
412,330503,4,5,,103230651,5284373,Inactive,238054374.0,5243.0,,,Activation of human P-gp ATPase in human Caco-2 cells at 100 uM,Other,18276145.0,
413,330504,8,1,,103230651,5284373,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco-2 cell membrane,Other,18276145.0,
414,330505,8,1,,103230651,5284373,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco-2 cell membrane,Other,18276145.0,
415,330506,3,4,,103230651,5284373,Unspecified,,,,,Ratio of permeability from apical to basolateral over basolateral to apical side of human Caco-2 cell membrane,Other,18276145.0,
416,338965,6,2,,103230651,5284373,Active,,,,IC50,Inhibition of PHA-stimulated human PBMC proliferation assessed as [3H]thymidine uptake after 3 days by scintillation counting,Confirmatory,11975489.0,
417,339500,7,5,,103230651,5284373,Active,51702775.0,5478.0,0.0368,Kd,Binding affinity to human Cyclophilin A,Confirmatory,18571405.0,
418,339501,7,5,,103230651,5284373,Active,215273869.0,5479.0,0.0098,Kd,Binding affinity to human Cyclophilin B,Confirmatory,18571405.0,
419,350876,4,3,,103230651,5284373,Active,,,4.7e-05,IC50,Reduction of chemotaxis in human neutrophils assessed as inhibition of fMLP-OMe-induced cell migration pretreated 10 mins before fMLP-OMe challenge,Confirmatory,19362486.0,
420,356719,6,2,,103230651,5284373,Active,,,0.012,IC50,Antiinflammatory activity in human PMNC assessed as inhibition of proliferation,Confirmatory,11473413.0,
421,357931,11,1,,103230651,5284373,Unspecified,,,,,Immunosuppressant activity in mouse T cells assessed as inhibition of concanavalin A-induced cell proliferation,Other,11575965.0,
422,357932,10,1,,103230651,5284373,Unspecified,,,,,Immunosuppressant activity in mouse B cells assessed as inhibition of LPS-induced cell proliferation,Other,11575965.0,
423,357957,6,2,,103230651,5284373,Active,,,0.34,IC50,Inhibition of PHA-induced human T cell proliferation after 24 hrs by MTT assay,Confirmatory,11678649.0,
424,358646,3,4,,103230651,5284373,Active,238054374.0,5243.0,,,Modulation of P-gp in human HCT15 cells assessed as increase in DINIB-induced cytotoxicity at 0.4 to 6.3 ug/mL,Other,11754602.0,
425,358652,3,4,,103230651,5284373,Active,238054374.0,5243.0,,,Modulation of P-gp in human UO31 cells assessed as increase in DINIB-induced cytotoxicity at 0.4 to 6.3 ug/mL,Other,11754602.0,
426,358658,3,4,,103230651,5284373,Active,238054374.0,5243.0,,,Modulation of P-gp in human CAKI1 cells assessed as increase in DINIB-induced cytotoxicity at 0.4 to 6.3 ug/mL,Other,11754602.0,
427,358907,3,4,,103230651,5284373,Inactive,,,,,Increase in DINIB-induced cytotoxicity against human LOXIMVI at 0.4 to 6.3 ug/mL,Other,11754602.0,
428,359250,3,4,,103230651,5284373,Unspecified,,,,,Reduction of P-gp-mediated [99mTc]sestamibi efflux in doxorubicin-resistant Brca1 and p53 deficient mouse mammary tumor T*23 xenografted mouse hereditary breast cancer model after 30 mins,Other,17626183.0,
429,364884,6,1,,103230651,5284373,Active,238054374.0,5243.0,1.41254,IC50,Inhibition of P-gp in human adriamycin-resistant A2780 cells by Hoechst 33342 assay,Confirmatory,18678495.0,
430,364887,7,5,,103230651,5284373,Unspecified,67462103.0,9429.0,63.0957,IC50,Inhibition of ABCG2 in human mitoxantrone-resistant MCF7 cells by Hoechst 33342 assay,Confirmatory,18678495.0,
431,365463,10,5,,103230651,5284373,Active,296439301.0,4363.0,4.78,IC50,Inhibition of human MRP1 in human 2008 cells,Confirmatory,18707884.0,
432,365464,10,5,,103230651,5284373,Active,308153583.0,1244.0,13.6,IC50,Inhibition of human MRP2 expressed in dog MDCK2 cells,Confirmatory,18707884.0,
433,365465,7,1,,103230651,5284373,Active,238054374.0,5243.0,4.92,IC50,Inhibition of P-gp in human A2780 cells,Confirmatory,18707884.0,
434,376750,8,1,,103230651,5284373,Active,,,0.012,IC50,Antiproliferative activity against human PBMC,Confirmatory,15679309.0,
435,386356,7,1,,103230651,5284373,Active,,,,,Inhibition of cross-linking of human Pgp TM6 L339C/TM7 F728C mutant expressed in HEK293 cells assessed as drug level causing 50% inhibition of cross linking by immunoblot,Other,17848563.0,
436,386357,7,1,,103230651,5284373,Active,,,,,Inhibition of cross-linking of human Pgp TM1 L65R/TM6 L339C/TM7 F728 mutant expressed in HEK293 cells assessed as drug level causing 50% inhibition of cross linking by immunoblot,Other,17848563.0,
437,386358,7,1,,103230651,5284373,Active,,,,,Inhibition of cross-linking of human Pgp TM3T199R/TM6 L339C/TM7 F728C mutant expressed in HEK293 cells assessed as drug level causing 50% inhibition of cross linking by immunoblot,Other,17848563.0,
438,386359,7,1,,103230651,5284373,Active,,,,,Inhibition of cross-linking of human Pgp TM5 I306R/TM6 L339C/TM7 F728C mutant expressed in HEK293 cells assessed as drug level causing 50% inhibition of cross linking by immunoblot,Other,17848563.0,
439,386360,7,1,,103230651,5284373,Active,,,,,Inhibition of cross-linking of human Pgp TM6 F343R/TM6 L339C/TM7 F728C mutant expressed in HEK293 cells assessed as drug level causing 50% inhibition of cross linking by immunoblot,Other,17848563.0,
440,386623,4,8,,103230651,5284373,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
441,393837,4,3,,103230651,5284373,Unspecified,,,10.0,IC50,Inhibition of IL2-induced proliferation of human T cells assessed as [3H]thymidine incorporation after 72 hrs by scintillation counting,Confirmatory,14593182.0,
442,393839,4,4,,103230651,5284373,Unspecified,,,10.0,IC50,Inhibition of fetal calf serum-induced proliferation of human foreskin fibroblast assessed as [3H]thymidine incorporation after 4 days by scintillation counting,Confirmatory,14593182.0,
443,393840,4,3,,103230651,5284373,Active,,,0.07400000000000001,IC50,Inhibition of allogenic cells-stimulated proliferation in human T cells by mixed lymphocyte reaction method,Confirmatory,14593182.0,
444,393841,4,3,,103230651,5284373,Inconclusive,,,,IC50,Inhibition of allogenic cells-stimulated proliferation in monkey T cells by mixed lymphocyte reaction method,Confirmatory,14593182.0,
445,393842,4,3,,103230651,5284373,Active,,,0.032,IC50,Inhibition of allogenic cells-stimulated proliferation in mouse T cells by mixed lymphocyte reaction method,Confirmatory,14593182.0,
446,394030,6,1,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in po dosed kidney transplanted cynomolgus monkey assessed as graft survival at 150 to 300 ng/ml trough level,Other,14593182.0,
447,394065,4,3,,103230651,5284373,Unspecified,,,10.0,IC50,Inhibition of human GM-CSF-induced proliferation in human HUO3 cells assessed as [3H]thymidine incorporation after 4 days by scintillation counting,Confirmatory,14593182.0,
448,394913,3,4,,103230651,5284373,Unspecified,,,,,"Effect on humoral immune response in sheep red blood cells-immunized CBA mouse spleen assessed as number of antibody forming unit per 10'6 viable cells at 10 ug, ip by local hemolysis assay",Other,18358570.0,
449,394914,3,4,,103230651,5284373,Unspecified,,,,,"Effect on humoral immune response in sheep red blood cells-immunized CBA mouse spleen assessed as number of antibody forming unit per 10'6 viable cells at 100 ug, ip by local hemolysis assay",Other,18358570.0,
450,394915,3,4,,103230651,5284373,Unspecified,,,,,"Effect on delayed type hypersensitivity in sheep red blood cells-immunized CBA mouse assessed as foot-pad edema at 10 ug, ip",Other,18358570.0,
451,394916,3,4,,103230651,5284373,Unspecified,,,,,"Effect on delayed type hypersensitivity in sheep red blood cells-immunized CBA mouse assessed as foot-pad edema at 100 ug, ip",Other,18358570.0,
452,394929,3,5,,103230651,5284373,Unspecified,,,,,Effect on cancavalin-A-induced proliferation in mouse splenocytes at 1 ug/ml assessed as proliferation rate by MTT assay,Other,18358570.0,
453,394930,3,5,,103230651,5284373,Unspecified,,,,,Effect on cancavalin-A-induced proliferation in mouse splenocytes at 0.1 ug/ml assessed as proliferation rate by MTT assay,Other,18358570.0,
454,394931,3,5,,103230651,5284373,Unspecified,,,,,Effect on cancavalin-A-induced proliferation in mouse splenocytes at 10 ug/ml assessed as proliferation rate by MTT assay,Other,18358570.0,
455,395103,7,1,,103230651,5284373,Active,238054374.0,5243.0,1.4,IC50,Inhibition of P-glycoprotein-mediated multidrug resistance in adriamycin-resistant human A2780/ADR cells by calcein AM assay,Confirmatory,19250834.0,
456,396920,6,3,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in human T cell assessed as inhibition of mitogenesis,Other,3373220.0,
457,396921,6,3,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in guinea pig T cell assessed as inhibition of mitogenesis,Other,3373220.0,
458,396925,6,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in human lymphocytes by mixed lymphocyte reaction assay,Other,3373220.0,
459,399511,10,1,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in BALB/c mouse splenic T lymphocytes assessed as inhibition of Con A-induced cell proliferation after 72 hrs by MTT assay,Other,14738397.0,
460,399512,10,1,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in BALB/c mouse splenic B lymphocytes assessed as inhibition of LPS-induced cell proliferation after 72 hrs by MTT assay,Other,14738397.0,
461,404304,3,10,,103230651,5284373,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
462,407204,6,3,,103230651,5284373,Active,,,25.2,EC50,Inhibition of P-glycoprotein-mediated rhodamine 123 absorption in guinea-pig ileum,Confirmatory,18524592.0,
463,407205,10,5,,103230651,5284373,Active,238054374.0,5243.0,45.5,EC50,Inhibition of P-glycoprotein-mediated [3H]vinblastine transport in human Caco-2 cells,Confirmatory,18524592.0,
464,408608,3,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction at 0.01 uM,Other,18438987.0,
465,408610,3,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction at 0.06 uM,Other,18438987.0,
466,408612,3,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction at 0.08 uM,Other,18438987.0,
467,409954,4,9,,103230651,5284373,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
468,409956,4,9,,103230651,5284373,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
469,415385,6,2,,103230651,5284373,Inactive,,,,EC50,Antiviral activity against SIV in human CEM cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,19328002.0,
470,415388,3,4,,103230651,5284373,Unspecified,,,,,Antiviral activity against SIV in human CEM cells assessed as inhibition of virus-induced cytopathogenicity at 10 uM,Other,19328002.0,
471,416849,7,2,,103230651,5284373,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes DUMC112.02 by CLSI protocol,Other,17664323.0,
472,416850,7,2,,103230651,5284373,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes DUMC160.03 by CLSI protocol,Other,17664323.0,
473,416851,3,6,,103230651,5284373,Unspecified,,,,,Toxicity to human skin assessed as damage of skin integrity at 2 fold MIC administered 30 mins post inoculation followed by once in every 2 days for 7 days by scanning electron microscopy,Other,17664323.0,
474,416852,3,3,,103230651,5284373,Inactive,,,,,Antifungal activity against Trichophyton mentagrophytes DUMC160.03 infected in human skin at 2 fold MIC administered 30 mins post infection followed by once in every 2 days for 7 days by scanning electron microscopy relative to control,Other,17664323.0,
475,416864,10,5,,103230651,5284373,Unspecified,238054374.0,5243.0,,IC50,Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells,Confirmatory,17664327.0,
476,420709,6,2,,103230651,5284373,Active,,,0.88,CC50,Cytotoxicity against splenocytes after 48 hrs by MTT assay,Confirmatory,19481938.0,
477,420710,6,3,,103230651,5284373,Active,,,0.01,IC50,Immunosuppressive activity in splenocytes assessed as inhibition of concanavalin A-induced proliferation after 48 hrs by [3H]thymidine incorporation assay,Confirmatory,19481938.0,
478,420711,3,3,,103230651,5284373,Unspecified,,,,,"Selectivity index, CC50 for splenocytes to IC50 for concanavalin A-induced splenocyte proliferation",Other,19481938.0,
479,420712,6,3,,103230651,5284373,Active,,,0.07,IC50,Immunosuppressive activity in splenocytes assessed as inhibition of LPS-induced proliferation after 48 hrs by [3H]thymidine incorporation assay,Confirmatory,19481938.0,
480,420713,3,3,,103230651,5284373,Unspecified,,,,,"Selectivity index, CC50 for splenocyte to IC50 for LPS-induced splenocytes proliferation",Other,19481938.0,
481,425652,7,2,,103230651,5284373,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
482,425653,7,2,,103230651,5284373,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
483,427507,7,2,,103230651,5284373,Active,,,0.0407,IC50,Inhibition of peptidyl-prolyl isomerase activity of Cyclophilin A,Confirmatory,19691347.0,
484,428049,8,1,,103230651,5284373,Active,,,42.0,TC50,Cytotoxicity against rat H42E cells assessed as intracellular ATP level,Confirmatory,19502058.0,
485,428050,8,1,,103230651,5284373,Active,,,42.0,TC50,Cytotoxicity against rat H42E cells assessed as alteration in mitochondrial function by MTT assay,Confirmatory,19502058.0,
486,428051,3,4,,103230651,5284373,Unspecified,,,,,Antiproliferative activity against rat H42E cells assessed as cell number,Other,19502058.0,
487,428052,8,1,,103230651,5284373,Unspecified,,,75.0,TC50,Cytotoxicity against rat H42E cells assessed as release of alpha-glutathione S transferase,Confirmatory,19502058.0,
488,428053,6,3,,103230651,5284373,Active,,,0.01,IC50,Immunosuppressive activity in mouse splenocytes assessed as inhibition of allogenic mixed lymphocyte reaction,Confirmatory,19502058.0,
489,428054,4,3,,103230651,5284373,Unspecified,,,100.0,IC50,Immunosuppressive activity in LPS-activated B lymphocyte assessed as inhibition of lymphoproliferation after 3 days by beta-scintillation counting,Confirmatory,19502058.0,
490,428055,4,3,,103230651,5284373,Active,,,0.55,IC50,Immunosuppressive activity in concanavalin A-activated T cell assessed as inhibition of lymphoproliferation after 3 days by beta-scintillation counting,Confirmatory,19502058.0,
491,428060,7,1,,103230651,5284373,Unspecified,,,,,"Immunosuppressive activity in BALB/c mouse skin allografted C57BL/6 mouse assessed as survival of allograft skin at 1 mg/kg, ip administered daily",Other,19502058.0,
492,432787,5,1,,103230651,5284373,Unspecified,,,,,Effect on drug distribution assessed as posaconazole level in plasma of transplant patient by MVista microbiological assay,Other,18025114.0,
493,432788,5,1,,103230651,5284373,Unspecified,,,,,Effect on drug distribution assessed as fluconazole level in plasma of transplant patient within 11 days of testing by gas-liquid chromatography,Other,18025114.0,
494,432789,5,1,,103230651,5284373,Unspecified,,,,,Effect on drug distribution assessed as fluconazole level in plasma of transplant patient within 3 days of testing by gas-liquid chromatography,Other,18025114.0,
495,432793,3,3,,103230651,5284373,Unspecified,,,,,Effect on posaconazole-mediated antifungal activity against Candida kefyr ATCC 46764 at 200 ng/ml by MVista microbiological assay,Other,18025114.0,
496,432794,3,3,,103230651,5284373,Inactive,,,,,Antifungal activity against Candida kefyr ATCC 46764 after 14 to 18 hrs,Other,18025114.0,
497,432795,3,3,,103230651,5284373,Unspecified,,,,,Antifungal activity against Candida kefyr ATCC 46764 at 0.5 ug/ml after 14 to 18 hrs,Other,18025114.0,
498,432796,3,3,,103230651,5284373,Unspecified,,,,,Antifungal activity against Candida kefyr ATCC 46764 at 1.5 ug/ml after 14 to 18 hrs,Other,18025114.0,
499,432797,3,3,,103230651,5284373,Unspecified,,,,,Antifungal activity against Candida kefyr ATCC 46764 at 3 ug/ml after 14 to 18 hrs,Other,18025114.0,
500,432798,9,1,,103230651,5284373,Unspecified,,,,,Effect on calcineurine level in plasma of transplant patient by MVista microbiological assay,Other,18025114.0,
501,434955,1,2,,56422786,5284373,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
502,434959,1,1,,85788570,5284373,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
503,434962,1,2,,56422786,5284373,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
504,434973,1,3,,56422786,5284373,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
505,434989,1,1,,56422786,5284373,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
506,435003,1,3,,56422786,5284373,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
507,435005,1,1,,56422786,5284373,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
508,435019,1,1,,56422786,5284373,Active,,,22.12,CC50,A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Mycobacterium Tuberculosis,Confirmatory,,
509,435022,2,2,,56422786,5284373,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
510,435030,1,2,,56422786,5284373,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
511,435030,1,2,,56422786,5284373,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
512,437035,3,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-induced cell proliferation at 1 uM after 48 hrs by MTT assay,Other,19596582.0,
513,437038,3,3,,103230651,5284373,Unspecified,,,,,Cytotoxicity against BALB/c mouse splenocytes at 1 uM after 48 hrs by MTT assay,Other,19596582.0,
514,437039,3,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity against concanavalin A-induced BALB/c mouse splenocytes assessed as inhibition of [3H]thymidine incorporation at 1 uM by liquid scintillation counting,Other,19596582.0,
515,437042,3,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity against concanavalin A-induced BALB/c mouse splenocytes assessed as T-cells activation at 1 uM after 24 hrs by FACS assay,Other,19596582.0,
516,444050,7,1,,103230651,5284373,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
517,444051,6,2,,103230651,5284373,Unspecified,,,,,Total clearance in human,Other,20070106.0,
518,444052,6,2,,103230651,5284373,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
519,444053,6,2,,103230651,5284373,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
520,444054,6,1,,103230651,5284373,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
521,444055,3,3,,103230651,5284373,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
522,444056,3,3,,103230651,5284373,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
523,444057,3,3,,103230651,5284373,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
524,444058,6,2,,103230651,5284373,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
525,445148,3,4,,103230651,5284373,Active,,,0.017,IC50,Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of [3H]thymidine incorporation after 4 days by allogenic mixed lymphocyte reaction assay,Confirmatory,19827831.0,
526,445149,3,4,,103230651,5284373,Active,,,0.01,IC50,Immunosuppressive activity in human splenocytes assessed as inhibition of [3H]thymidine incorporation after 4 days by allogenic mixed lymphocyte reaction assay,Confirmatory,19827831.0,
527,448456,3,3,,103230651,5284373,Active,,,,,Induction of P-gp-mediated rhodamine 123 uptake in BBMEC,Other,19728715.0,
528,449728,1,2,,56422786,5284373,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
529,449739,1,2,,11532934,5284373,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
530,449762,1,2,,56422786,5284373,Active,,,99.29,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
531,449763,1,3,,56422786,5284373,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
532,449764,1,1,,56422786,5284373,Active,,,99.57,IC50,A High Throughput Confirmatory Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in the absence of Glycerol,Confirmatory,,
533,449768,1,1,,11532934,5284373,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
534,457181,6,1,,103230651,5284373,Unspecified,,,,,Permeability by PAMPA assay,Other,20056544.0,
535,458866,5,3,,103230651,5284373,Active,,,0.054000000000000006,IC50,Immunosuppressive activity in lymphocytes by mixed lymphocyte reaction assay,Confirmatory,20064721.0,
536,463075,1,1,,11532934,5284373,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
537,463079,1,2,,56422786,5284373,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
538,463082,1,1,,56422786,5284373,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
539,463104,1,2,,56422786,5284373,Active,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
540,463115,1,1,,11532934,5284373,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
541,463141,1,2,,56422786,5284373,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
542,463187,1,1,,11532934,5284373,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
543,463190,1,2,,56422786,5284373,Active,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
544,463195,1,2,,56422786,5284373,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
545,463210,1,2,,56422786,5284373,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
546,463212,1,1,,56422786,5284373,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
547,463213,1,3,,56422786,5284373,Inactive,285809906.0,856395.0,,,Single concentration confirmation of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
548,463254,1,1,,11532934,5284373,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
549,470249,3,4,,103230651,5284373,Unspecified,,,,,Inhibition of human PBMC proliferation assessed as [3H]thymidine uptake at 5 uM after 3 days by scintillation counting,Other,19673515.0,
550,470250,3,4,,103230651,5284373,Unspecified,,,,,Inhibition of 0.2 ug/ml PHA-stimulated human PBMC proliferation assessed as [3H]thymidine uptake at 5 uM after 3 days by scintillation counting,Other,19673515.0,
551,470251,3,4,,103230651,5284373,Unspecified,,,,,Inhibition of 5 ug/ml PHA-stimulated human PBMC proliferation assessed as [3H]thymidine uptake at 5 uM after 3 days by scintillation counting,Other,19673515.0,
552,481439,3,4,,103230651,5284373,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
553,481441,3,6,,103230651,5284373,Unspecified,,,,,Aqueous diffusivity at 37C,Other,20373811.0,
554,481442,3,6,,103230651,5284373,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
555,481444,3,4,,103230651,5284373,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20373811.0,
556,481446,5,1,,103230651,5284373,Unspecified,,,,,Effective permeability across human jejunum,Other,20373811.0,
557,482109,3,5,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of P-gp-mediated paclitaxel-resistance in P-glycoprotein-expressing human LCC-6 cells assessed as fold decrease in paclitaxel IC50 for cytotoxic activity at 1 uM after 5 days by MTS assay relative to control,Other,20560605.0,
558,484670,3,3,,103230651,5284373,Unspecified,,,,,"Immunosuppressive activity in BALB/c mouse assessed as CD3 antibody-induced IL2 production at 15 mg/kg, po relative to control",Other,20483608.0,
559,485270,1,1,,56422786,5284373,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
560,485272,1,1,,56422786,5284373,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
561,485273,2,1,,56422786,5284373,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
562,485275,1,3,,56422786,5284373,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
563,485281,1,1,,11532934,5284373,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
564,485294,1,1,,11532934,5284373,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
565,485297,1,1,,11532934,5284373,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
566,485298,1,1,,11532934,5284373,Inconclusive,,,35.4813,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
567,485299,1,1,,56422786,5284373,Active,,,,,Single concentration confirmation of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
568,485313,1,2,,11532934,5284373,Inactive,255652944.0,4864.0,4.4668,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
569,485314,1,1,,11532934,5284373,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
570,485341,1,1,,11532934,5284373,Inactive,119389684.0,,2.8184,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
571,485344,1,1,,11532934,5284373,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
572,485346,1,1,,56422786,5284373,Active,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
573,485346,1,1,,56422786,5284373,Active,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
574,485347,1,2,,11532934,5284373,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
575,485349,1,1,,11532934,5284373,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
576,485350,1,2,,92125416,5284373,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
577,485353,2,1,,11532934,5284373,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
578,485358,1,1,,11532934,5284373,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
579,485364,1,1,,11532934,5284373,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
580,485367,1,2,,11532934,5284373,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
581,488837,1,1,,11532934,5284373,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
582,488839,1,1,,56422786,5284373,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
583,488839,1,1,,56422786,5284373,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
584,488847,1,3,,56422786,5284373,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
585,488862,1,1,,56422786,5284373,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
586,488890,1,2,,56422786,5284373,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
587,488895,1,2,,56422786,5284373,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
588,488896,1,1,,56422786,5284373,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
589,488899,1,1,,56422786,5284373,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
590,488965,1,2,,56422786,5284373,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
591,488966,1,1,,56422786,5284373,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
592,488975,1,2,,56422786,5284373,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
593,488977,1,2,,56422786,5284373,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
594,489027,1,1,,56422786,5284373,Inactive,,,80.0,EC50_Mean,Dose response counterscreen for uHTS small molecule activators of the adaptive arm of the Unfolded Protein Response via a luminescent-based reporter assay,Confirmatory,,
595,489028,1,2,,56422786,5284373,Inactive,88702791.0,4194.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
596,489028,1,2,,56422786,5284373,Inactive,89993689.0,4193.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
597,489030,2,1,,56422786,5284373,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
598,489031,2,1,,56422786,5284373,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
599,489032,1,1,,56422786,5284373,Inactive,,,80.0,EC50_Mean,Dose response confirmation of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Confirmatory,,
600,492947,1,1,,11532934,5284373,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
601,492953,1,1,,56422786,5284373,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
602,492956,1,1,,56422786,5284373,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
603,492967,1,2,,92125416,5284373,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
604,492972,1,1,,56422786,5284373,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
605,493005,1,1,,56422786,5284373,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
606,493008,1,1,,56422786,5284373,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
607,493008,1,1,,56422786,5284373,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
608,493008,1,1,,56422786,5284373,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
609,493008,1,1,,56422786,5284373,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
610,493011,1,1,,56422786,5284373,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
611,493012,1,1,,56422786,5284373,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
612,493014,1,1,,11532934,5284373,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
613,493033,1,2,,92125416,5284373,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
614,493036,1,2,,56422786,5284373,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
615,493056,1,1,,11532934,5284373,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
616,493084,1,1,,11532934,5284373,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
617,493087,1,1,,56422786,5284373,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
618,493091,1,1,,56422786,5284373,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
619,493098,1,1,,56422786,5284373,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
620,493131,1,1,,56422786,5284373,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
621,493140,1,1,,103914170,5284373,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
622,493160,1,1,,56422786,5284373,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
623,493187,1,2,,56422786,5284373,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
624,493244,1,1,,56422786,5284373,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
625,493244,1,1,,56422786,5284373,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
626,493244,1,1,,56422786,5284373,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
627,493244,1,1,,56422786,5284373,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
628,495176,4,2,,103230651,5284373,Active,,,0.0037,IC50,Inhibition of PPIase activity of cyclophilin 18 by protease coupled assay,Confirmatory,19734911.0,
629,496010,2,4,,103230651,5284373,Unspecified,,,,,Cytotoxicity against human Jurkat cells at 0.416 uM after 18 hrs,Other,19933795.0,
630,496013,4,2,,103230651,5284373,Active,,,,EC50,Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay,Confirmatory,19933795.0,
631,496018,3,8,,103230651,5284373,Active,51702775.0,5478.0,,,Inhibition of calcineurin phosphatase activity of human recombinant CyPA at 5 uM after 30 mins,Other,19933795.0,
632,496019,4,2,,103230651,5284373,Active,,,0.005,EC50,Antiinflammatory activity in human Jurkat cells assessed as inhibition of anti-CD3/CD28 antibody-induced IL-2 production treated for 1 hr before anti-CD3/CD28 antibody challenge measured after 6 hrs by immunosuppression assay,Confirmatory,19933795.0,
633,496020,2,5,,103230651,5284373,Unspecified,,,,,Plasma protein binding in human after 30 min by ultrafiltration,Other,19933795.0,
634,496022,4,1,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of human MDR1-mediated permeability from apical to basolateral side of transfected MDCK2 cells at 5 uM after 1 to 2 hrs by HPLC analysis,Other,19933795.0,
635,496024,4,1,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of human MDR1-mediated permeability from apical to basolateral side of transfected MDCK2 cells at 3 uM after 1 to 2 hrs by HPLC analysis,Other,19933795.0,
636,496026,4,1,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of human MDR1-mediated permeability from basolateral to apical side of transfected MDCK2 cells at 5 uM after 1 to 2 hrs by HPLC analysis,Other,19933795.0,
637,496028,4,1,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of human MDR1-mediated permeability from basolateral to apical side of transfected MDCK2 cells at 3 uM after 1 to 2 hrs by HPLC analysis,Other,19933795.0,
638,496030,2,11,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of human MDR1-mediated permeability in transfected MDCK2 cells assessed as efflux ratio of permeability form apical to basolateral over basolateral to apical side at 5 uM after 1 to 2 hrs by HPLC analysis,Other,19933795.0,
639,496032,2,11,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of human MDR1-mediated permeability in transfected MDCK2 cells assessed as efflux ratio of permeability form apical to basolateral over basolateral to apical side at 3 uM after 1 to 2 hrs by HPLC analysis,Other,19933795.0,
640,496033,4,4,,103230651,5284373,Unspecified,,,,,Intrinsic clearance in CD1 mouse liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH,Other,19933795.0,
641,496034,4,4,,103230651,5284373,Unspecified,,,,,Intrinsic clearance in human liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH,Other,19933795.0,
642,496035,4,3,,103230651,5284373,Unspecified,,,,,Half life in CD1 mouse liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH,Other,19933795.0,
643,496036,2,4,,103230651,5284373,Unspecified,,,,,Cytotoxicity against human Huh7ET cells assessed as lactate dehydrogenase release up to 10 uM after 72 hrs,Other,19933795.0,
644,496038,4,3,,103230651,5284373,Unspecified,,,,,Half life in human liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH,Other,19933795.0,
645,496039,4,7,,103230651,5284373,Active,116241312.0,1576.0,6.6,IC50,Inhibition of human recombinant CYP3A4 after 30 mins,Confirmatory,19933795.0,
646,496040,4,7,,103230651,5284373,Active,60416369.0,1557.0,7.0,IC50,Inhibition of human recombinant CYP2C19 after 30 mins,Confirmatory,19933795.0,
647,496041,4,7,,103230651,5284373,Active,6686268.0,1559.0,38.8,IC50,Inhibition of human recombinant CYP2C9 after 30 mins,Confirmatory,19933795.0,
648,496042,4,7,,103230651,5284373,Unspecified,117144.0,1544.0,100.0,IC50,Inhibition of human recombinant CYP1A2 after 30 mins,Confirmatory,19933795.0,
649,496043,4,7,,103230651,5284373,Unspecified,84028191.0,1565.0,100.0,IC50,Inhibition of human recombinant CYP2D6 after 30 mins,Confirmatory,19933795.0,
650,496156,2,4,,103230651,5284373,Unspecified,,,,,"Selectivity index, ratio of CC50 for human Huh7ET cells to EC50 for Hepatitis C virus infected in human Huh7ET cells",Other,19933795.0,
651,496158,2,7,,103230651,5284373,Unspecified,,,,,Inhibition of calcineurin phosphatase activity of CyPA at 0.12 uM,Other,19933795.0,
652,496160,6,2,,103230651,5284373,Active,,,0.00264,Ki,Inhibition of calcineurin phosphatase activity of CyPA,Confirmatory,19933795.0,
653,496163,4,2,,103230651,5284373,Active,,,0.0031,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3/CD28 antibody-induced IL-2 production treated for 1 hr before anti-CD3/CD28 antibody challenge measured after 6 hrs by immunosuppression assay,Confirmatory,19933795.0,
654,496165,2,4,,103230651,5284373,Unspecified,,,,,Cytotoxicity against human PBMC assessed as inhibition of cell proliferation at 0.3 uM after 18 hrs,Other,19933795.0,
655,496779,3,4,,103230651,5284373,Active,,,,,Inhibition of hexose-6-phosphate dehydrogenase-induced cell differentiation in mouse C2C12 cells assessed as myosin heavy chain fluorescence at 0.1 ug/ml for 3 days,Other,20081855.0,
656,496785,3,4,,103230651,5284373,Active,,,,,Inhibition of serum withdrawal-induced cell differentiation in mouse C2C12 cells assessed as myosin heavy chain expression,Other,20081855.0,
657,497686,5,5,,103230651,5284373,Active,51702775.0,5478.0,0.1,IC50,Binding affinity to human cyclophilin 18,Confirmatory,19734911.0,
658,497687,5,5,,103230651,5284373,Active,51702775.0,5478.0,0.009000000000000001,Kd,Binding affinity to human cyclophilin 18 assessed as reduction in calcineurin activity,Confirmatory,19734911.0,
659,501984,3,3,,103230651,5284373,Active,,,,,Inhibition of irradiated BALB/c mouse splenocyte-stimulated IL2 secretion in 2C mouse splenocyte at 100 ng/mL after 24 hrs by mixed lymphocyte reaction,Other,20674367.0,
660,504326,1,2,,56422786,5284373,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
661,504326,1,2,,56422786,5284373,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
662,504327,1,1,,11532934,5284373,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
663,504329,1,1,,56422786,5284373,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
664,504332,1,1,,11532934,5284373,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
665,504333,1,1,,11532934,5284373,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
666,504339,1,1,,56422786,5284373,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
667,504357,1,1,,56422786,5284373,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
668,504357,1,1,,56422786,5284373,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
669,504406,1,1,,56422786,5284373,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
670,504411,1,1,,56422786,5284373,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
671,504414,1,1,,56422786,5284373,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
672,504414,1,1,,56422786,5284373,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
673,504423,1,1,,56422786,5284373,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
674,504441,1,1,,56422786,5284373,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
675,504444,1,1,,56422786,5284373,Active,224028257.0,4780.0,6.5131,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
676,504454,1,3,,56422786,5284373,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
677,504462,1,1,,56422786,5284373,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
678,504466,1,1,,11532934,5284373,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
679,504467,1,1,,11532934,5284373,Inconclusive,116283940.0,79915.0,8.1961,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
680,504490,1,2,,56422786,5284373,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
681,504523,1,1,,56422786,5284373,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
682,504523,1,1,,56422786,5284373,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
683,504558,1,1,,56422786,5284373,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
684,504577,2,2,,56422786,5284373,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
685,504582,2,1,,56422786,5284373,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
686,504621,1,1,,56422786,5284373,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
687,504634,1,1,,56422786,5284373,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
688,504648,1,1,,56422786,5284373,Inconclusive,,,5.8048,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
689,504651,1,1,,11532934,5284373,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
690,504652,1,1,,11532934,5284373,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
691,504660,1,1,,11532934,5284373,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
692,504690,1,3,,56422786,5284373,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
693,504692,2,2,,56422786,5284373,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
694,504700,1,1,,56422786,5284373,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
695,504700,1,1,,56422786,5284373,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
696,504706,1,1,,11532934,5284373,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
697,504707,1,1,,56422786,5284373,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
698,504707,1,1,,56422786,5284373,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
699,504720,1,1,,56422786,5284373,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
700,504734,1,1,,56422786,5284373,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
701,504766,2,1,,56422786,5284373,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
702,504775,1,1,,56422786,5284373,Active,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
703,504803,1,1,,56422786,5284373,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
704,504810,1,2,,11532934,5284373,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
705,504812,1,2,,11532934,5284373,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
706,504832,1,1,,11532934,5284373,Active,,,0.3294,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
707,504834,1,1,,11532934,5284373,Active,,,0.3294,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
708,504842,1,1,,11532934,5284373,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
709,504845,1,1,,56422786,5284373,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
710,504847,1,1,,56422786,5284373,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
711,504884,1,2,,56422786,5284373,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
712,504891,1,1,,56422786,5284373,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
713,504894,1,1,,56422786,5284373,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
714,504937,1,2,,56422786,5284373,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
715,521220,3,3,,103230651,5284373,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
716,523609,4,3,,103230651,5284373,Active,,,0.21,EC50,Antiviral activity against HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay,Confirmatory,20176894.0,
717,523610,4,3,,103230651,5284373,Active,,,3.39,EC50,Antiviral activity against cyclosporine A-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay,Confirmatory,20176894.0,
718,523611,4,3,,103230651,5284373,Unspecified,,,10.0,EC50,Antiviral activity against cyclosporine A/NIM-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay,Confirmatory,20176894.0,
719,524790,7,2,,103230651,5284373,Active,,,0.00063,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
720,524791,7,2,,103230651,5284373,Active,,,0.00056,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
721,524792,7,2,,103230651,5284373,Active,,,0.00126,IC50,Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
722,524793,7,2,,103230651,5284373,Active,,,0.0007099999999999999,IC50,Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
723,524794,7,1,,103230651,5284373,Active,,,0.00056,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
724,524795,7,2,,103230651,5284373,Active,,,0.0008300000000000001,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
725,524796,7,1,,103230651,5284373,Active,,,0.00047000000000000004,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
726,528322,4,2,,103230651,5284373,Active,,,0.008329999999999999,IC50,Binding affinity to cyclophilin A by ELISA,Confirmatory,20943390.0,
727,528323,4,2,,103230651,5284373,Active,,,0.00878,IC50,Binding affinity to cyclophilin B by ELISA,Confirmatory,20943390.0,
728,528324,2,5,,103230651,5284373,Active,,,0.0067,EC50,Immunosuppressive activity against human Jurkat cells assessed as inhibition of phytohemagglutinin-M/phorbol myristate acetate-induced IL2 production,Confirmatory,20943390.0,
729,528325,2,4,,103230651,5284373,Active,,,0.37,EC50,Antiviral activity against HCV after 72 hrs by stable luciferase reporter gene assay,Confirmatory,20943390.0,
730,528326,2,5,,103230651,5284373,Active,,,5.81,IC50,Cytotoxicity against human HuH7 cells assessed as release of lactate dehydrogenase,Confirmatory,20943390.0,
731,540209,4,3,,103230651,5284373,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
732,540210,4,3,,103230651,5284373,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
733,540211,2,5,,103230651,5284373,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
734,540212,4,3,,103230651,5284373,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
735,540213,4,3,,103230651,5284373,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
736,540234,2,5,,103230651,5284373,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
737,540253,1,1,,56422786,5284373,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
738,540253,1,1,,56422786,5284373,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
739,540253,1,1,,56422786,5284373,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
740,540263,1,1,,56422786,5284373,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
741,540263,1,1,,56422786,5284373,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
742,540267,1,1,,56422786,5284373,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
743,540275,1,1,,11532934,5284373,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
744,540277,1,1,,11532934,5284373,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
745,540295,1,1,,56422786,5284373,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
746,540299,1,2,,92125416,5284373,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
747,540303,1,1,,56422786,5284373,Inconclusive,6679377.0,18792.0,2.5119,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
748,540303,1,1,,56422786,5284373,Inconclusive,7242179.0,18793.0,2.5119,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
749,540303,1,1,,56422786,5284373,Inconclusive,257471003.0,18815.0,2.5119,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
750,540308,1,1,,56422786,5284373,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
751,540317,1,1,,56422786,5284373,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
752,540336,1,1,,56422786,5284373,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
753,540336,1,1,,56422786,5284373,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
754,540364,1,2,,56422786,5284373,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
755,555950,4,3,,103230651,5284373,Active,,,0.35,EC50,Antiviral activity against compound-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR,Confirmatory,19104013.0,
756,555951,4,3,,103230651,5284373,Active,,,3.85,EC50,Antiviral activity against cyclosporine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR,Confirmatory,19104013.0,
757,555952,4,3,,103230651,5284373,Active,,,0.4,EC50,Antiviral activity against 2'-C-methyl-2'-fluoro-cytidine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR,Confirmatory,19104013.0,
758,555953,4,3,,103230651,5284373,Active,,,1.98,EC50,Antiviral activity against R479-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR,Confirmatory,19104013.0,
759,555954,4,3,,103230651,5284373,Active,,,0.004,EC50,Antiviral activity against BILN 2061-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR,Confirmatory,19104013.0,
760,555955,4,3,,103230651,5284373,Active,,,0.49,EC50,Antiviral activity against VX 950-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR,Confirmatory,19104013.0,
761,558940,2,4,,103230651,5284373,Unspecified,,,,,Cytotoxicity against human Huh7.5 cells assessed as cell viability at =< 40 uM after 48 hrs by MTT assay,Other,19451286.0,
762,558941,1,3,,103230651,5284373,Active,,,,,Antiviral activity against West Nile virus infected in human Huh7.5 cells at 8 to 20 uM after 48 hrs by plaque formation assay,Other,19451286.0,
763,558942,1,3,,103230651,5284373,Active,,,,,Antiviral activity against Dengue virus 2 infected in human Huh7.5 cells at 8 to 20 uM after 48 hrs by plaque formation assay,Other,19451286.0,
764,558943,1,3,,103230651,5284373,Active,,,,,Antiviral activity against Yellow fever virus infected in human Huh7.5 cells at 8 to 20 uM after 48 hrs by plaque formation assay,Other,19451286.0,
765,558944,2,3,,103230651,5284373,Active,,,,,Antiviral activity against Western equine encephalomyelitis virus infected in human Huh7.5 cells at 8 to 20 uM after 48 hrs by plaque formation assay,Other,19451286.0,
766,558945,1,3,,103230651,5284373,Active,,,,,Antiviral activity against Vesicular stomatitis virus infected in human Huh7.5 cells at 8 to 20 uM after 16 hrs by plaque formation assay,Other,19451286.0,
767,558946,1,3,,103230651,5284373,Active,,,,,Antiviral activity against Dengue virus 2 infected in human Huh7.5 cells at 8 to 20 uM after 48 hrs,Other,19451286.0,
768,558947,1,3,,103230651,5284373,Inactive,,,,,Antiviral activity against West Nile virus infected in human Huh7.5 cells at 8 uM after 48 hrs,Other,19451286.0,
769,558948,1,3,,103230651,5284373,Active,,,,,Antiviral activity against West Nile virus infected in human Huh7.5 cells at 20 uM after 48 hrs,Other,19451286.0,
770,558949,1,3,,103230651,5284373,Unspecified,,,,,Antiviral activity against West Nile virus infected in CyPA-deficient human Huh7.5 cells assessed as decrease in viral replication at 4 uM after 24 hrs by luciferase reporter gene assay,Other,19451286.0,
771,558950,1,3,,103230651,5284373,Unspecified,,,,,Antiviral activity against West Nile virus infected in CyPA-deficient human Huh7.5 cells assessed as decrease in viral replication at 8 uM after 24 hrs by luciferase reporter gene assay,Other,19451286.0,
772,558951,1,3,,103230651,5284373,Unspecified,,,,,Antiviral activity against West Nile virus infected in human Huh7.5 cells assessed as decrease in viral replication at 4 uM after 24 hrs by luciferase reporter gene assay,Other,19451286.0,
773,558952,1,3,,103230651,5284373,Unspecified,,,,,Antiviral activity against West Nile virus infected in human Huh7.5 cells assessed as decrease in viral replication at 8 uM after 24 hrs by luciferase reporter gene assay,Other,19451286.0,
774,558953,5,2,,103230651,5284373,Active,,,8.0,IC50,Antiviral activity against West Nile virus infected in african green monkey Vero cells assessed as decrease in viral RNA synthesis after 24 hrs by luciferase reporter gene assay,Confirmatory,19451286.0,
775,558954,1,4,,103230651,5284373,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells at =< 10 uM after 48 hrs by MTT assay,Other,19451286.0,
776,558955,5,2,,103230651,5284373,Unspecified,,,0.5,IC50,Antiviral activity against Dengue virus 1 infected in african green monkey Vero cells assessed as decrease in viral RNA synthesis after 24 hrs by luciferase reporter gene assay,Confirmatory,19451286.0,
777,558956,3,3,,103230651,5284373,Inactive,,,,,Antiviral activity against West Nile virus infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after =< 6 hrs by luciferase reporter gene assay,Other,19451286.0,
778,558957,3,3,,103230651,5284373,Inactive,,,,,Antiviral activity against Dengue virus 1 infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after =< 6 hrs by luciferase reporter gene assay,Other,19451286.0,
779,558958,3,3,,103230651,5284373,Inactive,,,,,Antiviral activity against Yellow fever virus infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after =< 6 hrs by luciferase reporter gene assay,Other,19451286.0,
780,558959,1,3,,103230651,5284373,Unspecified,,,,,Antiviral activity against West Nile virus infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after => 20 hrs by luciferase reporter gene assay,Other,19451286.0,
781,558960,1,3,,103230651,5284373,Unspecified,,,,,Antiviral activity against Dengue virus 1 infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after => 20 hrs by luciferase reporter gene assay,Other,19451286.0,
782,558961,1,3,,103230651,5284373,Unspecified,,,,,Antiviral activity against Yellow fever virus infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after => 20 hrs by luciferase reporter gene assay,Other,19451286.0,
783,558962,3,3,,103230651,5284373,Inactive,,,,,Inhibition of West Nile virus protease up to 100 uM,Other,19451286.0,
784,558963,3,3,,103230651,5284373,Inactive,,,,,Inhibition of West Nile virus nucleoside-triphosphatase up to 100 uM,Other,19451286.0,
785,558964,3,3,,103230651,5284373,Inactive,,,,,Inhibition of West Nile virus RdRp up to 100 uM,Other,19451286.0,
786,558965,3,3,,103230651,5284373,Active,,,,,Inhibition of West Nile virus NS5 polymerase at 0.8 uM,Other,19451286.0,
787,566105,4,3,,103230651,5284373,Active,,,0.054000000000000006,IC50,Immunosuppressive activity in peripheral blood lymphocytes isolated from two individuals assessed as proliferation using [methyl-3H]thymidine by mixed lymphocyte reaction assay,Confirmatory,21171614.0,
788,566106,2,4,,103230651,5284373,Unspecified,,,,,"Suppression of cardiac allograft rejection of C57BL/6 mouse to BALB/c mouse assessed as surviving days at 40 mg/kg, po treatment started from day of transplantation for 30 days by immunosuppressive assay",Other,21171614.0,
789,567808,4,3,,103230651,5284373,Active,,,15.82,CC50,Cytotoxicity against BALB/c mouse T cells after 48 hrs by MTT assay,Confirmatory,21131104.0,
790,567809,4,2,,103230651,5284373,Active,,,0.06,IC50,Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of anti-CD3/anti-CD28-stimulated cell proliferation after 72 hrs by MTT assay,Confirmatory,21131104.0,
791,567810,2,4,,103230651,5284373,Unspecified,,,,,"Selectivity index, ratio of CC50 for BALB/c mouse T cells to IC50 for immunosuppressive activity in BALB/c mouse T cells",Other,21131104.0,
792,573105,4,3,,103230651,5284373,Active,,,7.0,CC50,Cytotoxicity against human HuH6 cells after 3 days by MTT assay,Confirmatory,18625766.0,
793,573106,4,3,,103230651,5284373,Active,,,7.0,CC50,Cytotoxicity against human Huh-9-13 cells after 3 days by MTT assay,Confirmatory,18625766.0,
794,573107,4,3,,103230651,5284373,Active,,,24.0,CC50,Cytotoxicity against human Huh-Mono cells after 3 days by MTT assay,Confirmatory,18625766.0,
795,573108,4,3,,103230651,5284373,Active,,,0.3,EC50,Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay,Confirmatory,18625766.0,
796,573109,4,3,,103230651,5284373,Active,,,0.5,EC50,Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-9-13 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis,Confirmatory,18625766.0,
797,573110,4,3,,103230651,5284373,Active,,,0.24,EC50,Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH6 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis,Confirmatory,18625766.0,
798,573111,4,3,,103230651,5284373,Active,,,0.3,EC50,Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-Mono cells assessed as reduction in replicon RNA after 4 days by RT-qPCR analysis,Confirmatory,18625766.0,
799,573112,4,3,,103230651,5284373,Active,,,6.0,CC50,Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay,Confirmatory,18625766.0,
800,580942,10,2,,103230651,5284373,Active,238054374.0,5243.0,0.67,IC50,Inhibition of human MDR1 expressed in mouse L5178 cells assessed as increase in intracellular accumulation of rhodamine 123 by FACSCalibur flow cytometry,Confirmatory,24900226.0,
801,580951,4,2,,103230651,5284373,Active,,,0.034,Ki,Inhibition of Cyclophilin 40 PPIase activity,Confirmatory,24900244.0,
802,580952,4,2,,103230651,5284373,Active,,,0.22699999999999998,Ki,Inhibition of Cyclophilin 18 PPIase activity,Confirmatory,24900244.0,
803,580955,4,2,,103230651,5284373,Active,,,0.231,Ki,Inhibition of fluorescein labeled cyclosporin binding to Cyp18 by fluorescence polarization competition assay,Confirmatory,24900244.0,
804,580956,4,2,,103230651,5284373,Active,,,0.006999999999999999,Ki,Inhibition of fluorescein labeled cyclosporin binding to Cyp40 by fluorescence polarization competition assay,Confirmatory,24900244.0,
805,581763,2,3,,103230651,5284373,Unspecified,,,,,"Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent T lymphocytes at 10 mg/kg, po administered once daily for 28 days by flow cytometry",Other,18212100.0,
806,581766,1,5,,103230651,5284373,Unspecified,,,,,Antiproliferative activity against CD4+ human PBMC assessed as inhibition of [3H]thymidine incorporation at 0.83 uM after 18 hrs,Other,18212100.0,
807,581767,2,3,,103230651,5284373,Unspecified,,,,,"Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as IgM level at 10 mg/kg, po administered once daily for 28 days by ELISA",Other,18212100.0,
808,581768,4,3,,103230651,5284373,Active,,,0.055999999999999994,IC50,Antiproliferative activity against mouse PBMC with MLR assessed as inhibition of [3H]thymidine incorporation after 18 hrs,Confirmatory,18212100.0,
809,581770,1,4,,103230651,5284373,Unspecified,,,,,Cytotoxicity against human PBMC at 0.83 uM by MTT assay,Other,18212100.0,
810,581771,1,4,,103230651,5284373,Unspecified,,,,,Cytotoxicity against human MT4 cells at 0.83 uM by MTT assay,Other,18212100.0,
811,581772,1,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in human Jurkat cells assessed as inhibition of PHA-phorbol myristate acetate induced beta-galactosidase activity at 0.003 uM,Other,18212100.0,
812,581774,4,2,,103230651,5284373,Active,,,0.54,IC50,Antiviral activity against HIV-1 SF2 infected in human PBMC assessed as inhibition of viral replication by ELISA,Confirmatory,18212100.0,
813,581776,4,2,,103230651,5284373,Active,,,0.45,IC50,Antiviral activity against HIV-1 3B infected in human PBMC assessed as inhibition of viral replication by ELISA,Confirmatory,18212100.0,
814,581777,4,2,,103230651,5284373,Unspecified,,,0.83,IC50,Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay,Confirmatory,18212100.0,
815,581778,5,5,,103230651,5284373,Active,51702775.0,5478.0,0.00979,Ki,Inhibition of human recombinant cyclophilin-associted cis-trans propyl isomerase activity,Confirmatory,18212100.0,
816,581779,2,3,,103230651,5284373,Unspecified,,,,,"Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent T-helper cells at 10 mg/kg, po administered once daily for 28 days by flow cytometry",Other,18212100.0,
817,581782,2,3,,103230651,5284373,Unspecified,,,,,"Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent cytotoxic T cells at 10 mg/kg, po administered once daily for 28 days by flow cytometry",Other,18212100.0,
818,581919,4,2,,103230651,5284373,Unspecified,,,25.0,IC50,Antiviral activity against Coxsackie B3 infected in african green monkey Vero cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
819,581920,3,1,,103230651,5284373,Active,,,16.6,TC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,18212100.0,
820,581921,4,2,,103230651,5284373,Unspecified,,,14.8,IC50,Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
821,581922,4,2,,103230651,5284373,Unspecified,,,14.8,IC50,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
822,581923,3,1,,103230651,5284373,Active,,,9.9,TC50,Cytotoxicity against MDCK cells,Confirmatory,18212100.0,
823,581924,4,2,,103230651,5284373,Unspecified,,,14.8,IC50,Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
824,581925,4,2,,103230651,5284373,Inconclusive,,,,IC50,Antiviral activity against Parainfluenza 3 infected in african green monkey Vero cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
825,581926,4,2,,103230651,5284373,Unspecified,,,8.3,IC50,Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
826,581927,3,1,,103230651,5284373,Active,,,8.3,TC50,Cytotoxicity against human HeLa cells,Confirmatory,18212100.0,
827,581928,4,2,,103230651,5284373,Unspecified,,,8.3,IC50,Antiviral activity against VSV infected in human embryonic lung cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
828,581929,3,2,,103230651,5284373,Active,,,8.3,TC50,Cytotoxicity against human embryonic lung cells,Confirmatory,18212100.0,
829,581930,4,2,,103230651,5284373,Unspecified,,,8.3,IC50,Antiviral activity against SARS coronavirus infected in african green monkey Vero cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
830,581931,4,2,,103230651,5284373,Active,,,1.5,IC50,Antiviral activity against Feline coronavirus infected in CRFK assessed as inhibition of viral replication,Confirmatory,18212100.0,
831,581932,3,1,,103230651,5284373,Active,,,10.0,TC50,Cytotoxicity against CRFK,Confirmatory,18212100.0,
832,581933,4,2,,103230651,5284373,Active,,,2.3,IC50,Antiviral activity against HCV infected in human Huh 5.2 cells assessed as reduction in viral RNA level by luciferase reporter gene assay,Confirmatory,18212100.0,
833,581934,4,2,,103230651,5284373,Unspecified,,,9.9,IC50,Antiviral activity against BVDV infected in MDCK cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
834,581935,4,2,,103230651,5284373,Unspecified,,,16.6,IC50,Antiviral activity against Yellow fever virus 17D infected in african green monkey Vero cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
835,581936,3,2,,103230651,5284373,Active,,,10.0,TC50,Cytotoxicity against human Huh 5.2 cells,Confirmatory,18212100.0,
836,581937,4,2,,103230651,5284373,Unspecified,,,8.3,IC50,Antiviral activity against Herpes simplex virus 1 KOS infected in human embryonic lung cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
837,581938,4,2,,103230651,5284373,Unspecified,,,8.3,IC50,Antiviral activity against Herpes simplex virus 1 F infected in human embryonic lung cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
838,581939,4,2,,103230651,5284373,Unspecified,,,8.3,IC50,Antiviral activity against Herpes simplex virus 1 McIntyre infected in human embryonic lung cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
839,581940,4,4,,103230651,5284373,Unspecified,,,8.3,IC50,Antiviral activity against Herpes simplex virus 2 G infected in human embryonic lung cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
840,581941,4,2,,103230651,5284373,Unspecified,,,8.3,IC50,Antiviral activity against Herpes simplex virus 2 196 infected in human embryonic lung cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
841,581942,4,2,,103230651,5284373,Unspecified,,,8.3,IC50,Antiviral activity against Herpes simplex virus 2 Lyons infected in human embryonic lung cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
842,581943,4,2,,103230651,5284373,Active,,,3.3,IC50,Antiviral activity against VZV OKA infected in human embryonic lung cells assessed as inhibition of,Confirmatory,18212100.0,
843,581944,4,2,,103230651,5284373,Unspecified,,,18.3,IC50,Antiviral activity against Human cytomegalovirus AD169 infected in human embryonic lung cells assessed as reduction in viral yield,Confirmatory,18212100.0,
844,581945,4,2,,103230651,5284373,Unspecified,,,18.3,IC50,Antiviral activity against Human cytomegalovirus Davis infected in human embryonic lung cells assessed as reduction in viral yield,Confirmatory,18212100.0,
845,581946,4,2,,103230651,5284373,Inconclusive,,,,IC50,Antiviral activity against HBV infected in human hepAD38 cells assessed as inhibition of viral replication,Confirmatory,18212100.0,
846,581947,4,2,,103230651,5284373,Unspecified,,,8.3,IC50,Antiviral activity against Vaccinia virus infected in human embryonic lung cells assessed as reduction in viral yield measured after 3 days,Confirmatory,18212100.0,
847,581948,4,2,,103230651,5284373,Active,,,0.4,IC50,Antiviral activity against HPV-16 infected in Caski cells assessed as inhibition of viral replication after 3 days,Confirmatory,18212100.0,
848,581949,4,2,,103230651,5284373,Active,,,6.6,IC50,Antiviral activity against HPV-18 infected in human HeLa cells assessed as inhibition of viral replication after 3 days,Confirmatory,18212100.0,
849,581950,4,2,,103230651,5284373,Active,,,0.7,IC50,Antiviral activity against HPV-33 infected in CK1 cells assessed as inhibition of viral replication after 3 days,Confirmatory,18212100.0,
850,581951,3,1,,103230651,5284373,Active,,,0.3,TC50,Antiviral activity against HPV-16 infected in Caski cells assessed as inhibition of viral replication after 7 days,Confirmatory,18212100.0,
851,581952,3,1,,103230651,5284373,Active,,,4.6,TC50,Antiviral activity against HPV-18 infected in human HeLa cells assessed as inhibition of viral replication after 7 days,Confirmatory,18212100.0,
852,581953,3,1,,103230651,5284373,Active,,,0.3,TC50,Antiviral activity against HPV-33 infected in CK1 cells assessed as inhibition of viral replication after 7 days,Confirmatory,18212100.0,
853,581958,3,2,,103230651,5284373,Inconclusive,,,,TC50,Cytotoxicity against human HepAD38 cells,Confirmatory,18212100.0,
854,588209,2,3,,103230651,5284373,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
855,588210,2,4,,103230651,5284373,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
856,588211,2,3,,103230651,5284373,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
857,588212,2,3,,103230651,5284373,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
858,588213,2,3,,103230651,5284373,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
859,588334,1,1,,56422786,5284373,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
860,588335,1,1,,56422786,5284373,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
861,588342,1,1,,11532934,5284373,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
862,588352,1,2,,56422786,5284373,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
863,588354,1,1,,56422786,5284373,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
864,588358,1,2,,56422786,5284373,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
865,588391,1,1,,56422786,5284373,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
866,588405,1,1,,56422786,5284373,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
867,588413,1,2,,56422786,5284373,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
868,588436,1,1,,56422786,5284373,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
869,588453,1,1,,56422786,5284373,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
870,588456,1,1,,56422786,5284373,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
871,588458,1,1,,56422786,5284373,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
872,588473,1,1,,56422786,5284373,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
873,588473,1,1,,56422786,5284373,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
874,588475,1,2,,56422786,5284373,Active,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
875,588475,1,2,,56422786,5284373,Active,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
876,588478,1,2,,124799560,5284373,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
877,588489,1,1,,56422786,5284373,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
878,588492,1,1,,56422786,5284373,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
879,588493,1,2,,56422786,5284373,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
880,588497,1,2,,56422786,5284373,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
881,588497,1,2,,56422786,5284373,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
882,588497,1,2,,56422786,5284373,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
883,588499,1,3,,56422786,5284373,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
884,588499,1,3,,56422786,5284373,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
885,588499,1,3,,56422786,5284373,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
886,588501,1,2,,56422786,5284373,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
887,588501,1,2,,56422786,5284373,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
888,588501,1,2,,56422786,5284373,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
889,588511,1,2,,56422786,5284373,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
890,588513,1,1,,26757675,5284373,Inconclusive,348019627.0,2099.0,22.3872,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
891,588514,1,1,,26757675,5284373,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
892,588515,1,1,,26757675,5284373,Inconclusive,124375976.0,367.0,14.1254,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
893,588516,1,1,,26757675,5284373,Inconclusive,124375976.0,367.0,4.4668,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
894,588519,1,2,,92125416,5284373,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
895,588526,1,1,,26757675,5284373,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
896,588527,1,1,,26757675,5284373,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
897,588532,1,1,,26757675,5284373,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
898,588533,1,1,,26757675,5284373,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
899,588534,1,1,,26757675,5284373,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
900,588535,1,1,,26757675,5284373,Inconclusive,216409690.0,5467.0,28.1838,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
901,588536,1,1,,26757675,5284373,Inconclusive,216409692.0,5468.0,6.3096,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
902,588537,1,1,,26757675,5284373,Inconclusive,216409692.0,5468.0,10.0,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
903,588541,1,1,,26757675,5284373,Inconclusive,216409708.0,7421.0,17.7828,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
904,588543,1,1,,26757675,5284373,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
905,588544,1,1,,26757675,5284373,Inconclusive,325495497.0,6256.0,15.8489,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
906,588545,1,1,,26757675,5284373,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
907,588546,1,1,,26757675,5284373,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
908,588547,1,1,,26757675,5284373,Inconclusive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
909,588549,1,1,,56422786,5284373,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
910,588579,1,1,,56422786,5284373,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
911,588590,1,1,,56422786,5284373,Inactive,154350220.0,11201.0,89.1251,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
912,588591,1,1,,56422786,5284373,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
913,588621,1,1,,56422786,5284373,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
914,588627,1,1,,56422786,5284373,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
915,588664,1,2,,56422786,5284373,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
916,588664,1,2,,56422786,5284373,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
917,588674,1,2,,56422786,5284373,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
918,588675,1,1,,56422786,5284373,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
919,588676,1,1,,56422786,5284373,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
920,588689,1,1,,56422786,5284373,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
921,588692,2,1,,56422786,5284373,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
922,588726,1,2,,56422786,5284373,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
923,588727,1,1,,56422786,5284373,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
924,588795,1,1,,56422786,5284373,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
925,588814,1,3,,56422786,5284373,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
926,588819,1,4,,56422786,5284373,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
927,588834,2,1,,144204218,5284373,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
928,588850,1,1,,56422786,5284373,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
929,588852,1,3,,56422786,5284373,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
930,588855,1,1,,56422786,5284373,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
931,588856,1,1,,56422786,5284373,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
932,588981,1,10,,103230651,5284373,Unspecified,12643959.0,10599.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OATP1B1",Other,20190787.0,
933,588982,1,10,,103230651,5284373,Unspecified,27734563.0,28234.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OATP1B3",Other,20190787.0,
934,588987,1,10,,103230651,5284373,Unspecified,313104012.0,11309.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OATP2B1",Other,20190787.0,
935,588993,1,11,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MDR1",Other,20190787.0,
936,588995,1,9,,103230651,5284373,Unspecified,262527527.0,8647.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, BSEP",Other,20190787.0,
937,588996,1,10,,103230651,5284373,Unspecified,308153583.0,1244.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MRP2",Other,20190787.0,
938,588999,1,10,,103230651,5284373,Unspecified,126302568.0,5244.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MDR3",Other,20190787.0,
939,589039,1,10,,103230651,5284373,Unspecified,116241312.0,1576.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
940,592682,1,4,,103230651,5284373,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis,Other,21458999.0,
941,592683,1,4,,103230651,5284373,Unspecified,,,,,Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis,Other,21458999.0,
942,594598,5,2,,103230651,5284373,Active,,,0.01025,IC50,Inhibition of PPIase activity of Cyclophilin A by Spectrophotometry,Confirmatory,21396746.0,
943,594599,6,2,,103230651,5284373,Active,,,6.42,Kd,Binding affinity to Cyclophilin A,Confirmatory,21396746.0,
944,594600,1,5,,103230651,5284373,Unspecified,,,,,Cytotoxicity against human SKHEP1 cells at 20 uM after 48 hrs by MTT assay,Other,21396746.0,
945,594602,1,4,,103230651,5284373,Unspecified,,,,,Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication at 10 uM after 48 hrs by flow cytometry,Other,21396746.0,
946,595710,1,10,,103230651,5284373,Active,67462103.0,9429.0,,,Modulation of BCRP in human HCT116 cells assessed as intracellular accumulation of mitoxantrone at 10 uM after 30 mins by flow-cytometry,Other,21488686.0,
947,596404,1,4,,103230651,5284373,Active,,,0.013999999999999999,IC50,Immunosuppressive activity in BALB/c/C57BL/6 mouse T cells assessed as inhibition of alloantigen-induced cell proliferation after 96 hrs by measuring [3H]thymidine uptake by mixed lymphocyte reaction assay,Confirmatory,21456524.0,
948,596405,1,3,,103230651,5284373,Unspecified,,,,,Toxicity in ip dosed F344 rat lateral thorax transplanted with dorsal skin of LEW rat assessed as concentration required for cause death,Other,21456524.0,
949,596406,1,3,,103230651,5284373,Unspecified,,,,,"Immunosuppressive activity in F344 rat lateral thorax transplanted with dorsal skin of LEW rat assessed as increase of skin graft survival time at 1 mg/kg, ip",Other,21456524.0,
950,596407,1,3,,103230651,5284373,Unspecified,,,,,"Immunosuppressive activity in F344 rat lateral thorax transplanted with dorsal skin of LEW rat assessed as increase of skin graft survival time at 3 mg/kg, ip",Other,21456524.0,
951,596408,2,4,,103230651,5284373,Active,,,,,Inhibition of serine palmitoyltransferase in mouse spleen cells,Other,21456524.0,
952,598251,10,2,,103230651,5284373,Active,238054374.0,5243.0,0.65,IC50,Inhibition of human ABCB1-mediated rhodamine 123 efflux in mouse L5178 cells expressing human MDR1 after 20 mins by FACS analysis,Confirmatory,21341745.0,
953,598252,1,11,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of human ABCB1-mediated rhodamine 123 efflux in mouse L5178 cells expressing human MDR1 at 0.1 mM after 20 mins by FACS analysis relative to 5 mM sodium orthovanadate,Other,21341745.0,
954,602123,1,1,,56422786,5284373,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
955,602141,1,1,,56422786,5284373,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
956,602162,1,1,,56422786,5284373,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
957,602163,1,1,,56422786,5284373,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
958,602179,1,2,,56422786,5284373,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
959,602191,1,1,,56422786,5284373,Inactive,14389423.0,20778.0,35.0,AbsAC40_uM,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_Dose_CherryPick_Activity,Confirmatory,,
960,602229,1,1,,56422786,5284373,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
961,602233,1,1,,56422786,5284373,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
962,602244,1,2,,56422786,5284373,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
963,602247,1,2,,56422786,5284373,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
964,602248,1,2,,56422786,5284373,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
965,602250,1,2,,56422786,5284373,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
966,602252,1,1,,56422786,5284373,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
967,602252,1,1,,56422786,5284373,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
968,602261,1,1,,56422786,5284373,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
969,602274,1,2,,56422786,5284373,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
970,602281,1,1,,56422786,5284373,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
971,602281,1,1,,56422786,5284373,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
972,602310,1,2,,56422786,5284373,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
973,602313,1,1,,56422786,5284373,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
974,602314,1,2,,92125416,5284373,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
975,602329,1,1,,56422786,5284373,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
976,602332,1,1,,56422786,5284373,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
977,602340,1,2,,56422786,5284373,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
978,602342,2,1,,56422786,5284373,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
979,602346,1,1,,56422786,5284373,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
980,602363,1,1,,56422786,5284373,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
981,602393,1,1,,56422786,5284373,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
982,602396,1,2,,56422786,5284373,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
983,602399,1,2,,56422786,5284373,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
984,602405,1,1,,56422786,5284373,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
985,602410,1,1,,56422786,5284373,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
986,602429,1,1,,56422786,5284373,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
987,602438,1,1,,56422786,5284373,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
988,602440,1,1,,56422786,5284373,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
989,602449,1,2,,56422786,5284373,Active,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
990,602481,1,1,,56422786,5284373,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
991,621444,1,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in human Jurkat T cells assessed as inhibition of PMA-induced IL-2 production at 10 uM after 13 hrs by ELISA relative to control,Other,21873054.0,
992,621445,1,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in human Jurkat T cells assessed as inhibition of PMA-induced IL-2 production at 1 uM after 13 hrs by ELISA relative to control,Other,21873054.0,
993,621446,1,4,,103230651,5284373,Unspecified,,,,,Cytotoxicity against human Jurkat E6-1 cells assessed as cell viability at 10 uM after 72 hrs by MTT assay relative to control,Other,21873054.0,
994,623870,1,1,,56422786,5284373,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
995,623870,1,1,,56422786,5284373,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
996,623877,1,1,,56422786,5284373,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
997,623901,1,1,,56422786,5284373,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
998,624037,1,3,,56422786,5284373,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
999,624038,1,3,,56422786,5284373,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1000,624040,1,3,,56422786,5284373,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1001,624101,1,2,,85788570,5284373,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1002,624125,1,4,,56422786,5284373,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1003,624126,1,3,,56422786,5284373,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1004,624127,1,2,,56422786,5284373,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1005,624136,1,1,,85788570,5284373,Inactive,208342286.0,7157.0,,,mutant P53 Measured in Biochemical System Using Small Molecule MicroArray - 2077-01_Other_SinglePoint_HTS_Activity,Screening,,
1006,624137,1,1,,85788570,5284373,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
1007,624138,1,1,,85788570,5284373,Inactive,21618340.0,6774.0,,,SMM STAT-3 Measured in Biochemical System Using Small Molecule MicroArray - 2076-01_Other_SinglePoint_HTS_Activity_Set2,Screening,,
1008,624139,1,1,,85788570,5284373,Active,34577122.0,4790.0,,,NF-KappaB Measured in Biochemical System Using Small Molecule MicroArray - 2080-01_Other_SinglePoint_HTS_Activity,Screening,,
1009,624141,1,1,,85788570,5284373,Inactive,71774083.0,4609.0,,,SMM c-myc Measured in Biochemical System Using Small Molecule MicroArray - 2081-01_Other_SinglePoint_HTS_Activity,Screening,,
1010,624151,1,1,,85788570,5284373,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
1011,624156,1,1,,85788570,5284373,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1012,624168,1,1,,56422786,5284373,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1013,624169,1,1,,56422786,5284373,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1014,624170,1,1,,56422786,5284373,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1015,624171,1,1,,56422786,5284373,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1016,624172,1,1,,56422786,5284373,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1017,624173,1,3,,56422786,5284373,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1018,624178,1,1,,56422786,5284373,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1019,624202,1,1,,56422786,5284373,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1020,624204,1,2,,56422786,5284373,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1021,624246,1,1,,56422786,5284373,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1022,624256,1,2,,56422786,5284373,Inconclusive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1023,624260,1,1,,85788570,5284373,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1024,624263,1,1,,56422786,5284373,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1025,624263,1,1,,56422786,5284373,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1026,624267,1,2,,56422786,5284373,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1027,624267,1,2,,56422786,5284373,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1028,624268,1,3,,56422786,5284373,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1029,624288,1,1,,56422786,5284373,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1030,624296,1,1,,56422786,5284373,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1031,624297,1,1,,56422786,5284373,Inconclusive,7705682.0,51053.0,0.631,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1032,624304,1,2,,56422786,5284373,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1033,624330,1,2,,56422786,5284373,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1034,624349,1,2,,92125416,5284373,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1035,624349,1,2,,92308685,5284373,Active,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1036,624349,1,2,,121363087,5284373,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1037,624352,1,1,,56422786,5284373,Active,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1038,624354,1,1,,56422786,5284373,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1039,624377,1,1,,57264292,5284373,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1040,624378,1,1,,56422786,5284373,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput confirmation assay for agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1041,624379,1,1,,56422786,5284373,Inactive,9629429.0,,,,"Counterscreen for agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3): Luminescence-based cell-based high throughput screening assay to identify agonists of the Herpes Virus Virion Protein 16 (VP16)",Screening,,
1042,624414,1,1,,56422786,5284373,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1043,624415,1,2,,56422786,5284373,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1044,624416,1,1,,57264292,5284373,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1045,624417,1,1,,56422786,5284373,Inconclusive,1724069.0,2740.0,2.5119,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1046,624418,1,1,,56422786,5284373,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1047,624463,1,1,,56422786,5284373,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1048,624464,1,1,,56422786,5284373,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1049,624465,1,1,,56422786,5284373,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1050,624466,1,3,,57264292,5284373,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1051,624467,1,1,,57264292,5284373,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1052,624483,1,1,,56422786,5284373,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1053,624504,1,1,,56422786,5284373,Inactive,,,,,Single concentration confirmation of uHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based assay,Screening,,
1054,624622,3,1,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
1055,624623,3,1,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
1056,624626,1,9,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
1057,624628,1,9,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
1058,624629,1,9,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
1059,624640,3,7,,103230651,5284373,Unspecified,136727.0,7364.0,202.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT2B7,Confirmatory,15781124.0,
1060,624660,3,4,,103230651,5284373,Active,,,2.09,Ki,Inhibition of mycophenolic acid glucuronidation by human kidney microsomes,Confirmatory,15781124.0,
1061,625144,5,5,,103230651,5284373,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1062,625145,4,7,,103230651,5284373,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1063,625146,5,5,,103230651,5284373,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1064,625147,4,7,,103230651,5284373,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1065,625148,4,7,,103230651,5284373,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1066,625149,4,7,,103230651,5284373,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1067,625150,5,5,,103230651,5284373,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1068,625151,4,7,,103230651,5284373,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1069,625152,4,7,,103230651,5284373,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1070,625153,4,7,,103230651,5284373,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1071,625154,4,7,,103230651,5284373,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1072,625155,4,7,,103230651,5284373,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1073,625156,1,9,,103230651,5284373,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1074,625157,6,2,,103230651,5284373,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1075,625158,3,4,,103230651,5284373,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1076,625159,5,5,,103230651,5284373,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1077,625160,1,9,,103230651,5284373,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1078,625161,4,7,,103230651,5284373,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1079,625162,4,7,,103230651,5284373,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1080,625163,4,7,,103230651,5284373,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1081,625164,1,6,,103230651,5284373,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1082,625165,3,4,,103230651,5284373,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1083,625166,3,4,,103230651,5284373,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1084,625167,5,5,,103230651,5284373,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1085,625168,4,7,,103230651,5284373,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1086,625169,1,6,,103230651,5284373,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1087,625170,3,4,,103230651,5284373,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1088,625171,4,7,,103230651,5284373,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1089,625172,4,7,,103230651,5284373,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1090,625173,5,5,,103230651,5284373,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1091,625174,5,5,,103230651,5284373,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1092,625175,5,5,,103230651,5284373,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1093,625176,1,9,,103230651,5284373,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1094,625177,5,5,,103230651,5284373,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1095,625178,5,5,,103230651,5284373,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1096,625179,1,9,,103230651,5284373,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1097,625180,5,5,,103230651,5284373,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1098,625181,5,5,,103230651,5284373,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1099,625182,5,5,,103230651,5284373,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1100,625183,5,5,,103230651,5284373,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1101,625184,5,5,,103230651,5284373,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1102,625185,5,5,,103230651,5284373,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1103,625186,5,5,,103230651,5284373,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1104,625187,5,5,,103230651,5284373,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1105,625188,1,9,,103230651,5284373,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1106,625189,1,7,,103230651,5284373,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1107,625190,4,5,,103230651,5284373,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1108,625191,4,7,,103230651,5284373,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1109,625192,4,7,,103230651,5284373,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1110,625193,5,5,,103230651,5284373,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1111,625194,4,7,,103230651,5284373,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1112,625195,4,7,,103230651,5284373,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1113,625196,5,6,,103230651,5284373,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1114,625197,3,4,,103230651,5284373,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1115,625198,4,7,,103230651,5284373,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1116,625199,4,7,,103230651,5284373,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1117,625200,4,7,,103230651,5284373,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1118,625201,4,7,,103230651,5284373,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1119,625202,4,7,,103230651,5284373,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1120,625203,4,7,,103230651,5284373,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1121,625204,4,7,,103230651,5284373,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1122,625205,4,7,,103230651,5284373,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1123,625206,4,7,,103230651,5284373,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1124,625207,4,7,,103230651,5284373,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1125,625208,5,5,,103230651,5284373,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1126,625209,4,7,,103230651,5284373,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1127,625210,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1128,625211,1,6,,103230651,5284373,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1129,625212,3,4,,103230651,5284373,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1130,625213,4,7,,103230651,5284373,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1131,625214,1,9,,103230651,5284373,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1132,625215,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1133,625216,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1134,625217,4,7,,103230651,5284373,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1135,625218,4,7,,103230651,5284373,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1136,625219,3,4,,103230651,5284373,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1137,625220,4,7,,103230651,5284373,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1138,625221,4,7,,103230651,5284373,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1139,625222,4,7,,103230651,5284373,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1140,625223,4,7,,103230651,5284373,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1141,625224,3,4,,103230651,5284373,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1142,625225,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1143,625226,4,7,,103230651,5284373,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1144,625227,4,7,,103230651,5284373,Active,229462950.0,6865.0,4.138999999999999,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1145,625228,4,7,,103230651,5284373,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1146,625229,5,5,,103230651,5284373,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1147,625230,1,6,,103230651,5284373,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1148,625231,4,7,,103230651,5284373,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1149,625232,1,9,,103230651,5284373,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1150,625233,4,7,,103230651,5284373,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1151,625234,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1152,625235,4,7,,103230651,5284373,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1153,625236,5,5,,103230651,5284373,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1154,625237,4,7,,103230651,5284373,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1155,625238,4,7,,103230651,5284373,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1156,625239,4,7,,103230651,5284373,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1157,625240,1,9,,103230651,5284373,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1158,625241,4,7,,103230651,5284373,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1159,625242,4,7,,103230651,5284373,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1160,625243,5,5,,103230651,5284373,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1161,625244,5,5,,103230651,5284373,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1162,625245,5,5,,103230651,5284373,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1163,625246,1,9,,103230651,5284373,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1164,625247,5,5,,103230651,5284373,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1165,625248,5,5,,103230651,5284373,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1166,625249,5,5,,103230651,5284373,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1167,625250,5,5,,103230651,5284373,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1168,625251,5,5,,103230651,5284373,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1169,625252,4,7,,103230651,5284373,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1170,625253,4,7,,103230651,5284373,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1171,625254,4,7,,103230651,5284373,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1172,625255,4,7,,103230651,5284373,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1173,625256,4,7,,103230651,5284373,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1174,625257,4,7,,103230651,5284373,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1175,625258,4,7,,103230651,5284373,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1176,625259,4,7,,103230651,5284373,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1177,625260,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1178,625261,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1179,625262,3,4,,103230651,5284373,Active,,,14.899000000000001,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1180,625263,4,7,,103230651,5284373,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1181,625264,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1182,625265,1,6,,103230651,5284373,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1183,625266,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1184,625267,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1185,625268,4,2,,103230651,5284373,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1186,625268,4,2,,103230651,5284373,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1187,625268,4,2,,103230651,5284373,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1188,625268,4,2,,103230651,5284373,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1189,625269,4,7,,103230651,5284373,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1190,625270,4,7,,103230651,5284373,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1191,625271,5,5,,103230651,5284373,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1192,625272,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1193,625273,4,6,,103230651,5284373,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1194,625274,1,6,,103230651,5284373,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1195,625275,3,4,,103230651,5284373,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1196,625277,1,3,,103230651,5284373,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
1197,625279,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1198,625280,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1199,625281,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1200,625282,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1201,625283,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1202,625284,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1203,625285,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1204,625286,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1205,625287,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1206,625288,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1207,625289,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1208,625290,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1209,625291,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1210,625292,1,3,,103230651,5284373,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1211,625944,4,5,,103230651,5284373,Unspecified,51702775.0,5478.0,,Kd,Binding affinity to human recombinant cyclophilin-A by isothermal titration calorimetry assay,Confirmatory,21963115.0,
1212,625946,4,5,,103230651,5284373,Active,51702775.0,5478.0,0.0093,IC50,Inhibition of PPIase activity of human recombinant cyclophilin-A using succinyl-Ala-Ala-Pro-Phe-4-nitroanilide as substrate by protease coupled assay,Confirmatory,21963115.0,
1213,644404,3,2,,103230651,5284373,Active,,,13.78,CC50,Cytotoxicity against lymph node T cell after 24 hrs by MTT assay,Confirmatory,22300886.0,
1214,644405,3,2,,103230651,5284373,Active,,,0.07,IC50,Immunosuppressive activity in lymph node T cell assessed as inhibition of ConA-stimulated cell proliferation after 72 hrs by MTT assay,Confirmatory,22300886.0,
1215,644406,1,4,,103230651,5284373,Unspecified,,,,,"Selectivity index, ratio of CC50 for lymph node T cell to IC50 for lymph node T cell",Other,22300886.0,
1216,648432,1,4,,103230651,5284373,Unspecified,,,,,Immunosuppressant activity in human PBMC assessed as reduction in Con A-induced extracellular IL4 level at 90 uM after 72 hrs by ELISA relative to untreated control,Other,22101135.0,
1217,648433,1,3,,103230651,5284373,Unspecified,,,,,Immunosuppressant activity in human CD4+ T cells assessed as Con A-induced intracellular IL4 level at 90 uM after 72 hrs by flow cytometry (Rvb = 4.2+/-0.9%),Other,22101135.0,
1218,648435,1,4,,103230651,5284373,Unspecified,,,,,Inhibition of Con-A-induced phospho-STAT6 expression in human PBMC at 90 uM after 72 hrs by flow cytometry (Rvb = 10.52+/-1.9%),Other,22101135.0,
1219,648436,1,4,,103230651,5284373,Active,,,,,Inhibition of ConA-induced phospho-JAK1 expression in human PBMC at 90 uM after 72 hrs by flow cytometry,Other,22101135.0,
1220,648437,1,4,,103230651,5284373,Active,,,,,Inhibition of Con A-induced phospho-GATA3 expression in human PBMC at 90 uM after 72 hrs by flow cytometry,Other,22101135.0,
1221,648438,1,9,,103230651,5284373,Active,215274013.0,3716.0,,,Inhibition of PMA-induced JAK1 phosphorylation in human PBMC at 90 uM after 15 mins by Western blot analysis,Other,22101135.0,
1222,648439,1,9,,103230651,5284373,Active,215274013.0,3716.0,,,Inhibition of JAK1-mediated GATA3 phosphorylation in PMA-stimulated human PBMC at 90 uM after 30 mins by Western blot analysis,Other,22101135.0,
1223,648440,1,4,,103230651,5284373,Inactive,,,,,Inhibition of PMA-induced JAK1 expression in human PBMC at 90 uM after 15 mins by Western blot analysis,Other,22101135.0,
1224,648441,1,4,,103230651,5284373,Inactive,,,,,Inhibition of PMA-induced GATA3 expression in human PBMC at 90 uM after 15 mins by Western blot analysis,Other,22101135.0,
1225,648448,3,2,,103230651,5284373,Active,,,8.97,IC50,Inhibition of CD4 expression in human CD4+ T cells,Confirmatory,22101135.0,
1226,651548,1,1,,85788570,5284373,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1227,651550,1,1,,56422786,5284373,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1228,651560,1,1,,56422786,5284373,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1229,651572,1,2,,57264292,5284373,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1230,651582,1,1,,56422786,5284373,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1231,651602,1,1,,57264292,5284373,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1232,651602,1,1,,57264292,5284373,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1233,651602,1,1,,57264292,5284373,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1234,651610,2,1,,57264292,5284373,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1235,651631,4,1,,144204218,5284373,Inconclusive,269849759.0,7157.0,33.4915,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1236,651631,4,1,,144212166,5284373,Inconclusive,269849759.0,7157.0,12.6574,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1237,651632,4,1,,144204218,5284373,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1238,651632,4,1,,144212166,5284373,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1239,651633,4,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1240,651633,4,1,,144212166,5284373,Inconclusive,,,10.0541,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1241,651634,4,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1242,651634,4,1,,144212166,5284373,Inconclusive,,,7.1178,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1243,651635,1,3,,56422786,5284373,Active,171543895.0,6311.0,8.9125,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1244,651636,1,1,,56422786,5284373,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1245,651640,1,1,,57264292,5284373,Active,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1246,651644,1,1,,56422786,5284373,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1247,651647,1,1,,56422786,5284373,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1248,651654,1,1,,56422786,5284373,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1249,651658,1,1,,57264292,5284373,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1250,651661,2,1,,57264292,5284373,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1251,651687,1,1,,56422786,5284373,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1252,651699,1,1,,56422786,5284373,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1253,651699,1,1,,56422786,5284373,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1254,651702,1,2,,56422786,5284373,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1255,651704,2,1,,57264292,5284373,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1256,651710,1,1,,57264292,5284373,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1257,651711,2,1,,57264292,5284373,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1258,651718,1,2,,57264292,5284373,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1259,651723,1,1,,56422786,5284373,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1260,651724,1,1,,56422786,5284373,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1261,651725,1,1,,56422786,5284373,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1262,651741,1,1,,26757675,5284373,Active,20149576.0,4780.0,9.6885,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1263,651743,1,1,,26757675,5284373,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1264,651749,1,1,,26757675,5284373,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1265,651751,1,1,,26757675,5284373,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1266,651768,1,2,,56422786,5284373,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1267,651777,1,1,,26757675,5284373,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1268,651778,1,1,,26757675,5284373,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1269,651800,1,1,,57264292,5284373,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1270,651819,1,1,,56422786,5284373,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1271,651820,1,1,,56422786,5284373,Active,,,0.5623,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1272,651821,2,4,,57264292,5284373,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1273,651828,1,2,,92308685,5284373,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1274,651838,1,1,,26757675,5284373,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1275,651838,1,1,1.0,26757675,5284373,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1276,651838,1,1,2.0,26757675,5284373,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1277,651838,1,1,3.0,26757675,5284373,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1278,651838,1,1,4.0,26757675,5284373,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1279,651838,1,1,5.0,26757675,5284373,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1280,651838,1,1,6.0,26757675,5284373,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1281,651838,1,1,7.0,26757675,5284373,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1282,651838,1,1,8.0,26757675,5284373,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1283,651957,1,1,,57264292,5284373,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1284,651958,1,1,,57264292,5284373,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1285,651965,1,1,,56422786,5284373,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1286,651999,1,1,,56422786,5284373,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1287,652010,1,1,,57264292,5284373,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1288,652017,1,1,,57264292,5284373,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1289,652025,1,1,,56422786,5284373,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1290,652039,1,1,,57264292,5284373,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1291,652048,1,2,,56422786,5284373,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1292,652048,1,2,,144204218,5284373,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1293,652051,1,1,,56422786,5284373,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1294,652051,1,1,,144204218,5284373,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1295,652054,1,1,,56422786,5284373,Inconclusive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1296,652067,1,4,,57264292,5284373,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1297,652104,1,1,,56422786,5284373,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1298,652105,1,1,,56422786,5284373,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1299,652106,1,1,,56422786,5284373,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1300,652115,1,1,,57264292,5284373,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1301,652126,1,3,,57264292,5284373,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1302,652154,1,1,,57264292,5284373,Active,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1303,652162,2,1,,57264292,5284373,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1304,652163,1,1,,57264292,5284373,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1305,652197,1,1,,57264292,5284373,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1306,652257,1,1,,57264292,5284373,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1307,652500,1,3,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin-A-induced cell proliferation at 1 uM after 48 hrs by MTT assay,Other,24900363.0,
1308,652502,1,3,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in concanavalin-A-induced IL4 production at 1 uM after 48 hrs by ELISA,Other,24900363.0,
1309,652504,1,3,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in concanavalin-A-induced IFN-gamma production at 1 uM after 48 hrs by ELISA,Other,24900363.0,
1310,655423,1,3,,103230651,5284373,Active,,,,,"Immunosuppressive activity in C57BL/6 mouse transplanted with trunk skin of BALB/c mouse assessed as inhibition of skin graft rejection at 20 umol/kg, sc measured up to 19 days",Other,24900363.0,
1311,657444,2,2,,103230651,5284373,Active,,,0.07,IC50,Immunosuppressive activity in anti-CD3/anti-CD8 co-stimulated Balb/c mouse lymph node cells assessed as inhibition of cell proliferation after 72 hrs by ELISA,Confirmatory,22494616.0,
1312,657445,2,3,,103230651,5284373,Active,,,10.1,CC50,Cytotoxicity against Balb/c mouse lymph node cells after 48 hrs by MTT assay,Confirmatory,22494616.0,
1313,657446,1,3,,103230651,5284373,Unspecified,,,,,"Selectivity index, ratio of CC50 for Balb/c mouse lymph node cells to IC50 for anti-CD3/antiCD8 co-stimulated mouse Balb/c mouse lymph node cells",Other,22494616.0,
1314,657640,1,4,,103230651,5284373,Unspecified,,,,,Cytotoxicity against BALB/c mouse lymph node cells at 10 uM after 72 hrs MTT assay,Other,22520630.0,
1315,657641,1,4,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in BALB/c mouse lymph node cells assessed as inhibition of concanavalin A-stimulated cell proliferation at 1 uM administered 24 hrs post concanavalin A stimulation and measured 72 hrs after compound dosing by MTT assay,Other,22520630.0,
1316,664605,1,3,,103230651,5284373,Active,,,,,Noncompetitive inhibition of P-gp assessed as reduction in P-gp-associated ATPase activity by Pgp-GloTM Assay,Other,22365753.0,
1317,669781,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of human recombinant MDR1 expressed in mouse L5178Y cells assessed as inhibition of rhodamine-123 efflux at 10'-4 M preincubated for 10 mins measured after 20 mins by FACS analysis,Other,24900460.0,
1318,672543,5,1,,103230651,5284373,Active,238054374.0,5243.0,0.10232999999999999,IC50,Inhibition of P-glycoprotein-mediated daunorubicin efflux from human CCRF-CEM/VCR1000 cells after 240 secs by FACS flow cytometric analysis,Confirmatory,22452412.0,
1319,672896,2,3,,103230651,5284373,Unspecified,,,174.24,CC50,Cytotoxicity against BALB/c mouse lymph node cells after 24 hrs by MTT assay,Confirmatory,22727369.0,
1320,672897,2,2,,103230651,5284373,Active,,,2.12,IC50,Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of ConA-induced T cell proliferation incubated 24 hrs post ConA-induction for 72 hrs by MTT assay,Confirmatory,22727369.0,
1321,672898,1,3,,103230651,5284373,Unspecified,,,,,Selectivity index ratio of CC50 for BALB/c mouse lymph node cells to IC50 for BALB/c mouse ConA-induced T cell proliferation,Other,22727369.0,
1322,678712,1,8,,103230651,5284373,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
1323,678713,1,8,,103230651,5284373,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
1324,678714,1,8,,103230651,5284373,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1325,678715,1,8,,103230651,5284373,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1326,678716,1,8,,103230651,5284373,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
1327,678717,1,8,,103230651,5284373,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
1328,678721,1,5,,103230651,5284373,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
1329,678722,1,5,,103230651,5284373,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
1330,678741,1,8,,103230651,5284373,Unspecified,239938877.0,18671.0,,,"TP_TRANSPORTER: inhibition of Vinblastine efflux (Vinblastine: 0.002 uM, CsA: 1 uM) in P388/S and P388/ADR cells",Other,10901387.0,
1331,678796,2,7,,103230651,5284373,Unspecified,12643959.0,10599.0,,IC50,TP_TRANSPORTER: inhibition of Phalloidin uptake (Phalloidin: 1 uM) in OATP-C-expressing HEK293 cells,Confirmatory,14530907.0,
1332,678833,1,8,,103230651,5284373,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in mdr1a-expressing LLC-PK1 cell,Other,7560060.0,
1333,678981,3,6,,103230651,5284373,Unspecified,308153583.0,1244.0,4.7,Ki,TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicles from MRP2-expressing LLC PK1 cells,Confirmatory,10570049.0,
1334,678982,1,8,,103230651,5284373,Unspecified,308153583.0,1244.0,,,TP_TRANSPORTER: inhibition of EGCG in MRP2-expressing MDCKII cells,Other,14511674.0,
1335,679044,3,6,,103230651,5284373,Unspecified,3219824.0,25303.0,10.0,Ki,TP_TRANSPORTER: inhibition of BMG uptake in membrane vesicles from Mrp2-expressing HEK cells,Confirmatory,10421658.0,
1336,679096,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Cyclosporin at a concentration of 0.1 uM in MDR1-expressing MDCK cells,Other,12948019.0,
1337,679097,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Cyclosporin at a concentration of 0.1 uM in Caco-2 cells,Other,12948019.0,
1338,679112,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in Caco-2 cells,Other,12880295.0,
1339,679123,1,8,,103230651,5284373,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: transcellular transport in mdr1a-expressing LLC-PK1 cells,Other,17045309.0,
1340,679128,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transcellular transport in MDR1-expressing LLC-PK1 cells,Other,17045309.0,
1341,679129,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,0.6,EC50,TP_TRANSPORTER: reversal of Vinblastine accumulation (Vinblastine: 0.005 uM) in MDA435/LCC6 MDR1 cells,Confirmatory,11784143.0,
1342,679137,1,8,,103230651,5284373,Unspecified,126927.0,18669.0,,,TP_TRANSPORTER: transcellular transport in mdr1b-expressing LLC-PK1 cells,Other,17045309.0,
1343,679145,3,6,,103230651,5284373,Unspecified,12585136.0,83569.0,0.3,Ki,TP_TRANSPORTER: inhibition of Taurocholate uptake in membrane vesicles from Bsep-expressing Sf9 cells,Confirmatory,10648470.0,
1344,679238,2,7,,103230651,5284373,Unspecified,238054374.0,5243.0,8.4,Km,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells,Confirmatory,7681059.0,
1345,679263,2,7,,103230651,5284373,Unspecified,238054374.0,5243.0,3.8,Km,TP_TRANSPORTER: transepithelial transport (basal to apical) in Caco-2 cells,Confirmatory,8842452.0,
1346,679276,1,9,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (apical to basal) of Cyclosporin A at a concentration of 35.7 nM in MDR1-expressing LLC-PK1 cells,Other,11785684.0,
1347,679342,1,8,,103230651,5284373,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse,Other,7560060.0,
1348,679348,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCK cells,Other,10227700.0,
1349,679353,1,8,,103230651,5284373,Unspecified,74756298.0,89845.0,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 1 uM, CsA:10uM) in membrane vesicles from MRP7-expressing HEK293 cells",Other,12527806.0,
1350,679460,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transcellular transport in MDR1-expressing MDCKII cells,Other,17045309.0,
1351,679625,2,7,,103230651,5284373,Unspecified,67462103.0,9429.0,0.5,Ki,TP_TRANSPORTER: inhibition of ATPase in membrane vesicle from BCRP-expressing Sf9 cells,Confirmatory,11437380.0,
1352,679746,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Colchicine intracellular accumulation (Colchicine: 0.0175 uM, CsA: 50 uM) in CEM/VLB600 cells",Other,10087141.0,
1353,679891,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of imatinib mesilate uptake (imatinib mesilate: 10 uM, CsA: 10 uM) in MDR1-expressing LLC-PK1 cells",Other,12975485.0,
1354,679906,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Vinblastine efflux in MDR1-expressing BeWo cells,Other,12724138.0,
1355,679908,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Vinblastine binding (Vinblastine: 0.2 uM, CsA: 300-fold molar excess) in plasma membranes from CEM/VLB1.0 cells",Other,8960059.0,
1356,679909,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,0.02,Ki,TP_TRANSPORTER: inhibition of Verapamil stimulated ATP hydrolysis in membranes from MDR1-expressing Sf9 cells,Confirmatory,7514263.0,
1357,679921,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Saquinavir transepithelial transport (basal to apical)(Saquinavir: 10 uM, CsA: 4 uM) in HCT8-cells",Other,9732409.0,
1358,679926,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Rhodamine 123 transepithelial transport (basal to apical)(R123: 13 uM, CsA: 5 uM) in HCT8-cells",Other,9732409.0,
1359,679985,3,6,,103230651,5284373,Unspecified,296439301.0,4363.0,5.0,Ki,TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicle from MRP1-expressing HeLa cells,Confirmatory,7961706.0,
1360,680065,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Daunomycin efflux (Daunomycin: 10 uM, CyclosporinA: 2 uM) in K562/R7 cells",Other,14604686.0,
1361,680098,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: increase in saquinavir intracellular accumulation of Cyclosporin A at a concentration of 20uM in LLC-GA5-COL150 cells,Other,15504753.0,
1362,680102,1,8,,103230651,5284373,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: intracellular accumulation in P388/S and P388/ADR cells,Other,10901387.0,
1363,680103,1,8,,103230651,5284373,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in plasma concentration in PGP(-/-) mouse,Other,10220486.0,
1364,680107,1,8,,103230651,5284373,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in brain concentration in PGP(-/-) mouse,Other,10220486.0,
1365,680113,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of propranolol in Caco2 cells,Other,15023456.0,
1366,680137,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,1.8,Ki,TP_TRANSPORTER: inhibition of Calcein-AM efflux in CEM/VLB100 cells,Confirmatory,10198227.0,
1367,680138,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,3.41,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux (Calcein-AM: 0.25 uM) in CEM/VLB100 cells,Confirmatory,10891114.0,
1368,680304,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Cyclosporin A: 10 uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
1369,680428,1,7,,103230651,5284373,Unspecified,74761045.0,,,,"TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, CsA: 10 uM) in membrane vesicles from MRP3-expressing HEK293 cells",Other,11585759.0,
1370,680478,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of MRK-1 uptake (vinblastine: 10 uM, CsA: 10 uM) in MDR1-expressing LLC-PK1 cells",Other,12604693.0,
1371,680479,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of MRK-1 uptake (MRK-1: 10 uM, CsA: 10 uM) in MDR1-expressing LLC-PK1 cells",Other,12604693.0,
1372,680483,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Levofloxacin transepithelial transport (basal to apical) (Levofloxacin: 100 uM, CsA: 10 uM) in MDR1-expressing LLC-PK1 cells",Other,9262363.0,
1373,680487,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of JC-1 uptake (JC-1: ca 0.1 uM, CsA: 5 uM) in K562 and K562/ADR cells, flow cytometry",Other,9205004.0,
1374,680489,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Ivermectin binding (IVM: 0.2 uM, CsA: 300-fold molar excess) in plasma membranes from CEM/VLB1.0 cells",Other,8960059.0,
1375,680490,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Indinavir transepithelial transport (basal to apical) in Caco-2 cells,Other,10604964.0,
1376,680496,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of IAAP photoaffinity labelling (IAAP: 0.02 uM, CsA: 100-fold molar excess) in plasma membranes from CEM/VLB1.0 cells",Other,8960059.0,
1377,680506,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,3.66,IC50,TP_TRANSPORTER: inhibition of Doxorubicin transepithelial transport (basal to apical) (Digoxin: 0.8 uM) in MDR1-expressing LLC-PK1 cells,Confirmatory,9914792.0,
1378,680620,1,8,,103230651,5284373,Unspecified,1171883.0,50572.0,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.1 uM, CsA: 30 uM) in Oatp1-expressing LLC-PK1 cells",Other,11883641.0,
1379,680691,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: increase in Vinblastine intracellular accumulation of Cyclosporin A at a concentration of 20uM in LLC-GA5-COL150 cells,Other,15504753.0,
1380,680741,1,8,,103230651,5284373,Unspecified,12643959.0,10599.0,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.5 uM, CsA: 10uM) in OATP-C-expressing HeLa cells",Other,12490595.0,
1381,680764,1,8,,103230651,5284373,Unspecified,12643959.0,10599.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.004 uM, CsA: 10 uM) in Xenopus laevis oocytes",Other,12906759.0,
1382,680769,2,7,,103230651,5284373,Unspecified,12643959.0,10599.0,0.23800000000000002,Ki,TP_TRANSPORTER: inhibition of Cerivastatin uptake in OATP2-expressing MDCKII cells,Confirmatory,12538813.0,
1383,680812,1,8,,103230651,5284373,Unspecified,308153583.0,1244.0,,,"TP_TRANSPORTER: increase in Vincristine intracellular accumulation (Vincristine: 1 uM, CsA: 10 uM) in MRP2-expressing LLC PK1 cells",Other,10570049.0,
1384,680904,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: correlation between intestinal P-gp content and oral clearance in vivo, kidney transplant recipients",Other,9333100.0,
1385,680908,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: cell accumulation of doxorubicin in the presence of Cyclosporin A at a concentration of 1uM in K562/ADR cells,Other,14744620.0,
1386,680941,3,6,,103230651,5284373,Unspecified,262527527.0,8647.0,9.5,Ki,"TP_TRANSPORTER: inhibition of Taurochenodeoxycholate uptake(CsA 30uM, 30 % of control) in membrane vesicles prepared from High Five cells infected with the ABCB11 baculovirus",Confirmatory,12404239.0,
1387,681095,1,8,,103230651,5284373,Unspecified,296439301.0,4363.0,,,"TP_TRANSPORTER: inhibition of Rhodamine 123 efflux (R123: 10 uM, CsA: 20 uM) in HL60/Adr cells",Other,12373300.0,
1388,681119,3,6,,103230651,5284373,Unspecified,239938877.0,18671.0,4.8,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1389,681120,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells,Other,12699389.0,
1390,681122,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,0.8,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1391,681126,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,1.7,IC50,TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
1392,681127,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,1.8,IC50,TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
1393,681128,3,6,,103230651,5284373,Unspecified,126927.0,18669.0,0.7,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1394,681131,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,1.4,IC50,TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
1395,681132,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells,Other,11602674.0,
1396,681137,3,6,,103230651,5284373,Unspecified,239938877.0,18671.0,3.65,Ki,TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1a-expressing LLC-PK1 cells,Confirmatory,12235267.0,
1397,681138,3,6,,103230651,5284373,Unspecified,126927.0,18669.0,3.5,Ki,TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1b-expressing LLC-PK1 cells,Confirmatory,12235267.0,
1398,681139,3,6,,103230651,5284373,Unspecified,262527527.0,8647.0,7.8,IC50,TP_TRANSPORTER: increase in dihydrofluorescein intracellular accumulation (dihydrofluorescein: 1 uM) in SK-E2 cells (expressing BSEP),Confirmatory,12739759.0,
1399,681142,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,1.3,Ki,TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in MDR1-expressing LLC-PK1 cells,Confirmatory,11961113.0,
1400,681143,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,4.66,Ki,TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in MDR1-expressing LLC-PK1 cells,Confirmatory,11961113.0,
1401,681155,3,6,,103230651,5284373,Unspecified,262527527.0,8647.0,7.5,IC50,TP_TRANSPORTER: increase in bodipy intracellular accumulation (Bodipy: 0.2 uM) in SK-E2 cells (expressing BSEP),Confirmatory,12739759.0,
1402,681164,2,8,,103230651,5284373,Unspecified,238054374.0,5243.0,0.17,Km,TP_TRANSPORTER: ATP hydrolysis in membrane fraction from High Five (BTI-TN5B1-4) cells,Confirmatory,11785684.0,
1403,681175,3,6,,103230651,5284373,Unspecified,3219824.0,25303.0,1.96,Ki,TP_TRANSPORTER: inhibition of DNP-SG uptake in bile canalicular membrane vesicles from SD rat,Confirmatory,15618649.0,
1404,681302,1,8,,103230651,5284373,Unspecified,296439301.0,4363.0,,,"TP_TRANSPORTER: inhibition of CFDA efflux (CFDA: 1 uM, CsA: 20 uM) in HL60/Adr cells",Other,12373300.0,
1405,681332,3,6,,103230651,5284373,Unspecified,322510055.0,6555.0,24.0,Ki,TP_TRANSPORTER: inhibition of Taurocholate uptake in ASBT-expressing COS cells,Confirmatory,9458785.0,
1406,681337,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: Western blot, HK-2 cells",Other,12387747.0,
1407,681356,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,2.18,Ki,TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) in MDR1-expressing MDCK cells,Confirmatory,12134945.0,
1408,681358,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,1.3,IC50,TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells,Confirmatory,10820137.0,
1409,681378,3,6,,103230651,5284373,Unspecified,2498046.0,6554.0,1.0,IC50,TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells,Confirmatory,10565843.0,
1410,681383,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,,Ki,TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) in Caco-2 cells,Confirmatory,11405287.0,
1411,681385,1,8,,103230651,5284373,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: RT-PCR in HK-2 cell,Other,12387747.0,
1412,681464,1,7,,103230651,5284373,Unspecified,81911503.0,,,,"TP_TRANSPORTER: increase in Glibenclamide intracellular accumulation (Glibenclamide: 0.525 uM, CsA: 50 uM) in CC531mdr+ cells",Other,10087141.0,
1413,681474,1,7,,103230651,5284373,Unspecified,81911503.0,,,,"TP_TRANSPORTER: increase in Colchicine intracellular accumulation (Colchicine: 0.035 uM, CsA: 50 uM) in CC531mdr+ cells",Other,10087141.0,
1414,681479,1,7,,103230651,5284373,Unspecified,81911503.0,,,,"TP_TRANSPORTER: Western in vivo, liver of SD rat",Other,11458978.0,
1415,681481,1,7,,103230651,5284373,Unspecified,81911503.0,,,,"TP_TRANSPORTER: Western in vivo, liver of SD rat",Other,8928836.0,
1416,681482,1,7,,103230651,5284373,Unspecified,81911503.0,,,,"TP_TRANSPORTER: Western in vivo, kidney of SD rat",Other,8928836.0,
1417,681483,1,7,,103230651,5284373,Unspecified,81911503.0,,,,"TP_TRANSPORTER: Western in vivo, intestine of SD rat",Other,8928836.0,
1418,681550,1,7,,103230651,5284373,Unspecified,127792.0,24777.0,,,"TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 2.5 uM, CsA: 100 uM) in Ntcp-expressing CHO cells",Other,9486191.0,
1419,681557,1,8,,103230651,5284373,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: transepithelial transport of SN-38(Carboxylate form) (basal to apical) in Mdr1a-expressing LLC-PK1 cells,Other,12817897.0,
1420,681558,1,8,,103230651,5284373,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: transepithelial transport of CPT-11(Lactone form) (basal to apical) in Mdr1a-expressing LLC-PK1 cells,Other,12817897.0,
1421,681559,1,8,,103230651,5284373,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: transepithelial transport of CPT-11(Carboxylate form) (basal to apical) in Mdr1a-expressing LLC-PK1 cells,Other,12817897.0,
1422,681579,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,2.1,IC50,TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
1423,681580,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,4.3,IC50,TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
1424,681581,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,2.4,IC50,TP_TRANSPORTER: inhibition of Fluo-3-AM efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
1425,681582,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,1.7,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
1426,681596,3,6,,103230651,5284373,Unspecified,308153583.0,1244.0,8.11,Ki,TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) in MRP2-expressing MDCK cells,Confirmatory,12134946.0,
1427,681611,3,6,,103230651,5284373,Unspecified,238054374.0,5243.0,0.35,Ki,TP_TRANSPORTER: transepithelial transport of digoxin (basal to apical) in Caco-2 cells,Confirmatory,12636153.0,
1428,681666,1,8,,103230651,5284373,Unspecified,338817847.0,27413.0,,,TP_TRANSPORTER: inhibition of Taurochenodeoxycholate-stimulated ATPase activity (CsA: 30 uM) in membrane vesicles from Bsep-expressing Sf9 cells,Other,11343252.0,
1429,681669,1,8,,103230651,5284373,Unspecified,338817847.0,27413.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 1 uM, CsA: 20 uM) in Bsep-expressing LLC-PK1 cells",Other,10617675.0,
1430,681751,1,7,,103230651,5284373,Unspecified,81886651.0,29509.0,,,"TP_TRANSPORTER: inhibition of PAH uptake (PAH: 50 uM, CsA; 10 uM) in Xenopus laevis oocytes",Other,9374486.0,
1431,681854,1,8,,103230651,5284373,Unspecified,3914190.0,170698.0,,,"TP_TRANSPORTER: inhibition of Digoxin uptake (Digoxin: 0.05 uM, CsA: 30 uM) in Oatp2-expressing LLC-PK1 cells",Other,11883641.0,
1432,682121,3,6,,103230651,5284373,Unspecified,308153583.0,1244.0,21.0,Ki,TP_TRANSPORTER: inhibition of BMG uptake in membrane vesicles from MRP2-expressing HEK cells,Confirmatory,10421658.0,
1433,682148,1,8,,103230651,5284373,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: transepithelial transport of SN-38(Lactone form) (basal to apical) in Mdr1a-expressing LLC-PK1 cells,Other,12817897.0,
1434,683399,1,3,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of P-gp over expressed in human multidrug-resistant KBVIN cells assessed as intracellular accumulation of doxorubicin at 10uM after 3 hrs by fluorescence microplate reader analysis relative to control,Other,22612652.0,
1435,685500,2,2,,103230651,5284373,Unspecified,,,50.0,IC50,HARVARD: Cytotoxicity in HepG2 cell line,Confirmatory,22586124.0,
1436,685501,2,2,,103230651,5284373,Active,,,0.00165,IC50,HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells,Confirmatory,22586124.0,
1437,685502,2,2,,103230651,5284373,Active,,,0.138,IC50,HARVARD: Inhibition of blood stage Plasmodium falciparum 3D7 infection,Confirmatory,22586124.0,
1438,685503,2,2,,103230651,5284373,Active,,,0.095,IC50,HARVARD: Inhibition of blood stage Plasmodium falciparum Dd2 infection,Confirmatory,22586124.0,
1439,686940,1,1,,57264292,5284373,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1440,686964,1,1,,57264292,5284373,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1441,686970,1,2,,56422786,5284373,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1442,686971,1,2,,56422786,5284373,Active,,,5.8048,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1443,686977,2,1,,49698490,5284373,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
1444,686978,1,1,,56422786,5284373,Active,79154014.0,55775.0,2.9093,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1445,686978,1,1,,144204218,5284373,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1446,686979,1,1,,56422786,5284373,Active,79154014.0,55775.0,5.1735,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1447,686979,1,1,,144204218,5284373,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1448,686992,2,1,,57264292,5284373,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1449,686996,1,1,,57264292,5284373,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1450,687014,1,1,,57264292,5284373,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1451,687016,1,1,,57264292,5284373,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1452,695337,1,3,,103230651,5284373,Active,238054374.0,5243.0,,,Inhibition of human P-gp overexpressed in doxorubicin resistant A2780adr cells at 10 uM preincubated for 30 mins prior to calcein AM addition measured every 60 secs up to 90 mins by calcein AM accumulation assay,Other,23017888.0,
1453,695338,1,7,,103230651,5284373,Active,296439301.0,4363.0,,,Inhibition of human MRP1 expressed in 2008 cells at 10 uM preincubated for 30 mins prior to calcein AM addition measured every 60 secs up to 90 mins by calcein AM accumulation assay,Other,23017888.0,
1454,696201,1,2,,103230651,5284373,Active,,,,,Inhibition of Ca2+-induced mitochondrial permeability transition in human HL60 cells at 5 uM after 40 mins relative to control,Other,23026083.0,
1455,696918,1,7,,103230651,5284373,Active,238054374.0,5243.0,,,Inhibition of MDR1 in human HCT15 cells assessed as calcein-AM efflux at 10 uM by fluorescence assay,Other,21348461.0,
1456,697852,1,7,,103230651,5284373,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1457,697853,1,7,,103230651,5284373,Unspecified,21362409.0,100033901.0,,,Inhibition of horse BChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1458,699539,1,7,,103230651,5284373,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
1459,699540,1,7,,103230651,5284373,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1460,699541,1,7,,103230651,5284373,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1461,699542,2,7,,103230651,5284373,Active,12643959.0,10599.0,,IC50,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting,Confirmatory,22541068.0,
1462,699543,2,7,,103230651,5284373,Active,27734563.0,28234.0,,IC50,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting,Confirmatory,22541068.0,
1463,699544,2,7,,103230651,5284373,Active,313104012.0,11309.0,,IC50,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting,Confirmatory,22541068.0,
1464,700073,1,3,,103230651,5284373,Active,,,0.03,IC50,Immunosuppressant activity in mouse splenocytes by mixed-leukocyte reaction assay,Confirmatory,23017885.0,
1465,706779,2,2,,103230651,5284373,Unspecified,,,10.0,IC50,Cytotoxicity against human Jurkat cells after 4 days by MTT assay,Confirmatory,22984987.0,
1466,706965,2,2,,103230651,5284373,Active,,,0.011000000000000001,IC50,Immunosuppressive activity in mouse T cells assessed as inhibition of two way mixed lymphocyte reaction after 4 days by MTT assay,Confirmatory,22984987.0,
1467,706966,2,2,,103230651,5284373,Unspecified,,,100.0,IC50,Immunosuppressive activity in ICR mouse B cells assessed as inhibition of LPS-stimulated cell proliferation after 72 hrs by MTT assay,Confirmatory,22984987.0,
1468,710863,4,1,,103230651,5284373,Unspecified,,,,IC50,Antiproliferative activity against concanavalin A-stimulated BALB/c mouse splenocytes after 72 hrs by AlamarBlue assay,Confirmatory,23167554.0,
1469,711671,1,3,,103230651,5284373,Active,,,,,Inhibition of Pgp-mediated drug efflux in adriamycin-resistant human A2780 cells assessed as increase in intracellular adriamycin level at 5 uM after 40 mins by flow cytometry analysis,Other,24900323.0,
1470,711674,1,3,,103230651,5284373,Unspecified,,,,,Toxicity in adriamycin-resistant human A2780 cells at 5 uM after 1 hr by CCK-8 assay,Other,24900323.0,
1471,711677,1,3,,103230651,5284373,Active,,,,,Inhibition of Pgp-mediated drug efflux in adriamycin-resistant human A2780 cells assessed as increase in adriamycin uptake at 5 uM after 1 hr by flow cytometry analysis,Other,24900323.0,
1472,711678,1,3,,103230651,5284373,Active,,,,,Inhibition of Pgp-mediated drug efflux in adriamycin-resistant human A2780 cells assessed as increase in adriamycin uptake at 5 uM after 8 hrs by flow cytometry analysis,Other,24900323.0,
1473,711679,1,3,,103230651,5284373,Unspecified,,,,,Inhibition of Pgp-mediated drug efflux in adriamycin-resistant human A2780 cells assessed as increase in adriamycin-induced cytotoxicity at 5 uM after 1 hr by CCK-8 assay,Other,24900323.0,
1474,711680,1,3,,103230651,5284373,Unspecified,,,,,Inhibition of Pgp-mediated drug efflux in adriamycin-resistant human A2780 cells assessed as increase in adriamycin-induced cytotoxicity at 5 uM after 8 hrs by CCK-8 assay,Other,24900323.0,
1475,714200,1,2,,103230651,5284373,Unspecified,,,,,Inhibition of P-gp-mediated paclitaxel resistance in human LCC6MDR cells assessed as fold decrease in paclitaxel IC50 for cytotoxic activity at 1 uM after 5 days by MTS assay relative to parental cells,Other,22320402.0,
1476,714413,1,2,,103230651,5284373,Inconclusive,,,,,Inhibition of P-gp-mediated paclitaxel resistance in human LCC6MDR cells assessed as fold decrease in paclitaxel IC50 for cytotoxic activity at 0.5 uM after 5 days by MTS assay relative to parental cells,Other,22320402.0,
1477,714414,2,2,,103230651,5284373,Active,,,2.8,IC50,Cytotoxicity against human MDA435/LCC6MDR cells expressing MDR after 72 hrs,Confirmatory,22320402.0,
1478,714415,2,3,,103230651,5284373,Active,,,8.3,IC50,Cytotoxicity against human LCC-6 cells after 72 hrs,Confirmatory,22320402.0,
1479,714416,2,2,,103230651,5284373,Active,,,33.9,IC50,Cytotoxicity against mouse L929 cells after 72 hrs,Confirmatory,22320402.0,
1480,715592,1,2,,103230651,5284373,Unspecified,,,,,Cardioprotective activity in New Zealand White rabbit ischemia/reperfusion model assessed as reduction of infarct to risk area ratio at 10 mg/kg administered bolus 10 mins before coronary occlusion,Other,22925446.0,
1481,715593,1,2,,103230651,5284373,Unspecified,,,,,Cardioprotective activity in New Zealand White rabbit ischemia/reperfusion model assessed as reduction of infarct to risk area ratio at 10 mg/kg administered bolus 1 min before reperfusion,Other,22925446.0,
1482,719606,3,5,,103230651,5284373,Active,51702775.0,5478.0,0.01,Kd,Binding affinity to human cyclophilin A by fluorescence polarization assay,Confirmatory,24900335.0,
1483,719607,2,2,,103230651,5284373,Active,,,0.01,Kd,Binding affinity to cyclophilin A by surface plasmon resonance analysis,Confirmatory,24900335.0,
1484,719608,3,5,,103230651,5284373,Active,51702775.0,5478.0,0.01,Kd,Competitive binding affinity to biotinylated human recombinant T cell cyclophilin A expressed in Escherichia coli by spectrophotometric analysis,Confirmatory,24900335.0,
1485,720504,1,1,,56422786,5284373,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1486,720508,1,1,,57264292,5284373,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1487,720509,1,1,,57264292,5284373,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1488,720511,1,1,,57264292,5284373,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1489,720516,2,1,,144204218,5284373,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1490,720516,2,1,,144212166,5284373,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1491,720522,1,1,,56422786,5284373,Inactive,122893032.0,,,Potency,Nrf2 qHTS screen for inhibitors: Purified Fluc Biochemical Counterscreen for Hit Validation,Confirmatory,,
1492,720523,1,1,,56422786,5284373,Inconclusive,,,18.3564,Potency,Nrf2 qHTS screen for inhibitors: A549 ARE-Fluc Cytotoxicity Counterscreen for Hit Validation,Confirmatory,,
1493,720524,1,1,,56422786,5284373,Active,224028257.0,4780.0,16.3601,Potency,Nrf2 qHTS screen for inhibitors: Nrf2 A549 ARE-Fluc Confirmation Assay for Hit Validation,Confirmatory,,
1494,720532,1,1,,144204218,5284373,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1495,720533,1,1,,144204218,5284373,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1496,720542,1,2,,56422786,5284373,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1497,720543,1,1,,57264292,5284373,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1498,720551,1,2,,56422786,5284373,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1499,720552,2,1,,144204218,5284373,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1500,720552,2,1,,144212166,5284373,Inconclusive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1501,720553,1,2,,56422786,5284373,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1502,720579,2,1,,56422786,5284373,Inconclusive,222762.0,3707576.0,1.0,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1503,720580,1,1,,56422786,5284373,Inconclusive,222762.0,3707576.0,2.2387,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1504,720582,1,1,,57264292,5284373,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1505,720596,1,1,,57264292,5284373,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1506,720634,2,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1507,720634,2,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1508,720635,2,1,,144204218,5284373,Inconclusive,,,9.4392,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1509,720635,2,1,,144212166,5284373,Inconclusive,,,1.5935,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1510,720636,1,1,,26757675,5284373,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1511,720637,2,1,,144204218,5284373,Inconclusive,,,9.43918,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1512,720637,2,1,,144212166,5284373,Inconclusive,,,2.6242799999999997,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1513,720641,1,2,,92308685,5284373,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1514,720647,1,2,,57264292,5284373,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1515,720648,1,1,,57264292,5284373,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1516,720653,1,1,,26757675,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1517,720659,1,1,,26757675,5284373,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1518,720674,2,2,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1519,720674,2,2,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1520,720675,2,2,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1521,720675,2,2,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1522,720678,2,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1523,720678,2,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1524,720679,2,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1525,720679,2,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1526,720680,2,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1527,720680,2,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1528,720681,2,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1529,720681,2,1,,144212166,5284373,Inconclusive,,,5.0119,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1530,720682,2,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1531,720682,2,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1532,720683,2,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1533,720683,2,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1534,720684,2,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1535,720684,2,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1536,720685,2,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1537,720685,2,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1538,720686,2,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1539,720686,2,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1540,720687,2,2,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1541,720687,2,2,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1542,720691,4,1,,144204218,5284373,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1543,720691,4,1,,144212166,5284373,Inactive,311348376.0,2908.0,11.3801,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1544,720692,3,1,,144204218,5284373,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1545,720692,3,1,,144212166,5284373,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1546,720693,3,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1547,720693,3,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1548,720700,1,4,,57264292,5284373,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1549,720702,1,1,,57264292,5284373,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1550,720704,1,4,,57264292,5284373,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1551,720706,1,2,,57264292,5284373,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1552,720707,1,2,,56422786,5284373,Inactive,317373593.0,10411.0,2.5119,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1553,720708,1,2,,56422786,5284373,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1554,720709,1,2,,56422786,5284373,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1555,720711,1,2,,56422786,5284373,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1556,720717,1,3,,92125416,5284373,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1557,720717,1,3,,92308685,5284373,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1558,720719,2,1,,144204218,5284373,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1559,720719,2,1,,144212166,5284373,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1560,720725,2,1,,144204218,5284373,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1561,720725,2,1,,144212166,5284373,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1562,728305,1,4,,103230651,5284373,Active,,,,,Antioxidant activity in rat brain mitochondria assessed as inhibition of Ca2+/phosphate induced mitochondrial swelling by spectrophotometry,Other,23470245.0,
1563,728308,1,3,,103230651,5284373,Active,,,,,Antioxidant activity in rat liver mitochondria assessed as inhibition of Ca2+/phosphate induced mitochondrial swelling at 50 uM by spectrophotometry,Other,23470245.0,
1564,731548,1,2,,103230651,5284373,Active,,,0.054000000000000006,IC50,Immunosuppressive activity in human RPMI1788 cells cocultured with human PBMC assessed as inhibition of [3H]thymidine incorporation incubated for 6 days prior to [3H]thymidine addition measured after 18 hrs by liquid scintillation counting,Confirmatory,23347804.0,
1565,734049,1,2,,103230651,5284373,Unspecified,,,,,Inhibition of mPTP in mouse HT22 cells assessed as reduction in amyloid beta-induced mitochondrial membrane damage at 10 uM incubated for 10 mins prior to amyloid beta-challenge measured every 1 hr for 3 hrs by JC-1 based fluorometric analysis,Other,23353734.0,
1566,743012,3,1,,144204218,5284373,Active,,,23.7101,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1567,743012,3,1,,144212166,5284373,Active,,,2.8336,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1568,743014,3,1,,144204218,5284373,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1569,743014,3,1,,144212166,5284373,Active,,,4.0026,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1570,743015,3,1,,144204218,5284373,Active,,,23.7101,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1571,743015,3,1,,144212166,5284373,Active,,,1.7879,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1572,743033,3,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1573,743033,3,1,,144212166,5284373,Inconclusive,,,16.0749,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1574,743035,2,1,,144204218,5284373,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1575,743035,2,1,,144212166,5284373,Inconclusive,124375976.0,367.0,9.0396,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1576,743036,2,1,,144204218,5284373,Inconclusive,124375976.0,367.0,6.007000000000001,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1577,743036,2,1,,144212166,5284373,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1578,743040,3,1,,144204218,5284373,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1579,743040,3,1,,144212166,5284373,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1580,743041,3,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1581,743041,3,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1582,743042,3,1,,144204218,5284373,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1583,743042,3,1,,144212166,5284373,Inconclusive,124375976.0,367.0,10.0541,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1584,743053,2,1,,144204218,5284373,Inconclusive,124375976.0,367.0,12.9418,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1585,743053,2,1,,144212166,5284373,Inconclusive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1586,743054,2,1,,144204218,5284373,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1587,743054,2,1,,144212166,5284373,Inconclusive,124375976.0,367.0,5.65385,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1588,743063,2,1,,144204218,5284373,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1589,743063,2,1,,144212166,5284373,Inconclusive,124375976.0,367.0,9.760689999999999,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1590,743064,3,1,,144204218,5284373,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1591,743064,3,1,,144212166,5284373,Active,,,11.2809,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1592,743065,3,1,,144204218,5284373,Inconclusive,399498506.0,24831.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1593,743065,3,1,,144212166,5284373,Active,399498506.0,24831.0,8.9607,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1594,743066,3,1,,144204218,5284373,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1595,743066,3,1,,144212166,5284373,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1596,743067,2,1,,144204218,5284373,Inconclusive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1597,743067,2,1,,144212166,5284373,Inconclusive,399498506.0,24831.0,9.31131,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1598,743069,2,1,,144204218,5284373,Inconclusive,348019627.0,2099.0,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1599,743069,2,1,,144212166,5284373,Inconclusive,348019627.0,2099.0,4.5305,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1600,743074,2,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1601,743074,2,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1602,743075,2,1,,144204218,5284373,Inactive,348019627.0,2099.0,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1603,743075,2,1,,144212166,5284373,Inactive,348019627.0,2099.0,10.1426,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1604,743077,2,1,,144204218,5284373,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1605,743077,2,1,,144212166,5284373,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1606,743078,2,1,,144204218,5284373,Inconclusive,348019627.0,2099.0,25.3315,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1607,743078,2,1,,144212166,5284373,Inconclusive,348019627.0,2099.0,5.7035800000000005,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1608,743079,3,1,,144204218,5284373,Inactive,348019627.0,2099.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1609,743079,3,1,,144212166,5284373,Inconclusive,348019627.0,2099.0,8.9607,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1610,743080,3,1,,144204218,5284373,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1611,743080,3,1,,144212166,5284373,Inconclusive,348019627.0,2099.0,15.9347,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1612,743081,3,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1613,743081,3,1,,144212166,5284373,Inconclusive,,,12.6574,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1614,743083,3,1,,144204218,5284373,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1615,743083,3,1,,144212166,5284373,Active,119597822.0,1588.0,11.2809,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1616,743084,3,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1617,743084,3,1,,144212166,5284373,Active,,,11.2809,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1618,743085,3,1,,144204218,5284373,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1619,743085,3,1,,144212166,5284373,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1620,743086,3,1,,144204218,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1621,743086,3,1,,144212166,5284373,Inconclusive,,,20.0606,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1622,743091,2,1,,144204218,5284373,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1623,743091,2,1,,144212166,5284373,Inconclusive,348019627.0,2099.0,17.2059,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1624,743094,3,1,,144204218,5284373,Inconclusive,216409692.0,5468.0,6.007000000000001,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1625,743094,3,1,,144212166,5284373,Inconclusive,216409692.0,5468.0,16.0749,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1626,743122,2,1,,144204218,5284373,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1627,743122,2,1,,144212166,5284373,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1628,743126,1,1,,57264292,5284373,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1629,743139,2,1,,144204218,5284373,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1630,743139,2,1,,144212166,5284373,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1631,743140,2,1,,144204218,5284373,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1632,743140,2,1,,144212166,5284373,Inconclusive,216409692.0,5468.0,4.277080000000001,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1633,743191,3,1,,144212166,5284373,Inconclusive,216409692.0,5468.0,6.3995,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1634,743191,3,1,,170466812,5284373,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1635,743194,3,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1636,743194,3,1,,170466812,5284373,Inconclusive,,,13.3322,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1637,743199,2,1,,144212166,5284373,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1638,743199,2,1,,170466812,5284373,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1639,743202,4,1,,144212166,5284373,Active,20149576.0,4780.0,5.6538,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1640,743202,4,1,,170466812,5284373,Active,20149576.0,4780.0,5.9553,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1641,743203,3,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1642,743203,3,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1643,743209,3,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1644,743209,3,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1645,743210,4,1,,144212166,5284373,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1646,743210,4,1,,170466812,5284373,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1647,743211,3,1,,144212166,5284373,Inconclusive,,,3.2074,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1648,743211,3,1,,170466812,5284373,Inconclusive,,,13.3322,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1649,743212,3,1,,144212166,5284373,Inconclusive,216409690.0,5467.0,20.237000000000002,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1650,743212,3,1,,170466812,5284373,Inconclusive,216409690.0,5467.0,6.6819,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1651,743213,3,1,,144212166,5284373,Inconclusive,,,5.0833,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1652,743213,3,1,,170466812,5284373,Inconclusive,,,3.3489,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1653,743215,3,1,,144212166,5284373,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1654,743215,3,1,,170466812,5284373,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1655,743217,3,1,,144212166,5284373,Inconclusive,325495553.0,9971.0,14.3267,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1656,743217,3,1,,170466812,5284373,Inconclusive,325495553.0,9971.0,7.4972,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1657,743218,3,1,,144212166,5284373,Inconclusive,,,7.1804,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1658,743218,3,1,,170466812,5284373,Inconclusive,,,8.412,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1659,743219,3,1,,144212166,5284373,Active,20149576.0,4780.0,5.65385,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1660,743219,3,1,,170466812,5284373,Active,20149576.0,4780.0,5.1078,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1661,743220,3,1,,144212166,5284373,Inconclusive,325495553.0,9971.0,2.2706,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1662,743220,3,1,,170466812,5284373,Inconclusive,325495553.0,9971.0,47.3043,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1663,743221,3,1,,144212166,5284373,Inconclusive,,,11.3801,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1664,743221,3,1,,170466812,5284373,Active,,,11.8823,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1665,743222,3,1,,144212166,5284373,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1666,743222,3,1,,170466812,5284373,Inconclusive,216409708.0,7421.0,10.5901,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1667,743223,3,1,,144212166,5284373,Inconclusive,216409708.0,7421.0,6.3995,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1668,743223,3,1,,170466812,5284373,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1669,743224,3,1,,144212166,5284373,Inconclusive,,,8.0565,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1670,743224,3,1,,170466812,5284373,Inconclusive,,,13.3322,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1671,743225,3,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1672,743225,3,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1673,743226,2,1,,144212166,5284373,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1674,743226,2,1,,170466812,5284373,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1675,743227,2,1,,144212166,5284373,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1676,743227,2,1,,170466812,5284373,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1677,743228,3,1,,144212166,5284373,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1678,743228,3,1,,170466812,5284373,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1679,743238,1,1,,57264292,5284373,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1680,743239,2,1,,144212166,5284373,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1681,743239,2,1,,170466812,5284373,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1682,743240,2,1,,144212166,5284373,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1683,743240,2,1,,170466812,5284373,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1684,743241,2,1,,144212166,5284373,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1685,743241,2,1,,170466812,5284373,Inconclusive,216409708.0,7421.0,6.6819,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1686,743242,2,1,,144212166,5284373,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1687,743242,2,1,,170466812,5284373,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1688,743244,1,1,,144204218,5284373,Inconclusive,,,15.8489,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1689,743247,1,2,,57264292,5284373,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1690,743255,1,1,,56422786,5284373,Inconclusive,118600387.0,7398.0,354.81300000000005,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1691,743266,1,2,,56422786,5284373,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1692,743269,1,1,,57264292,5284373,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1693,743269,1,1,,57264292,5284373,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1694,743279,1,2,,56422786,5284373,Active,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1695,743287,1,1,,57264292,5284373,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
1696,743288,1,1,,26757675,5284373,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
1697,743292,1,1,,26757675,5284373,Active,,,22.3872,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
1698,743397,1,1,,57264292,5284373,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1699,743398,1,1,,57264292,5284373,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1700,762644,1,1,,103230651,5284373,Active,,,0.23,EC50,Antiviral activity against Hepatitis C virus,Confirmatory,23849880.0,
1701,762654,1,1,,103230651,5284373,Active,,,0.45,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells coinfected with HTLV1 assessed as reduction in virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,23849880.0,
1702,768683,2,3,,103230651,5284373,Active,296439301.0,4363.0,2.81,IC50,Inhibition of MRP1 (unknown origin) expressed in human 2008 cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay,Confirmatory,23851114.0,
1703,768684,2,1,,103230651,5284373,Active,238054374.0,5243.0,0.99,IC50,Inhibition of p-glycoprotein (unknown origin) expressed in human A2780Adr cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay,Confirmatory,23851114.0,
1704,770463,1,1,,103230651,5284373,Active,,,,,"Cellular uptake in human Jurkat T cells assessed as displacemnet of [O-(2-acetamido)-D-serine]8-cyclosporine N-{(5-aminopentyl)-[2,3,6,7-tetrahydro-11-oxo-1H,5H,11Hbenzopyrano(6,7,8-ij)quinolizine-10-carboxyl amide] from intracellular compartments after 90 mins by flow cytometric analysis",Other,23964991.0,
1705,770484,1,1,,103230651,5284373,Active,,,0.0014,IC50,Inhibition of NFAT activation in PMA/ionomycin-stimulated human Jurkat T cells incubated for 30 mins prior to PMA/ionomycin stimulation measured after 5 hrs by luciferase reporter gene assay,Confirmatory,23964991.0,
1706,770486,3,1,,103230651,5284373,Unspecified,,,,IC50,Inhibition of calcineurin phosphatase activity (unknown origin) assessed as R2 phosphopeptide dephosphorylation after 30 mins by malachite green staining assay in presence of calmodulin and CypA,Confirmatory,23964991.0,
1707,770489,2,3,,103230651,5284373,Active,51702775.0,5478.0,0.0122,Ki,Inhibition of CypA PPIase activity (unknown origin) using Glt-(Ala)n-Pro-Phe-4-nitroanilides as substrate,Confirmatory,23964991.0,
1708,774653,1,1,,103230651,5284373,Active,,,0.00114,IC50,Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei 427 after 3 days by Alamar Blue assay,Confirmatory,23927763.0,
1709,826913,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/5,Other,,
1710,826914,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/5,Other,,
1711,826915,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/5,Other,,
1712,826916,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/5,Other,,
1713,826917,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/5,Other,,
1714,826918,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/5,Other,,
1715,826919,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/5,Other,,
1716,826920,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/6,Other,,
1717,826921,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/6,Other,,
1718,826922,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/6,Other,,
1719,826923,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/6,Other,,
1720,826924,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/6,Other,,
1721,826925,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/6,Other,,
1722,826926,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/6,Other,,
1723,826927,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/6,Other,,
1724,826928,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/6,Other,,
1725,826929,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/6,Other,,
1726,826930,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/6,Other,,
1727,826931,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/6,Other,,
1728,826932,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/6,Other,,
1729,826933,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/6,Other,,
1730,826934,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/6,Other,,
1731,826935,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/6,Other,,
1732,826936,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/6,Other,,
1733,826937,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/7,Other,,
1734,826938,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/7,Other,,
1735,826939,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/7,Other,,
1736,826940,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/7,Other,,
1737,826941,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/7,Other,,
1738,826942,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/7,Other,,
1739,826943,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/7,Other,,
1740,826944,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/7,Other,,
1741,826945,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/7,Other,,
1742,826946,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/7,Other,,
1743,826947,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/7,Other,,
1744,826948,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/7,Other,,
1745,826949,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/7,Other,,
1746,826950,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/7,Other,,
1747,826951,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/7,Other,,
1748,826952,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/7,Other,,
1749,826953,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/7,Other,,
1750,826954,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/8,Other,,
1751,826955,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/8,Other,,
1752,826991,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/16,Other,,
1753,826992,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/16,Other,,
1754,826993,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/16,Other,,
1755,826994,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/16,Other,,
1756,826995,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/16,Other,,
1757,826996,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/16,Other,,
1758,826997,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/16,Other,,
1759,826998,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/16,Other,,
1760,826999,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/16,Other,,
1761,827000,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/5,Other,,
1762,827001,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/5,Other,,
1763,827002,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/5,Other,,
1764,827532,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/5,Other,,
1765,827533,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/5,Other,,
1766,827534,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/5,Other,,
1767,827535,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/5,Other,,
1768,827536,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/5,Other,,
1769,827537,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/5,Other,,
1770,827538,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/5,Other,,
1771,827539,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/5,Other,,
1772,827540,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/5,Other,,
1773,827541,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/5,Other,,
1774,827542,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/5,Other,,
1775,827543,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/5,Other,,
1776,827544,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/5,Other,,
1777,827545,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/5,Other,,
1778,827546,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/6,Other,,
1779,827547,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/6,Other,,
1780,827548,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/6,Other,,
1781,827549,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/6,Other,,
1782,827550,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/6,Other,,
1783,827551,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/6,Other,,
1784,827552,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/6,Other,,
1785,827553,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/6,Other,,
1786,827554,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/6,Other,,
1787,827555,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/6,Other,,
1788,827556,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/6,Other,,
1789,827557,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/6,Other,,
1790,827558,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/6,Other,,
1791,827559,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/6,Other,,
1792,827560,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/6,Other,,
1793,827561,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/6,Other,,
1794,827562,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/6,Other,,
1795,827563,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/7,Other,,
1796,827564,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/7,Other,,
1797,827565,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/7,Other,,
1798,827566,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/7,Other,,
1799,827601,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/15,Other,,
1800,827602,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/15,Other,,
1801,827603,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/15,Other,,
1802,827604,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/15,Other,,
1803,827605,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/15,Other,,
1804,827606,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/15,Other,,
1805,827607,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/15,Other,,
1806,827608,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/15,Other,,
1807,827609,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/15,Other,,
1808,827610,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/16,Other,,
1809,827611,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/16,Other,,
1810,827612,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/16,Other,,
1811,827613,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/16,Other,,
1812,827614,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/16,Other,,
1813,827615,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/16,Other,,
1814,827616,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/16,Other,,
1815,827617,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/16,Other,,
1816,827618,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/16,Other,,
1817,827619,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/16,Other,,
1818,828174,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/16,Other,,
1819,828175,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/16,Other,,
1820,828176,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/16,Other,,
1821,828177,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/16,Other,,
1822,828178,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/16,Other,,
1823,828179,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/16,Other,,
1824,828180,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/16,Other,,
1825,829189,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/8,Other,,
1826,829190,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/8,Other,,
1827,829191,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/8,Other,,
1828,829192,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/8,Other,,
1829,829193,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/8,Other,,
1830,829194,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/8,Other,,
1831,829195,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/8,Other,,
1832,829196,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/8,Other,,
1833,829197,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/8,Other,,
1834,829198,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/8,Other,,
1835,829199,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/8,Other,,
1836,829200,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/8,Other,,
1837,829201,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/8,Other,,
1838,829202,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/8,Other,,
1839,829203,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/8,Other,,
1840,829204,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/9,Other,,
1841,829205,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/9,Other,,
1842,829206,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/9,Other,,
1843,829207,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/9,Other,,
1844,829208,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/9,Other,,
1845,829209,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/9,Other,,
1846,829210,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/9,Other,,
1847,829211,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/9,Other,,
1848,829212,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/9,Other,,
1849,829213,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/9,Other,,
1850,829214,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/9,Other,,
1851,829215,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/9,Other,,
1852,829216,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/9,Other,,
1853,829217,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/9,Other,,
1854,829218,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/9,Other,,
1855,829219,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/9,Other,,
1856,829220,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/9,Other,,
1857,829221,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/10,Other,,
1858,829222,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/10,Other,,
1859,829223,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/10,Other,,
1860,829224,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/10,Other,,
1861,829225,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/10,Other,,
1862,829226,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/10,Other,,
1863,829227,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/10,Other,,
1864,829271,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/7,Other,,
1865,829272,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/7,Other,,
1866,829742,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/10,Other,,
1867,829743,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/10,Other,,
1868,829744,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/10,Other,,
1869,829745,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/10,Other,,
1870,829746,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/10,Other,,
1871,829747,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/10,Other,,
1872,829748,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/10,Other,,
1873,829749,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/10,Other,,
1874,829786,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/7,Other,,
1875,829787,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/7,Other,,
1876,829788,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/7,Other,,
1877,829789,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/7,Other,,
1878,829790,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/7,Other,,
1879,829791,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/7,Other,,
1880,829792,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/7,Other,,
1881,829793,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/7,Other,,
1882,829794,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/7,Other,,
1883,829795,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/7,Other,,
1884,829796,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/7,Other,,
1885,829797,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/8,Other,,
1886,829798,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/8,Other,,
1887,829799,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/8,Other,,
1888,829800,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/8,Other,,
1889,829801,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/8,Other,,
1890,829802,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/8,Other,,
1891,829803,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/8,Other,,
1892,829804,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/8,Other,,
1893,829805,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/8,Other,,
1894,829806,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/8,Other,,
1895,829807,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/8,Other,,
1896,829808,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/8,Other,,
1897,829809,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/8,Other,,
1898,829810,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/8,Other,,
1899,829811,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/8,Other,,
1900,829812,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/8,Other,,
1901,829813,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/8,Other,,
1902,829814,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/9,Other,,
1903,829815,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/9,Other,,
1904,829816,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/9,Other,,
1905,829817,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/9,Other,,
1906,829818,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/9,Other,,
1907,829819,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/9,Other,,
1908,829820,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/9,Other,,
1909,829821,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/9,Other,,
1910,829822,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/9,Other,,
1911,829823,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/9,Other,,
1912,829824,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/9,Other,,
1913,829825,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/9,Other,,
1914,829826,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/9,Other,,
1915,829827,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/9,Other,,
1916,829828,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/9,Other,,
1917,829829,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/9,Other,,
1918,830400,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/9,Other,,
1919,831467,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/10,Other,,
1920,831468,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/10,Other,,
1921,831469,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/11,Other,,
1922,831470,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/11,Other,,
1923,831471,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/11,Other,,
1924,831472,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/11,Other,,
1925,831473,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/11,Other,,
1926,831474,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/11,Other,,
1927,831475,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/11,Other,,
1928,831476,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/11,Other,,
1929,831477,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/11,Other,,
1930,831478,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/11,Other,,
1931,831479,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/11,Other,,
1932,831480,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/11,Other,,
1933,831481,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/11,Other,,
1934,831482,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/11,Other,,
1935,831483,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/11,Other,,
1936,831484,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/11,Other,,
1937,831485,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/11,Other,,
1938,831486,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/12,Other,,
1939,831487,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/12,Other,,
1940,831488,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/12,Other,,
1941,831489,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/12,Other,,
1942,831490,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/12,Other,,
1943,831491,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/12,Other,,
1944,831492,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/12,Other,,
1945,831493,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/12,Other,,
1946,831494,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/12,Other,,
1947,831495,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/12,Other,,
1948,831496,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/12,Other,,
1949,831497,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/12,Other,,
1950,831980,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/12,Other,,
1951,831981,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/12,Other,,
1952,831982,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/12,Other,,
1953,831983,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/12,Other,,
1954,831984,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/12,Other,,
1955,831985,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/13,Other,,
1956,831986,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/13,Other,,
1957,831987,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/13,Other,,
1958,831988,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/13,Other,,
1959,831989,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/13,Other,,
1960,831990,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/13,Other,,
1961,831991,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/13,Other,,
1962,831992,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/13,Other,,
1963,831993,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/13,Other,,
1964,831994,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/13,Other,,
1965,831995,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/13,Other,,
1966,832031,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/10,Other,,
1967,832032,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/10,Other,,
1968,832033,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/10,Other,,
1969,832034,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/10,Other,,
1970,832035,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/10,Other,,
1971,832036,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/10,Other,,
1972,832037,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/10,Other,,
1973,832038,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/10,Other,,
1974,832039,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/10,Other,,
1975,832040,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/10,Other,,
1976,832041,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/10,Other,,
1977,832042,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/10,Other,,
1978,832043,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/10,Other,,
1979,832044,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/10,Other,,
1980,832045,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/10,Other,,
1981,832046,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/10,Other,,
1982,832047,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/10,Other,,
1983,832048,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/11,Other,,
1984,832049,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/11,Other,,
1985,832050,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/11,Other,,
1986,832051,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/11,Other,,
1987,832052,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/11,Other,,
1988,832053,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/11,Other,,
1989,832054,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/11,Other,,
1990,832055,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/11,Other,,
1991,832056,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/11,Other,,
1992,832057,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/11,Other,,
1993,832058,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/11,Other,,
1994,832059,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/11,Other,,
1995,832060,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/11,Other,,
1996,832061,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/11,Other,,
1997,832062,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/11,Other,,
1998,832063,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/11,Other,,
1999,832064,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/11,Other,,
2000,832065,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/12,Other,,
2001,832066,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/12,Other,,
2002,832067,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/12,Other,,
2003,832643,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/12,Other,,
2004,832644,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/12,Other,,
2005,832645,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/12,Other,,
2006,832646,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/12,Other,,
2007,832647,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/12,Other,,
2008,832648,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/12,Other,,
2009,832649,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/12,Other,,
2010,832650,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/12,Other,,
2011,832651,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/12,Other,,
2012,833731,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/13,Other,,
2013,833732,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/13,Other,,
2014,833733,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/13,Other,,
2015,833734,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/13,Other,,
2016,833735,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/13,Other,,
2017,833736,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/13,Other,,
2018,833737,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/14,Other,,
2019,833738,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/14,Other,,
2020,833739,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/14,Other,,
2021,833740,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/14,Other,,
2022,833741,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/14,Other,,
2023,833742,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/14,Other,,
2024,833743,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/14,Other,,
2025,833744,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/14,Other,,
2026,833745,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/14,Other,,
2027,833746,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/14,Other,,
2028,833747,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/14,Other,,
2029,833748,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/14,Other,,
2030,833749,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/14,Other,,
2031,833750,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/14,Other,,
2032,833751,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/14,Other,,
2033,834248,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/14,Other,,
2034,834249,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/14,Other,,
2035,834250,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/15,Other,,
2036,834251,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/15,Other,,
2037,834252,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/15,Other,,
2038,834253,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/15,Other,,
2039,834254,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/15,Other,,
2040,834255,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/15,Other,,
2041,834256,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/15,Other,,
2042,834257,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/15,Other,,
2043,834258,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/15,Other,,
2044,834259,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/15,Other,,
2045,834260,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 604/15,Other,,
2046,834261,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 604/15,Other,,
2047,834262,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 604/15,Other,,
2048,834263,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 604/15,Other,,
2049,834264,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 604/15,Other,,
2050,834265,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 604/15,Other,,
2051,834266,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 604/15,Other,,
2052,834267,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/16,Other,,
2053,834268,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/16,Other,,
2054,834269,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/16,Other,,
2055,834270,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/16,Other,,
2056,834271,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/16,Other,,
2057,834272,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/16,Other,,
2058,834273,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/16,Other,,
2059,834274,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/16,Other,,
2060,834307,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/12,Other,,
2061,834308,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/12,Other,,
2062,834309,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/12,Other,,
2063,834310,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/12,Other,,
2064,834311,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/12,Other,,
2065,834312,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/13,Other,,
2066,834313,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/13,Other,,
2067,834314,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/13,Other,,
2068,834315,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/13,Other,,
2069,834316,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/13,Other,,
2070,834317,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/13,Other,,
2071,834318,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/13,Other,,
2072,834319,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/13,Other,,
2073,834320,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/13,Other,,
2074,834321,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/13,Other,,
2075,834322,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/13,Other,,
2076,834323,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/13,Other,,
2077,834324,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/13,Other,,
2078,834325,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/13,Other,,
2079,834326,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/13,Other,,
2080,834327,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/13,Other,,
2081,834328,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/13,Other,,
2082,834329,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/14,Other,,
2083,834330,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/14,Other,,
2084,834331,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/14,Other,,
2085,834332,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/14,Other,,
2086,834333,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/14,Other,,
2087,834334,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/14,Other,,
2088,834335,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/14,Other,,
2089,834928,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/14,Other,,
2090,834929,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 605/14,Other,,
2091,834930,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 605/14,Other,,
2092,834931,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 605/14,Other,,
2093,834932,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 605/14,Other,,
2094,834933,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 605/14,Other,,
2095,834934,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 605/14,Other,,
2096,834935,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 605/14,Other,,
2097,834936,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 605/14,Other,,
2098,834937,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 605/14,Other,,
2099,834938,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 605/15,Other,,
2100,834939,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 605/15,Other,,
2101,834940,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 605/15,Other,,
2102,834941,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 605/15,Other,,
2103,834942,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 605/15,Other,,
2104,834943,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 605/15,Other,,
2105,834944,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 605/15,Other,,
2106,834945,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 605/15,Other,,
2107,835051,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 604/5,Other,,
2108,835052,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 604/5,Other,,
2109,835053,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 604/5,Other,,
2110,835054,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 604/5,Other,,
2111,835055,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 604/5,Other,,
2112,835449,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 604/5,Other,,
2113,835450,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 604/5,Other,,
2114,835451,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 604/5,Other,,
2115,835452,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 604/5,Other,,
2116,835453,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 604/5,Other,,
2117,847414,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/11,Other,,
2118,847415,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/11,Other,,
2119,847416,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/11,Other,,
2120,847417,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/11,Other,,
2121,847418,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/11,Other,,
2122,847419,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/11,Other,,
2123,847420,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/11,Other,,
2124,847421,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/11,Other,,
2125,847422,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/11,Other,,
2126,847423,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/11,Other,,
2127,847424,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/11,Other,,
2128,847425,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/11,Other,,
2129,847426,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/11,Other,,
2130,847427,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/11,Other,,
2131,847428,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/11,Other,,
2132,847429,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/11,Other,,
2133,847430,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/12,Other,,
2134,847431,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/12,Other,,
2135,847432,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/12,Other,,
2136,847433,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/12,Other,,
2137,847434,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/12,Other,,
2138,847435,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/12,Other,,
2139,847436,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/12,Other,,
2140,847437,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/12,Other,,
2141,847438,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/12,Other,,
2142,847439,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/12,Other,,
2143,847440,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/12,Other,,
2144,847441,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/12,Other,,
2145,847442,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/12,Other,,
2146,847443,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/12,Other,,
2147,847444,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/12,Other,,
2148,847445,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/12,Other,,
2149,847446,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/12,Other,,
2150,847447,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/12,Other,,
2151,847448,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/12,Other,,
2152,847449,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/12,Other,,
2153,847450,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/12,Other,,
2154,847524,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/5,Other,,
2155,847525,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/5,Other,,
2156,847526,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/5,Other,,
2157,847527,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/5,Other,,
2158,847528,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/5,Other,,
2159,847529,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/5,Other,,
2160,847530,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/5,Other,,
2161,847531,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/5,Other,,
2162,847532,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/5,Other,,
2163,847533,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/5,Other,,
2164,847534,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/5,Other,,
2165,847535,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/5,Other,,
2166,847536,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/5,Other,,
2167,847537,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/5,Other,,
2168,847538,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/5,Other,,
2169,847539,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/5,Other,,
2170,847540,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/5,Other,,
2171,847541,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/5,Other,,
2172,847542,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/5,Other,,
2173,847543,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/5,Other,,
2174,847544,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/5,Other,,
2175,847545,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/6,Other,,
2176,847546,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/6,Other,,
2177,847993,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/6,Other,,
2178,847994,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/6,Other,,
2179,847995,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/6,Other,,
2180,847996,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/6,Other,,
2181,847997,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/6,Other,,
2182,847998,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/6,Other,,
2183,847999,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/6,Other,,
2184,848000,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/6,Other,,
2185,848001,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/6,Other,,
2186,848002,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/6,Other,,
2187,848003,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/6,Other,,
2188,848004,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/6,Other,,
2189,848005,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/6,Other,,
2190,848006,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/6,Other,,
2191,848007,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/6,Other,,
2192,848008,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/6,Other,,
2193,848009,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/6,Other,,
2194,848318,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/6,Other,,
2195,848319,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/6,Other,,
2196,848320,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/7,Other,,
2197,848321,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/7,Other,,
2198,848322,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/7,Other,,
2199,848323,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/7,Other,,
2200,848324,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/7,Other,,
2201,848325,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/7,Other,,
2202,848326,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/7,Other,,
2203,848327,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/7,Other,,
2204,848328,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/7,Other,,
2205,848329,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/7,Other,,
2206,848330,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/7,Other,,
2207,848331,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/7,Other,,
2208,848332,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/7,Other,,
2209,848333,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/7,Other,,
2210,848334,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/7,Other,,
2211,848335,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/7,Other,,
2212,848336,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/7,Other,,
2213,848337,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/7,Other,,
2214,848338,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/7,Other,,
2215,848339,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/7,Other,,
2216,848340,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/7,Other,,
2217,848341,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/8,Other,,
2218,848342,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/8,Other,,
2219,848343,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/8,Other,,
2220,848344,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/8,Other,,
2221,848345,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/8,Other,,
2222,848346,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/8,Other,,
2223,848347,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/8,Other,,
2224,916007,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/8,Other,,
2225,916008,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/8,Other,,
2226,916009,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/8,Other,,
2227,916010,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/8,Other,,
2228,916011,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/8,Other,,
2229,916012,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/8,Other,,
2230,916013,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/8,Other,,
2231,916014,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/8,Other,,
2232,916015,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/8,Other,,
2233,916016,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/8,Other,,
2234,916017,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/8,Other,,
2235,916018,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/8,Other,,
2236,916019,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/8,Other,,
2237,916020,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/8,Other,,
2238,916021,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/9,Other,,
2239,916022,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/9,Other,,
2240,916023,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/9,Other,,
2241,916024,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/9,Other,,
2242,916058,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/16,Other,,
2243,916059,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/16,Other,,
2244,916060,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/16,Other,,
2245,916061,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/16,Other,,
2246,916062,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/16,Other,,
2247,916063,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/16,Other,,
2248,916064,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/16,Other,,
2249,916065,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/16,Other,,
2250,916066,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/16,Other,,
2251,916067,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/16,Other,,
2252,916068,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/16,Other,,
2253,916069,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/16,Other,,
2254,916070,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/16,Other,,
2255,916071,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/16,Other,,
2256,916072,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/16,Other,,
2257,916073,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/16,Other,,
2258,916074,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/16,Other,,
2259,916075,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/16,Other,,
2260,916076,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/16,Other,,
2261,916077,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/16,Other,,
2262,916078,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/5,Other,,
2263,916079,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/5,Other,,
2264,916080,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/5,Other,,
2265,916081,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/5,Other,,
2266,916082,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/5,Other,,
2267,916083,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/5,Other,,
2268,916084,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/5,Other,,
2269,916085,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/5,Other,,
2270,916086,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/5,Other,,
2271,916087,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/5,Other,,
2272,916088,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/5,Other,,
2273,916089,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/5,Other,,
2274,916090,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/5,Other,,
2275,916091,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/5,Other,,
2276,916092,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/5,Other,,
2277,916093,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/5,Other,,
2278,916094,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/5,Other,,
2279,916095,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/5,Other,,
2280,916096,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/5,Other,,
2281,916140,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/13,Other,,
2282,916546,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/5,Other,,
2283,916547,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/5,Other,,
2284,916548,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/6,Other,,
2285,916549,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/6,Other,,
2286,916550,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/6,Other,,
2287,916551,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/6,Other,,
2288,916552,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/6,Other,,
2289,916553,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/6,Other,,
2290,916554,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/6,Other,,
2291,916591,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/13,Other,,
2292,916592,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/13,Other,,
2293,916593,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/13,Other,,
2294,916594,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/13,Other,,
2295,916595,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/13,Other,,
2296,916596,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/13,Other,,
2297,916597,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/13,Other,,
2298,916598,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/13,Other,,
2299,916599,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/13,Other,,
2300,916600,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/13,Other,,
2301,916601,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/13,Other,,
2302,916602,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/13,Other,,
2303,916603,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/13,Other,,
2304,916604,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/13,Other,,
2305,916605,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/13,Other,,
2306,916606,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/13,Other,,
2307,916607,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/13,Other,,
2308,916608,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/13,Other,,
2309,916609,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/13,Other,,
2310,916610,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/13,Other,,
2311,916611,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/14,Other,,
2312,916612,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/14,Other,,
2313,916613,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/14,Other,,
2314,916614,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/14,Other,,
2315,916615,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/14,Other,,
2316,916616,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/14,Other,,
2317,916617,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/14,Other,,
2318,916618,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/14,Other,,
2319,916619,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/14,Other,,
2320,916620,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/14,Other,,
2321,916621,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/14,Other,,
2322,916622,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/14,Other,,
2323,916623,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/14,Other,,
2324,916624,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/14,Other,,
2325,916625,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/14,Other,,
2326,916626,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/14,Other,,
2327,916627,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/14,Other,,
2328,916628,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/14,Other,,
2329,916629,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/14,Other,,
2330,916630,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/14,Other,,
2331,916631,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/14,Other,,
2332,916632,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/15,Other,,
2333,916633,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/15,Other,,
2334,916634,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/15,Other,,
2335,916635,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/15,Other,,
2336,917084,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/15,Other,,
2337,917509,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/9,Other,,
2338,917510,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/9,Other,,
2339,917511,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/9,Other,,
2340,917512,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/9,Other,,
2341,917513,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/9,Other,,
2342,917514,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/9,Other,,
2343,917515,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/9,Other,,
2344,917516,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/9,Other,,
2345,917517,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/9,Other,,
2346,917518,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/9,Other,,
2347,917519,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/9,Other,,
2348,917520,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/9,Other,,
2349,917521,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/9,Other,,
2350,917522,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/9,Other,,
2351,917523,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/9,Other,,
2352,917524,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/9,Other,,
2353,917525,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/9,Other,,
2354,917526,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/10,Other,,
2355,917527,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/10,Other,,
2356,917528,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/10,Other,,
2357,917968,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/10,Other,,
2358,917969,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/10,Other,,
2359,917970,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/10,Other,,
2360,917971,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/10,Other,,
2361,917972,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/10,Other,,
2362,917973,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/10,Other,,
2363,917974,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/10,Other,,
2364,917975,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/10,Other,,
2365,917976,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/10,Other,,
2366,917977,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/10,Other,,
2367,917978,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/10,Other,,
2368,917979,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/10,Other,,
2369,917980,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/10,Other,,
2370,917981,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/10,Other,,
2371,917982,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/10,Other,,
2372,917983,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/10,Other,,
2373,917984,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/10,Other,,
2374,917985,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/10,Other,,
2375,917986,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/11,Other,,
2376,917987,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/11,Other,,
2377,917988,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/11,Other,,
2378,917989,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/11,Other,,
2379,917990,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/11,Other,,
2380,917991,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/11,Other,,
2381,917992,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/11,Other,,
2382,917993,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/11,Other,,
2383,917994,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/11,Other,,
2384,917995,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/11,Other,,
2385,918029,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/6,Other,,
2386,918030,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/6,Other,,
2387,918031,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/6,Other,,
2388,918032,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/6,Other,,
2389,918033,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/6,Other,,
2390,918034,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/6,Other,,
2391,918035,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/6,Other,,
2392,918036,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/6,Other,,
2393,918037,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/6,Other,,
2394,918038,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/6,Other,,
2395,918039,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/6,Other,,
2396,918040,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/6,Other,,
2397,918041,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/6,Other,,
2398,918042,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/6,Other,,
2399,918043,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/7,Other,,
2400,918044,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/7,Other,,
2401,918045,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/7,Other,,
2402,918046,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/7,Other,,
2403,918047,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/7,Other,,
2404,918048,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/7,Other,,
2405,918049,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/7,Other,,
2406,918050,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/7,Other,,
2407,918051,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/7,Other,,
2408,918052,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/7,Other,,
2409,918053,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/7,Other,,
2410,918054,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/7,Other,,
2411,918055,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/7,Other,,
2412,918056,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/7,Other,,
2413,918057,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/7,Other,,
2414,918460,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/7,Other,,
2415,918461,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/7,Other,,
2416,918462,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/7,Other,,
2417,918463,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/7,Other,,
2418,918464,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/7,Other,,
2419,918465,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/7,Other,,
2420,918466,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/8,Other,,
2421,918467,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/8,Other,,
2422,918468,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/8,Other,,
2423,918469,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/8,Other,,
2424,918470,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/8,Other,,
2425,918471,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/8,Other,,
2426,918472,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/8,Other,,
2427,918473,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/8,Other,,
2428,918474,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/8,Other,,
2429,918475,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/8,Other,,
2430,918476,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/8,Other,,
2431,918477,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/8,Other,,
2432,918512,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/15,Other,,
2433,918513,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/15,Other,,
2434,918514,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/15,Other,,
2435,918515,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/15,Other,,
2436,918516,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/15,Other,,
2437,918517,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/15,Other,,
2438,918518,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/15,Other,,
2439,918519,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/15,Other,,
2440,918520,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/15,Other,,
2441,918521,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/15,Other,,
2442,918522,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/15,Other,,
2443,918523,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/15,Other,,
2444,918524,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/15,Other,,
2445,918525,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/15,Other,,
2446,918526,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/15,Other,,
2447,918527,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/15,Other,,
2448,918528,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/16,Other,,
2449,918529,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/16,Other,,
2450,918530,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/16,Other,,
2451,918531,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/16,Other,,
2452,918532,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/16,Other,,
2453,918533,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/16,Other,,
2454,918534,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/16,Other,,
2455,918535,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/16,Other,,
2456,918536,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/16,Other,,
2457,918537,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/16,Other,,
2458,918538,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/16,Other,,
2459,918539,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/16,Other,,
2460,918540,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/16,Other,,
2461,918541,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/16,Other,,
2462,918542,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/16,Other,,
2463,918543,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/16,Other,,
2464,918544,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/16,Other,,
2465,918545,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/16,Other,,
2466,918546,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/16,Other,,
2467,918547,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/16,Other,,
2468,918548,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/16,Other,,
2469,919340,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/11,Other,,
2470,919341,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/11,Other,,
2471,919342,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/11,Other,,
2472,919343,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/11,Other,,
2473,919344,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/11,Other,,
2474,919345,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/11,Other,,
2475,919346,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/11,Other,,
2476,919347,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/11,Other,,
2477,919348,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/11,Other,,
2478,919349,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/11,Other,,
2479,919350,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/11,Other,,
2480,919753,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/12,Other,,
2481,919754,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/12,Other,,
2482,919755,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/12,Other,,
2483,919756,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/12,Other,,
2484,919757,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/12,Other,,
2485,919758,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/12,Other,,
2486,919759,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/12,Other,,
2487,919760,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/12,Other,,
2488,919761,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/12,Other,,
2489,919762,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/12,Other,,
2490,919763,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/12,Other,,
2491,919764,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/12,Other,,
2492,919765,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/12,Other,,
2493,919766,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/12,Other,,
2494,919767,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/12,Other,,
2495,919768,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/12,Other,,
2496,919769,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/12,Other,,
2497,919770,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/12,Other,,
2498,919771,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/12,Other,,
2499,919772,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/12,Other,,
2500,919773,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/12,Other,,
2501,919774,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/13,Other,,
2502,919775,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/13,Other,,
2503,919776,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/13,Other,,
2504,919777,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/13,Other,,
2505,919778,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/13,Other,,
2506,919779,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/13,Other,,
2507,919780,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/13,Other,,
2508,919781,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/13,Other,,
2509,919782,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/13,Other,,
2510,919783,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/13,Other,,
2511,919784,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/13,Other,,
2512,919785,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/13,Other,,
2513,919786,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/13,Other,,
2514,919787,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/13,Other,,
2515,919788,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/13,Other,,
2516,919789,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/13,Other,,
2517,919823,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/8,Other,,
2518,919824,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/8,Other,,
2519,919825,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/8,Other,,
2520,919826,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/8,Other,,
2521,919827,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/8,Other,,
2522,919828,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/8,Other,,
2523,919829,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/8,Other,,
2524,919830,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/8,Other,,
2525,919831,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/8,Other,,
2526,919832,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/9,Other,,
2527,919833,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/9,Other,,
2528,919834,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/9,Other,,
2529,919835,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/9,Other,,
2530,919836,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/9,Other,,
2531,919837,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/9,Other,,
2532,919838,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/9,Other,,
2533,919839,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/9,Other,,
2534,919840,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/9,Other,,
2535,919841,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/9,Other,,
2536,920244,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/9,Other,,
2537,920245,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/9,Other,,
2538,920246,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/9,Other,,
2539,920247,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/9,Other,,
2540,920248,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/9,Other,,
2541,920249,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/9,Other,,
2542,920250,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/9,Other,,
2543,920251,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/9,Other,,
2544,920252,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/9,Other,,
2545,920253,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/9,Other,,
2546,920254,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/9,Other,,
2547,920255,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/10,Other,,
2548,920256,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/10,Other,,
2549,920257,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/10,Other,,
2550,920258,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/10,Other,,
2551,920259,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/10,Other,,
2552,920260,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 605/10,Other,,
2553,920261,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 605/10,Other,,
2554,920262,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 605/10,Other,,
2555,920263,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 605/10,Other,,
2556,920264,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 605/10,Other,,
2557,920265,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 605/10,Other,,
2558,920266,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 605/10,Other,,
2559,920267,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 605/10,Other,,
2560,920268,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 605/10,Other,,
2561,920269,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 605/10,Other,,
2562,920270,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 605/10,Other,,
2563,920271,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 605/10,Other,,
2564,921129,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/13,Other,,
2565,921130,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/13,Other,,
2566,921572,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/13,Other,,
2567,921573,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/13,Other,,
2568,921574,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/13,Other,,
2569,921575,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/14,Other,,
2570,921576,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/14,Other,,
2571,921577,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/14,Other,,
2572,921578,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/14,Other,,
2573,921579,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/14,Other,,
2574,921580,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/14,Other,,
2575,921581,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/14,Other,,
2576,921582,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/14,Other,,
2577,921583,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/14,Other,,
2578,921584,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/14,Other,,
2579,921585,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/14,Other,,
2580,921586,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/14,Other,,
2581,921587,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/14,Other,,
2582,921588,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/14,Other,,
2583,921589,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/14,Other,,
2584,921590,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/14,Other,,
2585,921591,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/14,Other,,
2586,921592,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/14,Other,,
2587,921593,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/14,Other,,
2588,921594,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/14,Other,,
2589,921595,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/14,Other,,
2590,921596,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/15,Other,,
2591,921597,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 604/15,Other,,
2592,921598,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 604/15,Other,,
2593,921599,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 604/15,Other,,
2594,921600,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 604/15,Other,,
2595,921601,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 604/15,Other,,
2596,921602,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 604/15,Other,,
2597,921603,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 604/15,Other,,
2598,921604,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 604/15,Other,,
2599,921605,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 604/15,Other,,
2600,921606,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 604/15,Other,,
2601,921607,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 604/15,Other,,
2602,921608,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 604/15,Other,,
2603,921609,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 604/15,Other,,
2604,921610,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 604/15,Other,,
2605,921611,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 604/15,Other,,
2606,921612,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 604/15,Other,,
2607,921613,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 604/15,Other,,
2608,921614,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 604/15,Other,,
2609,921615,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 604/15,Other,,
2610,921616,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 604/15,Other,,
2611,921617,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 604/16,Other,,
2612,921653,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 605/10,Other,,
2613,921654,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 605/10,Other,,
2614,921655,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 605/10,Other,,
2615,921656,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 605/10,Other,,
2616,921657,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 605/11,Other,,
2617,921658,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 605/11,Other,,
2618,921659,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 605/11,Other,,
2619,921660,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 605/11,Other,,
2620,921661,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 605/11,Other,,
2621,926448,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R071710,Other,,
2622,926449,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R071710,Other,,
2623,926450,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R071710,Other,,
2624,926451,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R071710,Other,,
2625,926452,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R071710,Other,,
2626,926453,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R071710,Other,,
2627,927082,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R071710,Other,,
2628,927083,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R071710,Other,,
2629,927084,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R071710,Other,,
2630,927085,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R071710,Other,,
2631,927086,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R071710,Other,,
2632,927087,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R071710,Other,,
2633,927088,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R071710,Other,,
2634,927089,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R071710,Other,,
2635,927090,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R071710,Other,,
2636,927091,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R071710,Other,,
2637,927092,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R071710,Other,,
2638,927093,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R071710,Other,,
2639,927094,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R071710,Other,,
2640,927095,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R071710,Other,,
2641,927096,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R071710,Other,,
2642,927097,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R071710,Other,,
2643,927098,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R071710,Other,,
2644,927099,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R071710,Other,,
2645,927100,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R071710,Other,,
2646,927101,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R071710,Other,,
2647,927102,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R071710,Other,,
2648,927103,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R071710,Other,,
2649,927104,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R071710,Other,,
2650,927105,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R071710,Other,,
2651,927106,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R071710,Other,,
2652,927107,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R071710,Other,,
2653,927108,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R071710,Other,,
2654,927109,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R071710,Other,,
2655,936491,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R031120,Other,,
2656,936492,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R031120,Other,,
2657,936493,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R031120,Other,,
2658,936494,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R031120,Other,,
2659,936495,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R031120,Other,,
2660,936496,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R031120,Other,,
2661,939142,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R031120,Other,,
2662,939143,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011009,Other,,
2663,939144,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011009,Other,,
2664,939145,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011009,Other,,
2665,939146,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011009,Other,,
2666,939147,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011009,Other,,
2667,939148,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011009,Other,,
2668,939149,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011009,Other,,
2669,939150,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011009,Other,,
2670,939151,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011009,Other,,
2671,939152,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011009,Other,,
2672,939153,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011009,Other,,
2673,939154,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011009,Other,,
2674,939155,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011009,Other,,
2675,939156,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011009,Other,,
2676,939157,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011009,Other,,
2677,939158,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011009",Other,,
2678,939159,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011009,Other,,
2679,939160,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011009,Other,,
2680,939161,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011009,Other,,
2681,940651,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011009,Other,,
2682,940652,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011009,Other,,
2683,940653,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011009,Other,,
2684,940654,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011009,Other,,
2685,940655,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011009,Other,,
2686,940656,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011009,Other,,
2687,940657,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011009,Other,,
2688,940658,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011009,Other,,
2689,940659,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011009,Other,,
2690,940660,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011009,Other,,
2691,940661,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011009,Other,,
2692,940662,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011009,Other,,
2693,940663,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011009,Other,,
2694,940664,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011009,Other,,
2695,940665,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011009,Other,,
2696,940666,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011009,Other,,
2697,940667,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011009,Other,,
2698,940668,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011009,Other,,
2699,940669,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011009",Other,,
2700,940670,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R071710,Other,,
2701,940671,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R071710,Other,,
2702,940672,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R071710,Other,,
2703,940673,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R071710,Other,,
2704,940674,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R071710,Other,,
2705,940675,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R071710,Other,,
2706,940676,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R071710,Other,,
2707,940677,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R071710,Other,,
2708,940678,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R071710,Other,,
2709,942697,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R071710,Other,,
2710,942698,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R071710,Other,,
2711,942699,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R071710,Other,,
2712,942700,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R071710,Other,,
2713,942701,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R071710,Other,,
2714,942702,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R071710,Other,,
2715,942703,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R071710,Other,,
2716,943334,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R071710,Other,,
2717,943335,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011009,Other,,
2718,943336,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011009",Other,,
2719,943337,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011009,Other,,
2720,943338,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011009,Other,,
2721,943339,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011009,Other,,
2722,943340,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011009,Other,,
2723,943341,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011009,Other,,
2724,943342,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011009,Other,,
2725,943343,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011009,Other,,
2726,943344,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011009,Other,,
2727,943345,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011009,Other,,
2728,943346,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011009,Other,,
2729,943347,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011009,Other,,
2730,943348,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011009,Other,,
2731,943349,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011009,Other,,
2732,943350,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011009,Other,,
2733,943351,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011009,Other,,
2734,943352,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011009,Other,,
2735,943353,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011009,Other,,
2736,943354,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011009,Other,,
2737,943355,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011009,Other,,
2738,943356,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011009,Other,,
2739,943357,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011009,Other,,
2740,943358,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011009,Other,,
2741,943359,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011009",Other,,
2742,943360,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011009,Other,,
2743,943361,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011009,Other,,
2744,943362,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011009,Other,,
2745,943363,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011009,Other,,
2746,943364,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011009,Other,,
2747,943365,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011009,Other,,
2748,943366,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011009,Other,,
2749,943367,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011009,Other,,
2750,943368,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011009,Other,,
2751,943369,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011009,Other,,
2752,945163,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R031120,Other,,
2753,945164,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R031120,Other,,
2754,945165,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R031120,Other,,
2755,945166,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R031120,Other,,
2756,945167,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R031120,Other,,
2757,945168,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R031120,Other,,
2758,945353,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011009,Other,,
2759,945354,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011009,Other,,
2760,945355,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011009,Other,,
2761,951108,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R071710,Other,,
2762,951109,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R071710,Other,,
2763,951110,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011009,Other,,
2764,951111,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011009,Other,,
2765,951112,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011009,Other,,
2766,951113,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011009,Other,,
2767,951114,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011009,Other,,
2768,951115,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011009,Other,,
2769,951116,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011009,Other,,
2770,951117,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011009,Other,,
2771,951118,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011009,Other,,
2772,951119,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011009,Other,,
2773,951750,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011009,Other,,
2774,951751,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011009,Other,,
2775,951752,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011009,Other,,
2776,951753,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011009,Other,,
2777,951754,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011009,Other,,
2778,951755,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011009,Other,,
2779,951756,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011009,Other,,
2780,951757,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011009,Other,,
2781,951758,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011009,Other,,
2782,951759,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011009,Other,,
2783,951760,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011009,Other,,
2784,951761,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011009,Other,,
2785,951762,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011009,Other,,
2786,951763,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011009,Other,,
2787,951764,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011009,Other,,
2788,951765,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011009,Other,,
2789,951766,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011009,Other,,
2790,951767,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011009,Other,,
2791,951768,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011009,Other,,
2792,951769,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011009,Other,,
2793,951770,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011009,Other,,
2794,951771,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011009,Other,,
2795,951772,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011009,Other,,
2796,951773,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011009,Other,,
2797,951774,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011009,Other,,
2798,951775,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011009,Other,,
2799,951776,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011009,Other,,
2800,951777,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011009,Other,,
2801,958782,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011009,Other,,
2802,958783,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011009,Other,,
2803,958784,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011009,Other,,
2804,958785,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011009,Other,,
2805,958786,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011009,Other,,
2806,958787,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011009,Other,,
2807,958788,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011009,Other,,
2808,958789,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011009,Other,,
2809,958790,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011009,Other,,
2810,958791,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011009,Other,,
2811,958792,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011009,Other,,
2812,958793,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011009,Other,,
2813,958794,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011009,Other,,
2814,959366,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011009,Other,,
2815,959367,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011009,Other,,
2816,959368,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011009,Other,,
2817,959369,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011009,Other,,
2818,959370,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011009,Other,,
2819,959371,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011009,Other,,
2820,959372,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R071710,Other,,
2821,959373,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R071710,Other,,
2822,959374,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R071710,Other,,
2823,959375,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R071710,Other,,
2824,959376,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R071710,Other,,
2825,959377,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R071710,Other,,
2826,959378,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R071710,Other,,
2827,959379,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R071710,Other,,
2828,959380,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R071710,Other,,
2829,959381,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R071710,Other,,
2830,959382,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R071710,Other,,
2831,959383,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R071710,Other,,
2832,959384,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R071710,Other,,
2833,959385,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R071710,Other,,
2834,959386,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R071710,Other,,
2835,959387,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R071710,Other,,
2836,959388,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R071710,Other,,
2837,962349,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R071710,Other,,
2838,962350,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R071710,Other,,
2839,962351,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R071710,Other,,
2840,962352,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R071710,Other,,
2841,962353,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R071710,Other,,
2842,962354,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R071710,Other,,
2843,962355,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R071710,Other,,
2844,962356,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R071710,Other,,
2845,962357,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R071710,Other,,
2846,962358,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R071710,Other,,
2847,962359,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R071710,Other,,
2848,962360,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R071710,Other,,
2849,962361,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R071710,Other,,
2850,962362,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R071710,Other,,
2851,962363,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R071710,Other,,
2852,962364,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R071710,Other,,
2853,962365,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R071710,Other,,
2854,962366,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R071710,Other,,
2855,962367,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R071710,Other,,
2856,962368,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R071710,Other,,
2857,962369,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R071710,Other,,
2858,962370,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R071710,Other,,
2859,962371,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R071710,Other,,
2860,962372,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R071710,Other,,
2861,962373,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R071710,Other,,
2862,962374,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R071710,Other,,
2863,962375,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R071710,Other,,
2864,962376,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R071710,Other,,
2865,962377,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R071710,Other,,
2866,962378,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R071710,Other,,
2867,963676,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R071710,Other,,
2868,963677,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R071710,Other,,
2869,963678,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R071710,Other,,
2870,963679,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R071710,Other,,
2871,964148,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R071710,Other,,
2872,964149,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R071710,Other,,
2873,964150,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R071710,Other,,
2874,964151,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R071710,Other,,
2875,970874,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R031120,Other,,
2876,970875,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R031120,Other,,
2877,970876,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R031120,Other,,
2878,970877,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R031120,Other,,
2879,971507,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R031120,Other,,
2880,971508,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R031120,Other,,
2881,971509,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R031120,Other,,
2882,971510,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R031120,Other,,
2883,971511,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R031120,Other,,
2884,971512,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R031120,Other,,
2885,971513,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R031120,Other,,
2886,971514,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R031120,Other,,
2887,971515,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R031120,Other,,
2888,971516,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R031120,Other,,
2889,971517,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R031120,Other,,
2890,971518,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011009,Other,,
2891,971519,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011009,Other,,
2892,971520,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011009,Other,,
2893,971521,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011009,Other,,
2894,972036,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011009,Other,,
2895,972037,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011009,Other,,
2896,972038,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011009,Other,,
2897,972039,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011009,Other,,
2898,972040,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011009,Other,,
2899,972041,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011009,Other,,
2900,972042,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011009,Other,,
2901,972043,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011009,Other,,
2902,972044,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011009,Other,,
2903,972045,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011009,Other,,
2904,972046,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011009,Other,,
2905,972047,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011009,Other,,
2906,972048,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011009,Other,,
2907,972049,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011009,Other,,
2908,972050,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011009,Other,,
2909,977599,1,1,,103230651,5284373,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2910,977602,1,2,,103230651,5284373,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2911,977611,3,1,,208012187,5284373,Active,,,0.0134,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,18076075.0,
2912,977611,3,1,,208012295,5284373,Active,,,0.07,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,19499554.0,
2913,977611,3,1,,310262827,5284373,Active,,,0.027000000000000003,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,23709667.0,
2914,996065,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R071710",Other,,
2915,996066,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
2916,996067,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
2917,996068,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R071710",Other,,
2918,996069,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R071710",Other,,
2919,996070,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R071710",Other,,
2920,996071,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R071710",Other,,
2921,996072,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R071710",Other,,
2922,996073,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R071710",Other,,
2923,996074,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R071710",Other,,
2924,996075,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R071710",Other,,
2925,996076,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
2926,996077,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R071710",Other,,
2927,1001602,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
2928,1001603,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011009",Other,,
2929,1001604,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011009",Other,,
2930,1001605,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011009",Other,,
2931,1001606,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
2932,1001607,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
2933,1001608,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011009,Other,,
2934,1001609,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011009",Other,,
2935,1001610,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011009,Other,,
2936,1001611,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011009",Other,,
2937,1001612,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
2938,1001613,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011009",Other,,
2939,1001614,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011009",Other,,
2940,1001615,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
2941,1001616,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
2942,1001617,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011009",Other,,
2943,1001618,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011009",Other,,
2944,1001619,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
2945,1001620,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
2946,1001621,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011009",Other,,
2947,1001622,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
2948,1001623,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
2949,1001624,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
2950,1002205,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
2951,1002206,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011009",Other,,
2952,1002207,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
2953,1002208,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
2954,1002209,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011009",Other,,
2955,1004082,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
2956,1004083,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011009,Other,,
2957,1004084,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011009,Other,,
2958,1004085,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011009",Other,,
2959,1004086,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
2960,1004087,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
2961,1004088,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011009",Other,,
2962,1004089,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011009,Other,,
2963,1004090,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
2964,1004091,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
2965,1004092,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
2966,1004093,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011009",Other,,
2967,1004094,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011009,Other,,
2968,1004095,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
2969,1004096,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011009",Other,,
2970,1004097,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011009",Other,,
2971,1004098,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
2972,1004099,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011009",Other,,
2973,1004100,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011009",Other,,
2974,1004101,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011009",Other,,
2975,1004102,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011009,Other,,
2976,1004103,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
2977,1004104,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011009",Other,,
2978,1004105,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011009",Other,,
2979,1004106,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011009,Other,,
2980,1004107,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011009",Other,,
2981,1004108,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011009",Other,,
2982,1004109,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
2983,1004110,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
2984,1004111,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
2985,1004693,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011009",Other,,
2986,1004694,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R071710",Other,,
2987,1004695,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
2988,1004696,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R071710",Other,,
2989,1004697,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R071710",Other,,
2990,1004698,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R071710",Other,,
2991,1004699,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R071710",Other,,
2992,1004700,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R071710",Other,,
2993,1004701,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R071710",Other,,
2994,1015775,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
2995,1015776,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011009",Other,,
2996,1015777,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S011009",Other,,
2997,1015778,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011009",Other,,
2998,1015779,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011009",Other,,
2999,1015780,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011009",Other,,
3000,1015781,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011009",Other,,
3001,1015782,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
3002,1015783,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011009",Other,,
3003,1015784,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011009",Other,,
3004,1015785,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011009",Other,,
3005,1016370,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011009",Other,,
3006,1016371,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011009",Other,,
3007,1016372,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011009",Other,,
3008,1016373,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011009",Other,,
3009,1016374,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011009",Other,,
3010,1016375,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S011009",Other,,
3011,1016376,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011009",Other,,
3012,1016377,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011009",Other,,
3013,1016378,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011009,Other,,
3014,1016379,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
3015,1016380,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011009",Other,,
3016,1016381,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011009",Other,,
3017,1016382,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S011009",Other,,
3018,1016383,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3019,1016384,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011009",Other,,
3020,1016385,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011009",Other,,
3021,1016386,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3022,1016387,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S011009",Other,,
3023,1016388,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S011009",Other,,
3024,1016389,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011009,Other,,
3025,1016390,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3026,1016391,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011009",Other,,
3027,1016392,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
3028,1016393,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3029,1016394,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3030,1016395,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011009",Other,,
3031,1016396,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3032,1016397,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011009",Other,,
3033,1020705,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Spleen; Assay: Lymphoid Depletion; Study_ID: S011009,Other,,
3034,1020706,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3035,1020707,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011009",Other,,
3036,1020708,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011009,Other,,
3037,1020709,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
3038,1020710,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011009",Other,,
3039,1020711,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011009",Other,,
3040,1020712,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011009",Other,,
3041,1020713,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3042,1020714,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
3043,1020715,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
3044,1020716,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S011009",Other,,
3045,1020717,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S011009",Other,,
3046,1020718,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011009",Other,,
3047,1020719,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011009",Other,,
3048,1020720,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011009",Other,,
3049,1020721,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011009",Other,,
3050,1020722,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011009",Other,,
3051,1021308,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011009,Other,,
3052,1021309,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011009",Other,,
3053,1021310,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011009,Other,,
3054,1021311,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011009",Other,,
3055,1021312,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
3056,1021313,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011009",Other,,
3057,1021314,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011009",Other,,
3058,1021315,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3059,1021316,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
3060,1021317,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011009",Other,,
3061,1021318,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011009",Other,,
3062,1021319,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3063,1021320,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011009",Other,,
3064,1021321,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S011009",Other,,
3065,1021322,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011009",Other,,
3066,1021323,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011009",Other,,
3067,1021324,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011009,Other,,
3068,1021325,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3069,1021326,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011009",Other,,
3070,1021327,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3071,1023193,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011009",Other,,
3072,1023194,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
3073,1023195,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
3074,1023196,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
3075,1023197,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
3076,1023198,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011009",Other,,
3077,1023199,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
3078,1023200,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
3079,1023201,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011009",Other,,
3080,1023202,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
3081,1023203,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S011009",Other,,
3082,1023204,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S011009",Other,,
3083,1023205,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011009",Other,,
3084,1023206,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011009",Other,,
3085,1023207,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011009",Other,,
3086,1023208,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Spleen; Assay: Extramedullary Hematopoiesis Increased; Study_ID: S011009,Other,,
3087,1023790,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S011009",Other,,
3088,1023791,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S011009",Other,,
3089,1023792,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011009,Other,,
3090,1023793,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011009,Other,,
3091,1023794,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011009",Other,,
3092,1023795,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
3093,1023796,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011009",Other,,
3094,1023797,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S011009",Other,,
3095,1023798,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3096,1023799,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011009",Other,,
3097,1023800,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011009",Other,,
3098,1023801,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011009",Other,,
3099,1023802,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011009",Other,,
3100,1023803,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S011009",Other,,
3101,1023804,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011009",Other,,
3102,1023805,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S011009",Other,,
3103,1023806,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S011009",Other,,
3104,1023807,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011009,Other,,
3105,1023808,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011009",Other,,
3106,1023809,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3107,1023810,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
3108,1023811,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3109,1023812,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011009",Other,,
3110,1023813,1,3,,103230651,5284373,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011009,Other,,
3111,1026666,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R071710",Other,,
3112,1026667,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R071710",Other,,
3113,1026668,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R071710",Other,,
3114,1026669,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R071710",Other,,
3115,1026670,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R071710",Other,,
3116,1026671,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
3117,1026672,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
3118,1026673,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R071710",Other,,
3119,1026674,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R071710",Other,,
3120,1026675,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R071710",Other,,
3121,1026676,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R071710",Other,,
3122,1026677,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R071710",Other,,
3123,1026678,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R071710",Other,,
3124,1026679,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R071710",Other,,
3125,1026680,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R071710",Other,,
3126,1026681,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R071710",Other,,
3127,1026682,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
3128,1026683,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R071710",Other,,
3129,1026684,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
3130,1026685,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R071710",Other,,
3131,1026686,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R071710",Other,,
3132,1026687,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R071710",Other,,
3133,1026688,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R071710",Other,,
3134,1027272,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R071710",Other,,
3135,1027273,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R071710",Other,,
3136,1027274,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R071710",Other,,
3137,1027275,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
3138,1027276,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
3139,1027277,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R071710",Other,,
3140,1027278,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R071710",Other,,
3141,1027279,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R071710",Other,,
3142,1027280,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R071710",Other,,
3143,1027281,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R071710",Other,,
3144,1027282,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R071710",Other,,
3145,1027283,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R071710",Other,,
3146,1027284,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R071710",Other,,
3147,1027285,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R071710",Other,,
3148,1029159,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
3149,1034701,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R071710",Other,,
3150,1034702,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R071710",Other,,
3151,1034703,1,3,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R071710",Other,,
3152,1034704,1,4,,103230651,5284373,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % 10%acacia/0.25%ps80/0.5%antifoam; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R071710",Other,,
3153,1039132,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/16,Other,,
3154,1039204,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/10,Other,,
3155,1039205,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/10,Other,,
3156,1039206,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/10,Other,,
3157,1039207,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/10,Other,,
3158,1039208,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/11,Other,,
3159,1039209,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/11,Other,,
3160,1039210,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/11,Other,,
3161,1039882,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/11,Other,,
3162,1039883,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/11,Other,,
3163,1039884,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/12,Other,,
3164,1039885,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/12,Other,,
3165,1039886,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/12,Other,,
3166,1039887,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/12,Other,,
3167,1039888,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/12,Other,,
3168,1039889,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/13,Other,,
3169,1039890,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/13,Other,,
3170,1039891,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/13,Other,,
3171,1039892,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/13,Other,,
3172,1039893,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/13,Other,,
3173,1039894,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/14,Other,,
3174,1039895,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/14,Other,,
3175,1039896,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/14,Other,,
3176,1039897,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/14,Other,,
3177,1039898,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/14,Other,,
3178,1039899,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/15,Other,,
3179,1039900,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/15,Other,,
3180,1039901,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/15,Other,,
3181,1039902,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/15,Other,,
3182,1039903,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/15,Other,,
3183,1039904,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/16,Other,,
3184,1039905,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/16,Other,,
3185,1039906,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/16,Other,,
3186,1039907,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/16,Other,,
3187,1039908,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/16,Other,,
3188,1039909,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/5,Other,,
3189,1039910,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/5,Other,,
3190,1039911,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/5,Other,,
3191,1039912,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/5,Other,,
3192,1039913,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/5,Other,,
3193,1039914,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/6,Other,,
3194,1039915,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/6,Other,,
3195,1039916,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/6,Other,,
3196,1039917,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/6,Other,,
3197,1039918,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/6,Other,,
3198,1039919,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/7,Other,,
3199,1039920,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/7,Other,,
3200,1039921,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/7,Other,,
3201,1042011,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/5,Other,,
3202,1042012,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/5,Other,,
3203,1042013,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/5,Other,,
3204,1042014,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/5,Other,,
3205,1042015,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/5,Other,,
3206,1042016,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/6,Other,,
3207,1042017,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/6,Other,,
3208,1042018,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/6,Other,,
3209,1042687,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/6,Other,,
3210,1042688,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/6,Other,,
3211,1042689,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/7,Other,,
3212,1042690,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/7,Other,,
3213,1042691,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/7,Other,,
3214,1042692,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/7,Other,,
3215,1042693,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/7,Other,,
3216,1042694,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/8,Other,,
3217,1042695,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/8,Other,,
3218,1042696,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/8,Other,,
3219,1042697,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/8,Other,,
3220,1042698,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/8,Other,,
3221,1042699,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/9,Other,,
3222,1042700,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 604/9,Other,,
3223,1042701,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 604/9,Other,,
3224,1042702,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 604/9,Other,,
3225,1042703,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 604/9,Other,,
3226,1042704,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 604/10,Other,,
3227,1044846,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/7,Other,,
3228,1044847,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/7,Other,,
3229,1044848,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/8,Other,,
3230,1044849,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/8,Other,,
3231,1044850,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/8,Other,,
3232,1044851,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/8,Other,,
3233,1044852,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/8,Other,,
3234,1044853,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/9,Other,,
3235,1044854,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/9,Other,,
3236,1044855,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/9,Other,,
3237,1044856,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/9,Other,,
3238,1044857,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/9,Other,,
3239,1044858,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/10,Other,,
3240,1044859,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/10,Other,,
3241,1044860,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/10,Other,,
3242,1044861,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/10,Other,,
3243,1044862,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/10,Other,,
3244,1044863,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/11,Other,,
3245,1044864,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/11,Other,,
3246,1044865,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/11,Other,,
3247,1044866,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/11,Other,,
3248,1045535,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/11,Other,,
3249,1045536,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/12,Other,,
3250,1045537,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/12,Other,,
3251,1045538,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/12,Other,,
3252,1045539,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/12,Other,,
3253,1045540,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/12,Other,,
3254,1045541,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/13,Other,,
3255,1045542,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/13,Other,,
3256,1045543,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/13,Other,,
3257,1045544,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/13,Other,,
3258,1045545,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/13,Other,,
3259,1045546,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/14,Other,,
3260,1045547,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/14,Other,,
3261,1045548,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/14,Other,,
3262,1045549,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/14,Other,,
3263,1045550,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/14,Other,,
3264,1045551,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/15,Other,,
3265,1045552,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/15,Other,,
3266,1045553,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/15,Other,,
3267,1045554,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/15,Other,,
3268,1045555,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 605/15,Other,,
3269,1045556,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 605/16,Other,,
3270,1045557,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 605/16,Other,,
3271,1045558,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 605/16,Other,,
3272,1045559,1,2,,103230651,5284373,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 605/16,Other,,
3273,1053197,1,1,,57264292,5284373,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3274,1057950,2,3,,103230651,5284373,Active,296439301.0,4363.0,2.7,IC50,Inhibition of MRP1 in human 2008 cells assessed as Calcein AM accumulation treated 30 mins before Calcein AM addition measured up to 90 mins by fluorescence assay,Confirmatory,24184213.0,
3275,1057951,2,3,,103230651,5284373,Active,238054374.0,5243.0,0.92,IC50,Inhibition of MDR1 in human doxorubicin-resistant A2780adr cells assessed as Calcein AM accumulation treated 30 mins before Calcein AM addition measured up to 90 mins by fluorescence assay,Confirmatory,24184213.0,
3276,1061931,1,4,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of MDR-1 (unknown origin) expressed in human Caco2 cells using Calcein-AM at 50 uM preincubated for 30 mins by fluorescence based PDSP assay relative to control,Other,24342237.0,
3277,1062338,1,1,,103230651,5284373,Unspecified,,,,,"Therapeutic index, ratio of IC50 for mouse L929 cells to EC50 for modulation of p-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversal of paclitaxel resistance",Other,24171478.0,
3278,1062339,2,1,,103230651,5284373,Active,238054374.0,5243.0,0.032,EC50,Modulation of p-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversal of paclitaxel resistance,Confirmatory,24171478.0,
3279,1062340,1,2,,103230651,5284373,Active,,,33.9,IC50,Cytotoxicity against mouse L929 cells assessed as growth inhibition after 3 days by MTS assay,Confirmatory,24171478.0,
3280,1062341,1,1,,103230651,5284373,Active,,,8.3,IC50,Cytotoxicity against human MDA435/LCC6MDR cells assessed as growth inhibition after 3 days by MTS assay,Confirmatory,24171478.0,
3281,1062342,1,1,,103230651,5284373,Active,,,2.8,IC50,Cytotoxicity against human MDA435/LCC6 cells assessed as growth inhibition after 3 days by MTS assay,Confirmatory,24171478.0,
3282,1065395,1,3,,103230651,5284373,Unspecified,,,,,Oral bioavailability in patient transplanted with kidney and bone marrow,Other,24044773.0,
3283,1079931,1,1,,103230651,5284373,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3284,1079932,1,1,,103230651,5284373,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3285,1079933,1,1,,103230651,5284373,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3286,1079934,1,1,,103230651,5284373,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3287,1079935,1,1,,103230651,5284373,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3288,1079936,1,1,,103230651,5284373,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3289,1079937,1,1,,103230651,5284373,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3290,1079938,1,1,,103230651,5284373,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3291,1079939,1,1,,103230651,5284373,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3292,1079940,1,1,,103230651,5284373,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3293,1079941,1,1,,103230651,5284373,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3294,1079942,1,1,,103230651,5284373,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3295,1079943,1,1,,103230651,5284373,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3296,1079944,1,1,,103230651,5284373,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3297,1079945,1,1,,103230651,5284373,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3298,1079946,1,1,,103230651,5284373,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3299,1079947,1,1,,103230651,5284373,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3300,1079948,1,1,,103230651,5284373,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3301,1079949,1,1,,103230651,5284373,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3302,1117190,1,2,,103230651,5284373,Unspecified,,,,,"Selectivity index, ratio of CC50 for BALB/C Mus musculus (mouse) lymph node cells to IC50 for conA-induced BALB/C lymph node cells",Other,,
3303,1117191,1,2,,103230651,5284373,Active,,,0.06,IC50,Immunosuppressive activity in BALB/C Mus musculus (mouse) lymph node cells assessed as inhibition of conA-induced proliferation incubated at 24 hr post conA-challenge measured after 72 hr by MTT assay,Confirmatory,,
3304,1117192,1,2,,103230651,5284373,Active,,,14.96,CC50,Cytotoxicity against BALB/C Mus musculus (mouse) lymph node cells after 24 hr by MTT assay,Confirmatory,,
3305,1117298,1,2,,170466812,5284373,Inactive,,,0.631,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
3306,1117304,1,2,,170466812,5284373,Inactive,,,3.9811,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
3307,1117305,1,2,,170466812,5284373,Inactive,,,4.4668,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
3308,1117310,1,1,,170466812,5284373,Inactive,,,0.630957,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
3309,1117312,1,1,,170466812,5284373,Inactive,,,4.46684,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
3310,1117314,1,1,,170466812,5284373,Inactive,,,3.98107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
3311,1117319,1,2,,11532934,5284373,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3312,1117319,1,2,,11532934,5284373,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3313,1118628,1,1,,103230651,5284373,Unspecified,,,,,Oral bioavailability in rat,Other,,
3314,1118629,1,1,,103230651,5284373,Unspecified,,,,,Fraction of the dose absorbed in rat,Other,,
3315,1118630,1,1,,103230651,5284373,Unspecified,,,,,Oral bioavailability in human,Other,,
3316,1119205,1,1,,103230651,5284373,Active,,,,EC50,Antiviral activity against Hepatitis C virus genotype 1b I389luc-ubi-neo/NS3-3'/5.1 subgenomic replicon infected in human Huh5-2 cells after 4 days by luciferase assay,Confirmatory,,
3317,1119206,1,1,,103230651,5284373,Active,,,4.4,CC50,Cytostatic activity against human Huh5-2 cells assessed as decrease in cell proliferation after 3 days by MTS method,Confirmatory,,
3318,1119207,1,1,,103230651,5284373,Unspecified,,,,,"Selectivity index, ratio of CC50 for human Huh5-2 cells to EC50 for Hepatitis C virus genotype 1b I389luc-ubi-neo/NS3-3'/5.1 subgenomic replicon infected in human Huh5-2 cells",Other,,
3319,1119208,1,3,,103230651,5284373,Active,51702775.0,5478.0,0.95,IC50,Inhibition of recombinant GST-tagged CypA (unknown origin)/HCV Con1 NS5A-His interaction after 16 hrs by ELISA,Confirmatory,,
3320,1119209,1,3,,103230651,5284373,Active,51702775.0,5478.0,0.0096,IC50,Inhibition of PPIase activity of recombinant CypA (unknown origin) assessed as chymotrypsin-mediated N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide hydrolysis after 1 hr by spectrophotometric analysis,Confirmatory,,
3321,1119210,1,1,,103230651,5284373,Unspecified,,,,,Solubility of the compound in phosphate buffered saline at pH 7.4 after 4 hrs by LC-MS/MS analysis,Other,,
3322,1119211,1,2,,103230651,5284373,Unspecified,,,,,Half life in mouse liver microsomes at 1 uM by LC-MS/MS analysis,Other,,
3323,1119212,1,2,,103230651,5284373,Unspecified,,,,,Half life in human liver microsomes at 1 uM by LC-MS/MS analysis,Other,,
3324,1119213,1,1,,103230651,5284373,Unspecified,,,,,Half life in human hepatocytes at 1 uM by LC-MS/MS analysis,Other,,
3325,1119214,1,1,,103230651,5284373,Active,,,0.198,EC50,Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7 cells assessed as decrease in subgenomic RNA level after 72 hrs by RT-PCR analysis,Confirmatory,,
3326,1119215,1,1,,103230651,5284373,Active,,,0.13699999999999998,EC50,Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human Huh7 cells assessed as decrease in subgenomic RNA level after 72 hrs by RT-PCR analysis,Confirmatory,,
3327,1119216,1,1,,103230651,5284373,Active,,,0.455,EC50,Antiviral activity against Hepatitis C virus genotype 2a JFH-1 infected in human Huh7 cells assessed as decrease in subgenomic RNA level after 72 hrs by RT-PCR analysis,Confirmatory,,
3328,1119217,1,1,,103230651,5284373,Active,,,0.003,IC50,Immunosuppressive activity in human PBMC isolated from two individuals assessed as inhibition of proliferation using [3H]thymidine by mixed lymphocyte reaction assay,Confirmatory,,
3329,1119218,1,2,,103230651,5284373,Unspecified,,,,,Fraction unbound in human plasma at 1 uM after 5 hrs by dialysis chamber method,Other,,
3330,1119219,1,1,,103230651,5284373,Unspecified,,,,,"n-octanol-potassium phosphate buffer partition coefficient, log D of the compound at pH 7.4 after 1 hr by LC-MS analysis",Other,,
3331,1119221,1,1,,103230651,5284373,Inactive,,,,,Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human Huh7 cells assessed as viral rebound by measuring replicon RNA content at 0.5 to 1 uM after drug removal by RT-qPCR analysis,Other,,
3332,1119223,1,3,,103230651,5284373,Active,308153583.0,1244.0,,,Inhibition of ATPase activity of MRP2 (unknown origin) expressed in membrane assessed as amount of phosphate released using probenecid as substrate at 9 uM by molybdenum blue assay,Other,,
3333,1119225,1,3,,103230651,5284373,Active,238054374.0,5243.0,0.7290000000000001,IC50,Inhibition of MDR1 (unknown origin) expressed in MDCK1 cells assessed as reduction of loperamide substrate permeability after 60 mins by LC-MS/MS analysis,Confirmatory,,
3334,1140175,1,1,,103230651,5284373,Inactive,,,,,Increase in doxorubicin uptake in wild type human Saos2 cells at 5 uM after 3 hrs by flow cytometric analysis,Other,24720452.0,
3335,1140177,1,1,,103230651,5284373,Inactive,,,,,Increase in doxorubicin uptake in P-gp-deficient human Me30966 cells at 5 uM after 3 hrs by flow cytometric analysis,Other,24720452.0,
3336,1140179,1,3,,103230651,5284373,Active,238054374.0,5243.0,,,Inhibition of p-gp in doxorubicin-resistant human Saos2 cells assessed as increase in doxorubicin uptake at 5 uM after 3 hrs by flow cytometric analysis,Other,24720452.0,
3337,1140181,1,1,,103230651,5284373,Inactive,,,,,Increase in doxorubicin retention in wild type human Saos2 cells at 5 uM after 2 hrs by flow cytometric analysis,Other,24720452.0,
3338,1140183,1,1,,103230651,5284373,Inactive,,,,,Increase in doxorubicin retention in P-gp-deficient human Me30966 cells at 5 uM after 2 hrs by flow cytometric analysis,Other,24720452.0,
3339,1140185,1,3,,103230651,5284373,Active,238054374.0,5243.0,,,Inhibition of p-gp in doxorubicin-resistant human Saos2 cells assessed as increase in intracellular doxorubicin retention at 5 uM after 2 hrs by flow cytometric analysis,Other,24720452.0,
3340,1140187,1,3,,103230651,5284373,Active,238054374.0,5243.0,,,Inhibition of p-gp in doxorubicin-resistant human Saos2 cells assessed as intracellular doxorubicin distribution in nuclei at 5 uM after 2 to 3 hrs by laser scanning confocal microscopic analysis,Other,24720452.0,
3341,1142011,1,3,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Reversal of Pgp-1-mediated multidrug resistance in human SW620 cells assessed as potentiation of paclitaxel cytotoxicity at 3 uM treated for 2 hrs prior to paclitaxel challenge measured after 72 hrs by MTT assay relative to paclitaxel alone-treated control,Other,24773054.0,
3342,1142015,1,3,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Reversal of Pgp-1-mediated multidrug resistance in human SW620/Ad300 cells overexpressing ABCB1 assessed as potentiation of paclitaxel cytotoxicity at 3 uM treated for 2 hrs prior to paclitaxel challenge measured after 72 hrs by MTT assay relative to paclitaxel alone-treated control,Other,24773054.0,
3343,1142019,1,3,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Reversal of Pgp-1-mediated multidrug resistance in human HEK293 cells assessed as potentiation of paclitaxel cytotoxicity at 3 uM treated for 2 hrs prior to paclitaxel challenge measured after 72 hrs by MTT assay relative to paclitaxel alone-treated control,Other,24773054.0,
3344,1142023,1,3,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Reversal of Pgp-1-mediated multidrug resistance in human HEK293 cells overexpressing human ABCB1 assessed as potentiation of paclitaxel cytotoxicity at 3 uM treated for 2 hrs prior to paclitaxel challenge measured after 72 hrs by MTT assay relative to paclitaxel alone-treated control,Other,24773054.0,
3345,1142395,1,1,,103230651,5284373,Unspecified,,,,,Cytotoxicity against hCMEC/D3 cells at 0.1 to 50 uM after 4 hrs by Alamar Blue assay,Other,24779610.0,
3346,1142396,1,1,,103230651,5284373,Inactive,,,,,Activity at P-gp in hCMEC/D3 cells at 0.1 to 50 uM after 15 mins by calcein-AM assay,Other,24779610.0,
3347,1155554,1,1,,103230651,5284373,Unspecified,,,,,Inhibition of calcium-induced mPTP opening in C57/bl6 mouse liver mitochondria assessed as increase in calcium retention capacity at 1 uM by fluorimetry,Other,24918261.0,
3348,1155559,1,1,,103230651,5284373,Active,,,,,Inhibition of calcium-induced mPTP opening in C57/bl6 mouse liver mitochondria assessed as increase in calcium retention capacity at 0.1 to 5 uM by fluorimetry,Other,24918261.0,
3349,1155564,1,1,,103230651,5284373,Unspecified,,,,,"Cardioprotective effect in New Zealand rabbit ischemia/reperfusion-induced left anterior descending coronary artery ligation myocardial infarction model assessed as ratio of area at risk to infarct area at 10 mg/kg, iv administered as bolus dose 5 min prior to reperfusion (Rvb = 57.3%)",Other,24918261.0,
3350,1159509,1,1,,144212166,5284373,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3351,1159509,1,1,,170466812,5284373,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3352,1159515,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3353,1159515,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3354,1159516,1,1,,144212166,5284373,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3355,1159516,1,1,,170466812,5284373,Inconclusive,119611100.0,22926.0,9.5205,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3356,1159517,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3357,1159517,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3358,1159518,1,1,,144212166,5284373,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3359,1159518,1,1,,170466812,5284373,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3360,1159519,1,1,,144212166,5284373,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3361,1159519,1,1,,170466812,5284373,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3362,1159520,1,1,,144212166,5284373,Inconclusive,,,20.0606,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3363,1159520,1,1,,170466812,5284373,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3364,1159521,1,1,,144212166,5284373,Inconclusive,15928672.0,19885.0,7.1178,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3365,1159521,1,1,,170466812,5284373,Inconclusive,15928672.0,19885.0,1.6785,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3366,1159523,1,1,,144212166,5284373,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3367,1159523,1,1,,170466812,5284373,Inconclusive,15928672.0,19885.0,10.5909,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3368,1159524,1,1,,56422786,5284373,Inconclusive,,,6.3096,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3369,1159525,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3370,1159525,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3371,1159526,1,1,,144212166,5284373,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3372,1159526,1,1,,170466812,5284373,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3373,1159527,1,1,,144212166,5284373,Inconclusive,325495497.0,6256.0,3.5987,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3374,1159527,1,1,,170466812,5284373,Inconclusive,325495497.0,6256.0,1.8996,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3375,1159528,1,1,,144212166,5284373,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3376,1159528,1,1,,170466812,5284373,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3377,1159529,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3378,1159529,1,1,,170466812,5284373,Inconclusive,,,6.007000000000001,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3379,1159531,1,1,,144212166,5284373,Inconclusive,325495497.0,6256.0,4.03782,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3380,1159531,1,1,,170466812,5284373,Inconclusive,325495497.0,6256.0,6.00704,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3381,1159550,3,1,,252401631,5284373,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
3382,1159551,1,1,,144212166,5284373,Inconclusive,,,5.6538,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3383,1159551,1,1,,170466812,5284373,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3384,1159552,1,1,,144212166,5284373,Inconclusive,325495463.0,5914.0,22.5084,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3385,1159552,1,1,,170466812,5284373,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3386,1159553,2,1,,144212166,5284373,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3387,1159553,2,1,,170466812,5284373,Inactive,325495463.0,5914.0,5.308,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3388,1159555,1,1,,144212166,5284373,Inconclusive,325495463.0,5914.0,15.0433,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3389,1159555,1,1,,170466812,5284373,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3390,1159606,1,1,,56422786,5284373,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
3391,1159607,2,1,,312596538,5284373,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
3392,1159614,1,2,,170466812,5284373,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
3393,1159620,1,1,,103230651,5284373,Active,,,,,Summary of drug indications.,Other,,
3394,1166177,1,1,,103230651,5284373,Unspecified,,,,,"Reduction in concanavalin A-induced IL2 production in Balb/c mouse at 3 mg/kg, po dosed 2 hrs before concanavalin A challenge by ELISA method",Other,25254961.0,
3395,1169073,1,1,,103230651,5284373,Unspecified,,,,,Apparent permeability in RRCK cells at 8 uM at pH 7.4 incubated for 2 hrs by LC-MS/MS method,Other,25313329.0,
3396,1169076,1,1,,103230651,5284373,Unspecified,,,,,Oral bioavailability in Wistar rat at 10 mg/kg measured over 8 hrs by LC-MS method,Other,25313329.0,
3397,1169139,1,1,,103230651,5284373,Unspecified,,,,,Oral bioavailability in rat,Other,25313332.0,
3398,1169141,1,1,,103230651,5284373,Unspecified,,,,,Apparent permeability in RRCK cells,Other,25313332.0,
3399,1176909,1,1,,103230651,5284373,Active,,,0.1,IC50,Immunosupressive activity in OVA323-339 peptide-stimulated OT-2 T cell receptor transgenic mouse splenocytes assessed as inhibition of T cell proliferation after 3 days by MTT assay,Confirmatory,25537268.0,
3400,1177610,1,1,,103230651,5284373,Unspecified,,,,,Immunosuppressive activity in mouse T cells assessed as inhibition of ConA-induced cell proliferation at 100 uM,Other,25089845.0,
3401,1178328,1,1,,103230651,5284373,Active,,,0.06,EC50,Immunosuppressive activity in lymphocytes (unknown origin) by mixed lymphocyte reaction assay,Confirmatory,24831536.0,
3402,1182022,1,2,,103230651,5284373,Active,238054374.0,5243.0,,,Inhibition of human P-glycoprotein expressed in NCI/ADR-RES cells assessed as reduction of calcein-AM transport after 20 mins by fluorescence assay,Other,24992153.0,
3403,1185178,1,1,,103230651,5284373,Unspecified,,,,,Inhibition of beta-amyloid peptide-induced mitochondrial permeability transition pore opening in mouse HT22 cells assessed as increase in green/red fluorescence ratio at 5 uM pre-incubated for 10 mins before Abeta peptide addition by JC-1 assay,Other,25050879.0,
3404,1185179,1,2,,103230651,5284373,Unspecified,,,,,Toxicity against mouse HT22 cells assessed as cell viability at 5 uM after 24 hrs by MTT assay,Other,25050879.0,
3405,1199781,1,1,,103230651,5284373,Unspecified,,,,,Inhibition of p-gp (unknown origin) in doxorubicin-resistant human K562/R7 cells assessed as increase in daunorubicin accumulation measured as fluorescence ratio at 10 uM incubated for 1 hr with 10 uM daunorubicin by flow cytometry relative to control,Other,25634041.0,
3406,1199782,1,1,,103230651,5284373,Active,,,0.7,IC50,Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay,Confirmatory,25634041.0,
3407,1199783,1,1,,103230651,5284373,Unspecified,,,,,Intrinsic cytotoxicity against human K562 cells assessed as cell survival at 10 uM after 24 hrs by MTT assay,Other,25634041.0,
3408,1201805,1,2,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of MDR1 in human NCI-ADR-RES cells assessed as increase in rhodamine-123 uptake at 50 uM after 1 hr by fluorescence assay relative to control,Other,25817769.0,
3409,1206429,1,2,,103230651,5284373,Active,238054374.0,5243.0,0.919,IC50,Inhibition of ABCB1 in human A2780adr cells pre-incubated for 30 mins followed by calcein AM addition and further incubated for 60 mins by calcein AM assay,Confirmatory,25855895.0,
3410,1206430,1,2,,103230651,5284373,Unspecified,238054374.0,5243.0,,,Inhibition of ABCB1 in human A2780adr cells at 10 uM pre-incubated for 30 mins followed by calcein AM addition and further incubated for 60 mins by calcein AM assay,Other,25855895.0,
3411,1206431,1,2,,103230651,5284373,Unspecified,296439301.0,4363.0,,,Inhibition of MRP1 in human A2780adr cells at 10 uM pre-incubated for 30 mins followed by calcein AM addition and further incubated for 60 mins by calcein AM assay,Other,25855895.0,
3412,1207634,1,2,,103230651,5284373,Active,5921694.0,100135490.0,2.0,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Confirmatory,22761000.0,
3413,1209455,1,2,,103230651,5284373,Active,262527527.0,8647.0,0.5,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
3414,1209456,1,2,,103230651,5284373,Active,12585136.0,83569.0,0.6,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
3415,1209457,1,1,,103230651,5284373,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
3416,1209605,1,1,,103230651,5284373,Unspecified,,,,,Apparent oral intrinsic clearance in renal transplant patient,Other,22205779.0,
3417,1209607,1,2,,103230651,5284373,Active,116241312.0,1576.0,0.3,Ki,Competitive inhibition of CYP3A4 in human liver microsomes,Confirmatory,22205779.0,
3418,1209608,1,2,,103230651,5284373,Active,116241312.0,1576.0,7.6,Ki,Competitive inhibition of recombinant CYP3A4 (unknown origin) expressed in supersomes,Confirmatory,22205779.0,
3419,1209609,1,2,,103230651,5284373,Unspecified,116241312.0,1576.0,,IC50,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation after 7.5 mins by LC-MS method,Confirmatory,22205779.0,
3420,1209610,1,2,,103230651,5284373,Unspecified,116241312.0,1576.0,,IC50,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated for 15 mins before substrate addition by LC-MS method,Confirmatory,22205779.0,
3421,1209611,1,2,,103230651,5284373,Unspecified,,,,IC50,Inhibition of CYP3A-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by LC-MS method,Confirmatory,22205779.0,
3422,1209612,1,2,,103230651,5284373,Unspecified,,,,IC50,Inhibition of CYP3A-mediated 1'-OH midazolam formation in human liver microsomes preincubated for 15 mins before substrate addition by LC-MS method,Confirmatory,22205779.0,
3423,1209613,1,2,,103230651,5284373,Active,116241312.0,1576.0,0.89,Ki,Reversible competitive inhibition of human CYP3A4-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study,Confirmatory,22205779.0,
3424,1209614,1,2,,103230651,5284373,Active,,,0.98,Ki,Reversible competitive inhibition of CYP3A-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study,Confirmatory,22205779.0,
3425,1209615,1,2,,103230651,5284373,Inactive,117157.0,1577.0,,,Inhibition of human CYP3A5 expressed in supersomes assessed inhibition of 1'-OH midazolam formation at 0.25 to 10 uM after 7.5 mins by LC-MS method,Other,22205779.0,
3426,1209616,1,2,,103230651,5284373,Inactive,117157.0,1577.0,,,Inhibition of human CYP3A5 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated at 0.25 to 10 uM for 15 mins before substrate addition by LC-MS method,Other,22205779.0,
3427,1209617,1,2,,103230651,5284373,Inactive,117157.0,1577.0,,,Inhibition of human CYP3A5-mediated 1'-OH midazolam formation in human liver microsomes at 0.25 to 10 uM after 7.5 mins by LC-MS method,Other,22205779.0,
3428,1209618,1,2,,103230651,5284373,Inactive,117157.0,1577.0,,,Inhibition of human CYP3A5-mediated 1'-OH midazolam formation in human liver microsomes preincubated at 0.25 to 10 uM for 15 mins before substrate addition by LC-MS method,Other,22205779.0,
3429,1209651,1,1,,103230651,5284373,Unspecified,,,,,Apparent permeability from apical to basolateral side of MDCK1 cells expressing MDR1 at 25 uM after 2 hrs by LC-MS/MS analysis,Other,22315332.0,
3430,1209653,1,1,,103230651,5284373,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral over basolateral to apical side in MDCK1 cells expressing MDR1 at 25 uM after 2 hrs by LC-MS/MS analysis,Other,22315332.0,
3431,1209760,1,2,,103230651,5284373,Active,262527527.0,8647.0,,,Inhibition of ABCB11-mediated taurocholate efflux in sandwich-cultured human adult hepatocytes at 40 uM,Other,23129211.0,
3432,1209761,1,2,,103230651,5284373,Active,262527527.0,8647.0,,,Inhibition of ABCB11-mediated taurocholate total uptake in sandwich-cultured human adult hepatocytes at 40 uM,Other,23129211.0,
3433,1214583,1,1,,103230651,5284373,Unspecified,,,,,Inhibition of P-gp in human Caco2 cells assessed as reduction in digoxin efflux at 50 uM,Other,23382458.0,
3434,1214607,1,1,,103230651,5284373,Active,,,2.9,IC50,Inhibition of P-gp in human Caco2 cells assessed as reduction in digoxin efflux,Confirmatory,23382458.0,
3435,1218863,1,2,,103230651,5284373,Active,12643959.0,10599.0,0.7,IC50,Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using pitavastatin substrate,Confirmatory,22587986.0,
3436,1218864,1,2,,103230651,5284373,Active,12643959.0,10599.0,0.7,IC50,Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate,Confirmatory,22587986.0,
3437,1218865,1,2,,103230651,5284373,Active,12643959.0,10599.0,1.2,IC50,Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estrone-3-sulfate substrate,Confirmatory,22587986.0,
3438,1218867,1,2,,103230651,5284373,Active,12643959.0,10599.0,0.2,Ki,Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as protein-mediated pitavastatin uptake,Confirmatory,22587986.0,
3439,1221956,1,1,,103230651,5284373,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
3440,1221957,1,1,,103230651,5284373,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
3441,1221958,1,1,,103230651,5284373,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
3442,1221960,1,1,,103230651,5284373,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3443,1221961,1,1,,103230651,5284373,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3444,1221962,1,1,,103230651,5284373,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3445,1221963,1,1,,103230651,5284373,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3446,1221964,1,1,,103230651,5284373,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3447,1221965,1,1,,103230651,5284373,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3448,1221966,1,1,,103230651,5284373,Unspecified,,,,,Ratio of plasma AUC in po dosed mdr1 knock out mouse to plasma AUC in po dosed wild type mouse,Other,21051535.0,
3449,1221982,1,1,,103230651,5284373,Unspecified,,,,,Fraction absorbed in human,Other,21051535.0,
3450,1224294,1,1,,103230651,5284373,Unspecified,,,,,Induction of apoptosis in pMel-1 TCR transgenic C57BL/6 mouse gp100 (25 to 33)-activated CD8-positive T cells assessed as live divided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 55.2%),Other,24900866.0,
3451,1224295,1,1,,103230651,5284373,Unspecified,,,,,Induction of apoptosis in pMel-1 TCR transgenic C57BL/6 mouse gp100 (25 to 33)-activated CD8-positive T cells assessed as live undivided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 23.4%),Other,24900866.0,
3452,1224296,1,1,,103230651,5284373,Unspecified,,,,,Induction of apoptosis in pMel-1 TCR transgenic C57BL/6 mouse gp100 (25 to 33)-activated CD8-positive T cells assessed as dead undivided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 6.77%),Other,24900866.0,
3453,1224297,1,1,,103230651,5284373,Unspecified,,,,,Induction of apoptosis in pMel-1 TCR transgenic C57BL/6 mouse gp100 (25 to 33)-activated CD8-positive T cells assessed as dead divided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 14.7%),Other,24900866.0,
3454,1224298,1,1,,103230651,5284373,Unspecified,,,,,Induction of apoptosis in LLO118 TCR transgenic mouse LLO (190 to 205)-activated CD4-positive T cells assessed as live divided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 40.6%),Other,24900866.0,
3455,1224299,1,1,,103230651,5284373,Unspecified,,,,,Induction of apoptosis in LLO118 TCR transgenic mouse LLO (190 to 205)-activated CD4-positive T cells assessed as live undivided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 41.6%),Other,24900866.0,
3456,1224300,1,1,,103230651,5284373,Unspecified,,,,,Induction of apoptosis in LLO118 TCR transgenic mouse LLO (190 to 205)-activated CD4-positive T cells assessed as dead undivided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 14.7%),Other,24900866.0,
3457,1224301,1,1,,103230651,5284373,Unspecified,,,,,Induction of apoptosis in LLO118 TCR transgenic mouse LLO (190 to 205)-activated CD4-positive T cells assessed as dead divided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 3.04%),Other,24900866.0,
3458,1224302,1,1,,103230651,5284373,Active,,,,,Antiinflammatory activity in LLO118 TCR transgenic mouse IL-2-competent CD4-positive T cells assessed as inhibition of LLO (190 to 205)-induced IL-2 production at 0.01 to 100 nM for 2 days by flow cytometric analysis,Other,24900866.0,
3459,1224306,1,1,,103230651,5284373,Active,,,,,Antiinflammatory activity in LLO118 TCR transgenic mouse Th1 cells assessed as inhibition of IFN-gamma production at 100 nM for 2 days by flow cytometric analysis,Other,24900866.0,
3460,1224307,1,1,,103230651,5284373,Active,,,,,Antiinflammatory activity in LLO118 TCR transgenic mouse Th17 cells assessed as inhibition of IL-17 production at 10 to 100 nM for 2 days by flow cytometric analysis,Other,24900866.0,
3461,1224318,1,1,,103230651,5284373,Inactive,,,,,Immunosuppressive activity in C57BL/6J mouse KLH-induced delayed-type hypersensitivity model assessed as alleviation of footpad swelling at 16 nmol administered on day 7 and 8 post-sensitization measured on day 9,Other,24900866.0,
3462,1224321,1,1,,103230651,5284373,Active,,,0.08900000000000001,IC50,Immunosuppressive activity in lymphocytes by MLR assay,Confirmatory,24900866.0,
3463,1224834,3,1,,144212166,5284373,Inconclusive,,,11.2809,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3464,1224834,3,1,,170466812,5284373,Active,,,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3465,1224835,1,1,,144212166,5284373,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3466,1224835,1,1,,170466812,5284373,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3467,1224836,1,1,,144212166,5284373,Active,,,12.6574,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3468,1224836,1,1,,170466812,5284373,Inconclusive,,,9.4392,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3469,1224837,1,1,,144212166,5284373,Inconclusive,,,7.9863,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3470,1224837,1,1,,170466812,5284373,Inconclusive,,,8.4127,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3471,1224838,1,1,,144212166,5284373,Inactive,66775687.0,9970.0,11.2809,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3472,1224838,1,1,,170466812,5284373,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3473,1224839,1,1,,144212166,5284373,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3474,1224839,1,1,,170466812,5284373,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3475,1224840,3,1,,144212166,5284373,Inconclusive,,,7.9863,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3476,1224840,3,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3477,1224841,3,1,,144212166,5284373,Active,325495545.0,2101.0,15.9347,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3478,1224841,3,1,,170466812,5284373,Active,325495545.0,2101.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3479,1224842,3,1,,144212166,5284373,Inactive,325495545.0,2101.0,14.2018,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3480,1224842,3,1,,170466812,5284373,Inactive,325495545.0,2101.0,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3481,1224843,1,1,,144212166,5284373,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3482,1224843,1,1,,170466812,5284373,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3483,1224844,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3484,1224844,1,1,,170466812,5284373,Inconclusive,,,8.4852,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3485,1224845,1,1,,144212166,5284373,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3486,1224845,1,1,,170466812,5284373,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3487,1224846,1,1,,144212166,5284373,Inconclusive,11995455.0,3091.0,12.7687,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3488,1224846,1,1,,170466812,5284373,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3489,1224847,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3490,1224847,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3491,1224848,3,1,,144212166,5284373,Active,325495545.0,2101.0,10.0541,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3492,1224848,3,1,,170466812,5284373,Active,325495545.0,2101.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3493,1224849,3,1,,144212166,5284373,Inactive,325495545.0,2101.0,10.0541,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3494,1224849,3,1,,170466812,5284373,Inactive,325495545.0,2101.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3495,1224857,2,1,,170466812,5284373,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3496,1224859,2,1,,170466812,5284373,Inactive,,,35.4813,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3497,1224863,1,1,,176483936,5284373,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3498,1224865,1,2,,56422786,5284373,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3499,1224867,1,1,,144212166,5284373,Inconclusive,,,12.7687,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3500,1224867,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3501,1224868,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3502,1224868,1,1,,170466812,5284373,Inconclusive,,,3.0107,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3503,1224869,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3504,1224869,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3505,1224870,1,1,,144212166,5284373,Inconclusive,,,11.3801,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3506,1224870,1,1,,170466812,5284373,Inconclusive,,,16.9301,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3507,1224871,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3508,1224871,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3509,1224872,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3510,1224872,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3511,1224873,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3512,1224873,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3513,1224874,1,1,,144212166,5284373,Inconclusive,,,1.4327,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3514,1224874,1,1,,170466812,5284373,Inconclusive,,,2.6832,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3515,1224875,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3516,1224875,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3517,1224876,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3518,1224876,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3519,1224877,1,1,,144212166,5284373,Inconclusive,,,12.7687,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3520,1224877,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3521,1224878,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3522,1224878,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3523,1224879,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3524,1224879,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3525,1224880,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3526,1224880,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3527,1224881,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3528,1224881,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3529,1224882,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3530,1224882,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3531,1224883,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3532,1224883,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3533,1224884,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3534,1224884,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3535,1224885,1,1,,144212166,5284373,Inconclusive,,,16.0749,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3536,1224885,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3537,1224886,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3538,1224886,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3539,1224887,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3540,1224887,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3541,1224888,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3542,1224888,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3543,1224889,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3544,1224889,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3545,1224890,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3546,1224890,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3547,1224892,1,1,,144212166,5284373,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3548,1224892,1,1,,170466812,5284373,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3549,1224893,1,1,,144212166,5284373,Inconclusive,66775687.0,9970.0,17.879,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3550,1224893,1,1,,170466812,5284373,Inconclusive,66775687.0,9970.0,21.1317,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3551,1224894,1,1,,144212166,5284373,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3552,1224894,1,1,,170466812,5284373,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3553,1224895,1,1,,144212166,5284373,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3554,1224895,1,1,,170466812,5284373,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3555,1224896,1,1,,144212166,5284373,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3556,1224896,1,1,,170466812,5284373,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3557,1224905,2,1,,92308685,5284373,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3558,1224905,2,1,,92308685,5284373,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3559,1226783,1,1,,103230651,5284373,Unspecified,,,,,"AUC (0 to infinity) in Wistar-Han rat at 10 mg/kg, po after 0.033 to 24 hrs by LC-MS/MS method",Other,25950816.0,
3560,1226784,1,1,,103230651,5284373,Unspecified,,,,,"Cmax in Wistar-Han rat at 10 mg/kg, po after 0.033 to 24 hrs by LC-MS/MS method",Other,25950816.0,
3561,1226785,1,1,,103230651,5284373,Unspecified,,,,,Oral bioavailability in Wistar-Han rat at 10 mg/kg after 0.033 to 24 hrs by LC-MS/MS method,Other,25950816.0,
3562,1226786,1,1,,103230651,5284373,Unspecified,,,,,"AUC (0 to infinity) in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-MS/MS method",Other,25950816.0,
3563,1226787,1,1,,103230651,5284373,Unspecified,,,,,"Clearance in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-MS/MS method",Other,25950816.0,
3564,1226788,1,1,,103230651,5284373,Unspecified,,,,,"Volume of distribution at steady state in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-MS/MS method",Other,25950816.0,
3565,1226789,1,1,,103230651,5284373,Unspecified,,,,,"Half life in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-MS/MS method",Other,25950816.0,
3566,1226796,1,1,,103230651,5284373,Unspecified,,,,,Apparent permeability from apical to basolateral side in low-efflux MDCK cells expressing low levels of endogenous P-glycoprotein at 2 mM incubated for 2 hrs by LC-MS/MS method,Other,25950816.0,
3567,1226797,1,1,,103230651,5284373,Unspecified,,,,,Intrinsic clearance in human liver microsomes,Other,25950816.0,
3568,1228904,1,1,,103230651,5284373,Active,,,30.0,IC50,Cytotoxicity against mouse L929 cells after 3 days by MTS assay,Confirmatory,25985195.0,
3569,1228907,1,1,,103230651,5284373,Active,238054374.0,5243.0,0.032,EC50,Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing paclitaxel resistance measured as cell survival after 5 days by MTS assay,Confirmatory,25985195.0,
3570,1228908,1,1,,103230651,5284373,Inconclusive,238054374.0,5243.0,,EC50,Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing vinblastine resistance measured as cell survival after 5 days by MTS assay,Confirmatory,25985195.0,
3571,1228909,1,1,,103230651,5284373,Inconclusive,238054374.0,5243.0,,EC50,Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing vincristine resistance measured as cell survival after 5 days by MTS assay,Confirmatory,25985195.0,
3572,1228910,1,1,,103230651,5284373,Active,238054374.0,5243.0,0.043,EC50,Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing doxorubicin resistance measured as cell survival after 5 days by MTS assay,Confirmatory,25985195.0,
3573,1228911,1,1,,103230651,5284373,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse L292 cells to EC50 for modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing paclitaxel resistance",Other,25985195.0,
3574,1259241,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3575,1259241,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3576,1259242,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3577,1259242,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3578,1259243,1,1,,144212166,5284373,Active,124375976.0,367.0,25.2548,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3579,1259243,1,1,,170466812,5284373,Active,124375976.0,367.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3580,1259244,1,1,,144212166,5284373,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3581,1259244,1,1,,170466812,5284373,Inconclusive,348019627.0,2099.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3582,1259247,1,1,,144212166,5284373,Active,124375976.0,367.0,23.8421,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3583,1259247,1,1,,170466812,5284373,Active,124375976.0,367.0,19.5704,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3584,1259248,1,1,,144212166,5284373,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3585,1259248,1,1,,170466812,5284373,Active,348019627.0,2099.0,16.7855,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3586,1259310,1,1,,333473044,5284373,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3587,1259313,1,1,,56422786,5284373,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3588,1259318,1,1,,57264292,5284373,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3589,1259344,1,1,,144204218,5284373,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3590,1259355,1,1,,144204218,5284373,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3591,1259356,1,1,,144204218,5284373,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3592,1259364,1,1,,144212166,5284373,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3593,1259364,1,1,,170466812,5284373,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3594,1259365,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3595,1259365,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3596,1259366,1,1,,144212166,5284373,Active,,,11.2809,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3597,1259366,1,1,,170466812,5284373,Active,,,9.4392,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3598,1259367,1,1,,144212166,5284373,Active,,,10.0541,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3599,1259367,1,1,,170466812,5284373,Inconclusive,,,4.2163,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3600,1259368,1,1,,144212166,5284373,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3601,1259368,1,1,,170466812,5284373,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3602,1259369,1,1,,144212166,5284373,Active,109731339.0,2737.0,8.9607,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3603,1259369,1,1,,170466812,5284373,Inconclusive,109731339.0,2737.0,6.6824,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3604,1259377,1,1,,144212166,5284373,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3605,1259377,1,1,,170466812,5284373,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3606,1259378,1,1,,144212166,5284373,Inconclusive,54288833.0,2100.0,6.3437,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3607,1259378,1,1,,170466812,5284373,Inconclusive,54288833.0,2100.0,16.7855,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3608,1259379,1,1,,144212166,5284373,Inconclusive,,,14.2018,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3609,1259379,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3610,1259380,1,1,,144212166,5284373,Inconclusive,,,5.039,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3611,1259380,1,1,,170466812,5284373,Inconclusive,,,5.9557,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3612,1259381,1,1,,144212166,5284373,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3613,1259381,1,1,,170466812,5284373,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3614,1259382,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3615,1259382,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3616,1259383,1,1,,144212166,5284373,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3617,1259383,1,1,,170466812,5284373,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3618,1259384,1,1,,144212166,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3619,1259384,1,1,,170466812,5284373,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3620,1259385,1,1,,144212166,5284373,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3621,1259385,1,1,,170466812,5284373,Inconclusive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3622,1259386,1,1,,144212166,5284373,Inconclusive,,,10.0541,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3623,1259386,1,1,,170466812,5284373,Inconclusive,,,9.4392,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3624,1259387,1,1,,144212166,5284373,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3625,1259387,1,1,,170466812,5284373,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3626,1259388,1,1,,144212166,5284373,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3627,1259388,1,1,,170466812,5284373,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3628,1259389,1,1,,175607730,5284373,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3629,1259390,1,1,,144212166,5284373,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3630,1259390,1,1,,170466812,5284373,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3631,1259391,1,1,,144212166,5284373,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3632,1259391,1,1,,170466812,5284373,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3633,1259392,1,1,,144212166,5284373,Inconclusive,109731339.0,2737.0,3.77871,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3634,1259392,1,1,,170466812,5284373,Active,109731339.0,2737.0,1.0590899999999999,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3635,1259393,1,1,,144212166,5284373,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3636,1259393,1,1,,170466812,5284373,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3637,1259394,1,1,,144212166,5284373,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3638,1259394,1,1,,170466812,5284373,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3639,1259395,1,1,,144212166,5284373,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3640,1259395,1,1,,170466812,5284373,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3641,1259396,1,1,,144212166,5284373,Active,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3642,1259396,1,1,,170466812,5284373,Active,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3643,1259400,1,1,,170466812,5284373,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3644,1259401,1,1,,144212166,5284373,Inconclusive,325495545.0,2101.0,15.0433,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3645,1259401,1,1,,170466812,5284373,Active,325495545.0,2101.0,11.4358,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3646,1259402,1,1,,144212166,5284373,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3647,1259402,1,1,,170466812,5284373,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3648,1259403,1,1,,144212166,5284373,Active,325495545.0,2101.0,13.1526,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3649,1259403,1,1,,170466812,5284373,Inconclusive,325495545.0,2101.0,11.4358,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3650,1259404,1,1,,144212166,5284373,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3651,1259404,1,1,,170466812,5284373,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3652,1259407,1,1,,363899540,5284373,Inactive,,,,,CCRIS mutagenicity studies,Other,,
3653,1259408,1,1,,363897581,5284373,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
3654,1259410,1,1,,363899540,5284373,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
3655,1259411,1,1,,363899540,5284373,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
3656,1259415,1,1,,57264292,5284373,Active,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3657,1259423,1,2,,354939082,5284373,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
